CA2601227A1 - Mecano growth factor peptides and their use - Google Patents
Mecano growth factor peptides and their use Download PDFInfo
- Publication number
- CA2601227A1 CA2601227A1 CA002601227A CA2601227A CA2601227A1 CA 2601227 A1 CA2601227 A1 CA 2601227A1 CA 002601227 A CA002601227 A CA 002601227A CA 2601227 A CA2601227 A CA 2601227A CA 2601227 A1 CA2601227 A1 CA 2601227A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- peptide
- seq
- extended
- terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 634
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 384
- 239000003102 growth factor Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract description 309
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims abstract description 207
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims abstract description 118
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims abstract description 115
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims description 137
- 235000001014 amino acid Nutrition 0.000 claims description 124
- 210000004899 c-terminal region Anatomy 0.000 claims description 65
- 210000003205 muscle Anatomy 0.000 claims description 62
- 241000282414 Homo sapiens Species 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 49
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 47
- 235000004279 alanine Nutrition 0.000 claims description 45
- 230000006320 pegylation Effects 0.000 claims description 40
- 239000004475 Arginine Substances 0.000 claims description 37
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 37
- 230000004071 biological effect Effects 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 36
- 230000004048 modification Effects 0.000 claims description 31
- 238000012986 modification Methods 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 22
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 22
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 22
- 102000001708 Protein Isoforms Human genes 0.000 claims description 20
- 108010029485 Protein Isoforms Proteins 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 19
- 230000001095 motoneuron effect Effects 0.000 claims description 18
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 17
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 210000004165 myocardium Anatomy 0.000 claims description 16
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 15
- 206010028289 Muscle atrophy Diseases 0.000 claims description 14
- 208000014674 injury Diseases 0.000 claims description 14
- 208000010125 myocardial infarction Diseases 0.000 claims description 14
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical group CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 13
- 208000028867 ischemia Diseases 0.000 claims description 13
- 201000000585 muscular atrophy Diseases 0.000 claims description 13
- 210000002027 skeletal muscle Anatomy 0.000 claims description 13
- 230000000324 neuroprotective effect Effects 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 11
- 230000008439 repair process Effects 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 8
- 101800001415 Bri23 peptide Proteins 0.000 claims description 7
- 101800000655 C-terminal peptide Proteins 0.000 claims description 7
- 102400000107 C-terminal peptide Human genes 0.000 claims description 7
- 208000021642 Muscular disease Diseases 0.000 claims description 7
- 230000020763 muscle atrophy Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 6
- 208000028389 Nerve injury Diseases 0.000 claims description 6
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 201000006938 muscular dystrophy Diseases 0.000 claims description 6
- 230000003680 myocardial damage Effects 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 230000008764 nerve damage Effects 0.000 claims description 6
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 5
- 208000010428 Muscle Weakness Diseases 0.000 claims description 5
- 206010028372 Muscular weakness Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 229930028154 D-arginine Natural products 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 230000003293 cardioprotective effect Effects 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 210000002161 motor neuron Anatomy 0.000 claims description 4
- 208000018360 neuromuscular disease Diseases 0.000 claims description 4
- 210000005070 sphincter Anatomy 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 206010014498 Embolic stroke Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000000474 Poliomyelitis Diseases 0.000 claims description 3
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 claims description 3
- 230000006931 brain damage Effects 0.000 claims description 3
- 231100000874 brain damage Toxicity 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 3
- 230000003073 embolic effect Effects 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000036119 Frailty Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010003549 asthenia Diseases 0.000 claims description 2
- 208000020538 atrophic muscular disease Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 210000003903 pelvic floor Anatomy 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 208000001076 sarcopenia Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims 4
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims 2
- -1 L-form amino acid Chemical class 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 229930195711 D-Serine Natural products 0.000 claims 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 97
- 235000009697 arginine Nutrition 0.000 description 44
- 230000000694 effects Effects 0.000 description 44
- 239000002609 medium Substances 0.000 description 33
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 25
- 241000700159 Rattus Species 0.000 description 25
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 24
- 229950004398 broxuridine Drugs 0.000 description 24
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 24
- 230000004663 cell proliferation Effects 0.000 description 23
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 15
- 210000000663 muscle cell Anatomy 0.000 description 15
- 102100036912 Desmin Human genes 0.000 description 14
- 108010044052 Desmin Proteins 0.000 description 14
- 210000005045 desmin Anatomy 0.000 description 14
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 13
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 13
- 101000832103 Homo sapiens Signal transducer and activator of transcription 5A Proteins 0.000 description 13
- 102000052934 human STAT5A Human genes 0.000 description 13
- 229940090044 injection Drugs 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 230000006907 apoptotic process Effects 0.000 description 11
- QPFBVCAQCZYOIT-UHFFFAOYSA-N 5-hydroxy-8-[5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4-oxochromen-6-yl]-2-(4-hydroxyphenyl)-7-methoxychromen-4-one Chemical compound COC=1C=C2OC(C=3C=CC(O)=CC=3)=CC(=O)C2=C(O)C=1C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 QPFBVCAQCZYOIT-UHFFFAOYSA-N 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 8
- 101710176384 Peptide 1 Proteins 0.000 description 8
- 230000009435 amidation Effects 0.000 description 8
- 238000007112 amidation reaction Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 210000003098 myoblast Anatomy 0.000 description 8
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 8
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 7
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000012679 serum free medium Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 5
- 102000018389 Exopeptidases Human genes 0.000 description 5
- 108010091443 Exopeptidases Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000001114 myogenic effect Effects 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000003349 alamar blue assay Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000000431 effect on proliferation Effects 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 3
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000004112 neuroprotection Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108010065307 rat mechano-growth factor Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005961 cardioprotection Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000011556 gerbil model Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000001964 muscle biopsy Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000022379 skeletal muscle tissue development Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101100284231 Caenorhabditis elegans his-24 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 208000021401 Facial Nerve injury Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101500025815 Homo sapiens Bri23 peptide Proteins 0.000 description 1
- 101500027322 Homo sapiens C-terminal peptide Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108010051583 Ventricular Myosins Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229930185229 antidesmin Natural products 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000009811 bilateral tubal ligation Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940013767 bupivacaine injection Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940082319 dexamethasone and antibiotic Drugs 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000021268 myoblast fusion Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010012122 proinsulin-like growth factor II (117-156) Proteins 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000013363 skeletal muscle disease Diseases 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005482 strain hardening Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to biologically active polypeptides derived from the E
peptide that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor (MGF). These peptides are modified to improve their stability compared to the naturally occurring E
peptide.
peptide that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor (MGF). These peptides are modified to improve their stability compared to the naturally occurring E
peptide.
Description
DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
MECHANO GROWTH FACTOR PEPTIDES AND THEIR USE
FIELD OF THE INVENTION
This invention relates to biologically active polypeptides derived from the E
domain that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor (MGF). These peptides are modified to improve their stability compared to the naturally occurring E domain peptide.
BACKGROUND TO THE INVENTION
Mammalian IGF-I polypeptides have a number of isoforms, which arise as a result of alternative mRNA splicing. Broadly, there are two types of isoform, liver-type isoforms and non-liver-type ones. Liver-type isoforms may be expressed in the liver or elsewhere but, if expressed elsewhere, are equivalent to those expressed in the liver. They have a systemic action and are the main isoforms in mammals. Non-liver-type isoforms are less common and some are believed to have an autocrine/
paracrine action. The MGF isoform to which this invention relates is of the latter type.
In MGF (Yang et al, 1996; McKoy et al, 1999), alternative splicing introduces an insert which changes the reading frame of the C-terminal portion of the inolecule.
This insert is 49 base pairs long in human MGF. A 52 base pair insert has a similar effect in rat and rabbit MGF. The result is that MGF is sliglltly longer than liver-type IGF-I (because the terminator codon appears later owing to the reading frame shift) and that the C-terminal E domain has a different sequence. It is also smaller overall because it lacks glycosylation.
In human MGF, the C-terminus is formed by a 24 amino acid E domain, sometimes termed an Ec peptide (SEQ ID NO: 27). In rat and rabbit MGF, the corresponding E
domains, sometimes termed Eb peptides, are 25 amino acids in length (SEQ ID
NOS:
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
MECHANO GROWTH FACTOR PEPTIDES AND THEIR USE
FIELD OF THE INVENTION
This invention relates to biologically active polypeptides derived from the E
domain that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor (MGF). These peptides are modified to improve their stability compared to the naturally occurring E domain peptide.
BACKGROUND TO THE INVENTION
Mammalian IGF-I polypeptides have a number of isoforms, which arise as a result of alternative mRNA splicing. Broadly, there are two types of isoform, liver-type isoforms and non-liver-type ones. Liver-type isoforms may be expressed in the liver or elsewhere but, if expressed elsewhere, are equivalent to those expressed in the liver. They have a systemic action and are the main isoforms in mammals. Non-liver-type isoforms are less common and some are believed to have an autocrine/
paracrine action. The MGF isoform to which this invention relates is of the latter type.
In MGF (Yang et al, 1996; McKoy et al, 1999), alternative splicing introduces an insert which changes the reading frame of the C-terminal portion of the inolecule.
This insert is 49 base pairs long in human MGF. A 52 base pair insert has a similar effect in rat and rabbit MGF. The result is that MGF is sliglltly longer than liver-type IGF-I (because the terminator codon appears later owing to the reading frame shift) and that the C-terminal E domain has a different sequence. It is also smaller overall because it lacks glycosylation.
In human MGF, the C-terminus is formed by a 24 amino acid E domain, sometimes termed an Ec peptide (SEQ ID NO: 27). In rat and rabbit MGF, the corresponding E
domains, sometimes termed Eb peptides, are 25 amino acids in length (SEQ ID
NOS:
13/14). Liver-type IGF-I instead contains an Ea peptide at the C-terminus. The sequences of the Ea and Ec/Eb peptides are unrelated to one another because of the reading frame shift discussed above.The presence of a splice variant with what can now be seen to be the MGF C-terminal was first noted by Chew et al (1995), who identified it in liver tissue during studies on patients suffering from liver cancer, but did not investigate it at all in ternns of potential function or therapeutic significance.
Goldspink and co-workers have already identified MGF for use against disorders of skeletal muscle, notably muscular dystrophy; for use against disorders of cardiac muscle, notably in the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart; for the treatment of neurological disorders in general; and for nerve repair in particular (W097/3 3997;
Goldspink and co-workers have already identified MGF for use against disorders of skeletal muscle, notably muscular dystrophy; for use against disorders of cardiac muscle, notably in the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart; for the treatment of neurological disorders in general; and for nerve repair in particular (W097/3 3997;
3;
WO01/85781; W003/066082). It is becoming increasingly clear that liver-type IGF-I
and MGF have different roles and functions. Thus, Hill and Goldspink (2003) have shown that, in the rat anterior tibialis muscle, MGF is expressed rapidly in response to mechanical damage caused by electrical stimulation or resulting from bupivacaine injection, but that its expression then declines within a few days.
Conversely, liver-type IGF-I is more slowly upregulated and its increase is commensurate with the decline in MGF expression. In addition, Yang and Goldspink (2002) have shown, using the mouse C2C 12 muscle cell line as an in vitro model, that a 24 amino acid peptide related to the Ec peptide from the C-terminus of human MGF, but with Histidine in the penultimate position rather than the native Arginine, and an additional C-tenninal cysteine, has a distinct activity compared to that of mature IGF-I in that it increases myoblast proliferation but inhibits myotube formation.
Dluzniewska et al (September 2005) have also demonstrated a strong neuroprotective effect of the a related peptide, again with with Histidine in the penultimate position rather than the native Arginine and some modifications by way of conversion of L-Arginine to D-Arginine at positions 14 and 15, plus C-terminal amidation and PEGylation.
WO01/85781; W003/066082). It is becoming increasingly clear that liver-type IGF-I
and MGF have different roles and functions. Thus, Hill and Goldspink (2003) have shown that, in the rat anterior tibialis muscle, MGF is expressed rapidly in response to mechanical damage caused by electrical stimulation or resulting from bupivacaine injection, but that its expression then declines within a few days.
Conversely, liver-type IGF-I is more slowly upregulated and its increase is commensurate with the decline in MGF expression. In addition, Yang and Goldspink (2002) have shown, using the mouse C2C 12 muscle cell line as an in vitro model, that a 24 amino acid peptide related to the Ec peptide from the C-terminus of human MGF, but with Histidine in the penultimate position rather than the native Arginine, and an additional C-tenninal cysteine, has a distinct activity compared to that of mature IGF-I in that it increases myoblast proliferation but inhibits myotube formation.
Dluzniewska et al (September 2005) have also demonstrated a strong neuroprotective effect of the a related peptide, again with with Histidine in the penultimate position rather than the native Arginine and some modifications by way of conversion of L-Arginine to D-Arginine at positions 14 and 15, plus C-terminal amidation and PEGylation.
SUMMARY OF THE INVENTION
However, the present inventors have found that the native human MGF C terminal Ec peptide has a short half-life in human plasma. Hence, stabilising modifications can enhance its potential for use as a pharmaceutical.
The inventors have also demonstrated that stabilised MGF C-terminal E peptides have neuroprotective and cardioprotective properties, as well as the ability to increase the strength of normal and dystrophic skeletal muscle.
Accordingly, the invention provides a polypeptide comprising up to 50 amino acid residues;
said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I (IGF-I);
said polypeptide incorporating one or more modifications that give it increased stability compared to the unmodified MGF E peptide;
and said polypeptide possessing biological activity.
The invention also provides an extended polypeptide comprising a polypeptide of the invention, extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide.
The invention also provides a composition comprising a polypeptide or extended polypeptide of the invention and a carrier.
The invention also provides a pharmaceutical composition comprising a polypeptide or extended polypeptide of the invention and a pharmaceutically acceptable carrier.
The invention also provides a polypeptide or extended polypeptide of the invention for use in a method of treatment of the human or animal body.
The invention also provides a method of treating a muscular disorder by administering to a patient in need thereof an effective amount of a polypeptide or extended polypeptide of the invention. Said muscular disorder may be, for example, a disorder of skeletal muscle or a disorder of cardiac muscle.
The invention also provides a metliod of treating a neurological disorder by administering to a patient in need thereof an effective amount of a polypeptide or extended polypeptide of the invention.
The invention also provides use of a polypeptide or extended polypeptide of the invention in the manufacture of a medicament for use in a treatment as defined above.
The invention also provides a method of treating a neurological disorder by administering to a patient in need thereof an effective amount of:
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I); or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide or extended polypeptide possessing biological activity.
The invention also provides a method of treating a disorder of cardiac muscle by administering to a patient in need thereof an effective amount of:
However, the present inventors have found that the native human MGF C terminal Ec peptide has a short half-life in human plasma. Hence, stabilising modifications can enhance its potential for use as a pharmaceutical.
The inventors have also demonstrated that stabilised MGF C-terminal E peptides have neuroprotective and cardioprotective properties, as well as the ability to increase the strength of normal and dystrophic skeletal muscle.
Accordingly, the invention provides a polypeptide comprising up to 50 amino acid residues;
said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I (IGF-I);
said polypeptide incorporating one or more modifications that give it increased stability compared to the unmodified MGF E peptide;
and said polypeptide possessing biological activity.
The invention also provides an extended polypeptide comprising a polypeptide of the invention, extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide.
The invention also provides a composition comprising a polypeptide or extended polypeptide of the invention and a carrier.
The invention also provides a pharmaceutical composition comprising a polypeptide or extended polypeptide of the invention and a pharmaceutically acceptable carrier.
The invention also provides a polypeptide or extended polypeptide of the invention for use in a method of treatment of the human or animal body.
The invention also provides a method of treating a muscular disorder by administering to a patient in need thereof an effective amount of a polypeptide or extended polypeptide of the invention. Said muscular disorder may be, for example, a disorder of skeletal muscle or a disorder of cardiac muscle.
The invention also provides a metliod of treating a neurological disorder by administering to a patient in need thereof an effective amount of a polypeptide or extended polypeptide of the invention.
The invention also provides use of a polypeptide or extended polypeptide of the invention in the manufacture of a medicament for use in a treatment as defined above.
The invention also provides a method of treating a neurological disorder by administering to a patient in need thereof an effective amount of:
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I); or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide or extended polypeptide possessing biological activity.
The invention also provides a method of treating a disorder of cardiac muscle by administering to a patient in need thereof an effective amount of:
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I); or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide possessing biological activity.
The invention also provides use of a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I (IGF-I); or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide possessing biological activity in the manufacture of a medicament for use in the treatment of a neurological disorder or a disorder of cardiac muscle.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Sequence alignment, showing sequences encoded by part of the sequence of each of human, rat and rabbit MGF and human, rat and rabbit liver-type IGF-I
(Amino acids 26 to 110 of SEQ ID NO: 2 and to 26 to 111 of SEQ ID NOS: 4 and 6:
see below), and highlighting differences between MGF and liver-type IGF-I at C-terminus; created by 49 base pair insert in human MGF and 52 base pair insert in rat/rabbit MGF, leading to reading frame shift and divergence at C-terminus.
Figure 2: Effect of Alanine substitution and C-terniinal and N-terminal truncation on stability and biological activity - further sequence alignment, comparing modified sequences of Peptides 1-6 (SEQ ID NOS: 15-20) and Short peptides 1-4 (SEQ NOS: 21-24), and detailing impact of changes on stability as measured by incubation in human plasma and biological activity as measured by testing on muscle cell line (see Examples for details of test procedures).
In the Figure, the first two columns on the left hand side identify the peptides and give their sequences, identifying the changes made by way of substitution. The third column gives the results of the tests for stability (see Example 5 for details) and the final one on the right hand side gives the results of the tests for biological activity (again, see Example 5 for details).
Figure 3: Increase in strength of a murine dystrophic muscle following injection of stabilised peptide after 3 weeks -(A) percentage change in tetanic force in dystrophic muscle of mdx mice following injection of stabilised peptide (left hand column) and IGF (right hand column).
(B) percentage change in tetanic force in dystrophic muscle of mdx mice following injection of stabilised peptide (left hand column) and PBS vehicle control (right hand column).
Figure 4: Cardioprotection following adniinistration of stabilised peptide -comparison of ejection fractions achieved following administration to infarcted ovine heart of stabilised peptide (third column, referred to as "Ec domain"), full length MGF (fourth column), mature IGF-I (second column) and control preparation (first column).
Figure 5: Pressure/volume loop data showing preservation of function following myocardial in fraction (MI) - for normal (top left) and infarcted (MI) murine (top right) ventricle, and showing effect of stabilised peptide delivered systemically to the MI heart (bottom right, referred to as "MGF peptide") and the normal heart (bottom left). All panels show pressure (mmHg) on the Y-axis and Relative Volume Units on the X-axis.
Figure 6: Neuroprotective effects in rat brain slice system - from left to right, percentage of dead cells after treatment with stabilised peptide (referred to as "MGF"), IGF-I, TBH, TBH + stabilised peptide (24 hours), TBH + IGF-I (24 hours), TBH + stabilised peptide (48 hours), TBH + IGF-I (48 hours).
Figure 7: Western blots demonstrating the greater stability of the stabilised peptide that incorporates conversion of Arginine from L to D form and N-terminal PEGylation - the stability of the stabilised peptide compared to a corresponding one lacking the L to D form conversions and N-terminal PEGylation was investigated by incubation in fresh liuman plasma for a range of different time intervals. Western blotting was then used to assess the survival of each peptide over those time intervals: A = 0 minutes; B= 30 minutes; C = 2 hours; D = 24 hours.
The results for the peptide with L-D conversion and N-terminal PEGylation are shown on the right; those for the peptide lacking the L to D form conversions and N-terminal PEGylation are on the left.
Figure 8: Effect of.8 amino acid C-terminal peptides on proliferation of C2C12 muscle cells:
(A) DMGF and CMGF Peptides : C2C12 Cells were provided at 2000cell/well, in a medium containing DMEM (1000mg/L glucose), plus BSA(100ug/ml), plus IGF-I
(2ng per ml) and incubated for 36 hours. Cell proliferation was then assessed using an Alamar Blue assay. The left hand group of readings shows the results for experiments with concentrations of the DMGF peptide (See Example 1.3.1 for details) of 2, 5, 50 and 100 ng/ml. The middle group of readings shows the results for experiments with concentrations of the CMGF peptide (See Example 1.3.1 for details) of 2, 5, 50 and 100 ng/ml. The left hand group of readings shows the results for experiments with concentrations of IGF-I alone (See Example 1.5 for details) of 2, 5, 50 and 100 ng/ml. Y-axis values are fluorescence (wavelength of excitation 535nm, measurement at 590nm; mean plus standard error) in an Alamar Blue assay.
(B) Peptides A2, A4, A6 and A8: C2C12 muscle cells at a 500 cells/well.
Cultivation was carried out for 24 hours in 10% FBS, followed by starvation for 24 hours in 0.1% BSA, stimulation for 24 hours and then treatment with BrdU for 5 hours.
Concentrations of 0.1, 1, 10 and 100 ng/ml of peptides A2, A4, A6 and A8 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I (See the right-hand set of results).
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing no cells, medium only, 5% FBS and no BrdU were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first column on the left relates to a control in which no cells were present. The next four relate to peptide A2 at concentrations of 0.1, 1, 10 and 100 ng/ml. The next four relate to peptide A4 at concentrations of 0.1, 1, 10 and 100 ng/ml. The central three relate to controls containing medium only (med), 5% FBS) and no BrdU. The next four relate to peptide A6 at concentrations of 0.1, 1, 10 and 100 ng/ml. The next four relate to peptide A8 at concentrations of 0.1, 1, 10 and 100 ng/ml. The right-hand group of results relate to IGF-I (See Example 1.5) at concentrations of 0.1, 1, 10 and 100 ng/ml.
Figure 9 : Effect on proliferation on HSMM cells (A) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I.
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing medium only, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium only. The next three relate to IGF-I
(See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FBS, background staining and no cells respectively.
*
means P < 0.05 compared to medium only control.
(B) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 in combination with 2 ng/ml IGF-I were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I. BrdU incorporation was measured to assess the level of cell proliferation achieved. Controls containing medium supplemented with 2 ng/ml IGF-I, no cells (BLK), and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next three relate to IGF-I (See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FBS, medium supplemented with 2 ng/ml IGF-I and no cells respectively. *
means P < 0.01 and ** means P < 0.001 compared to medium control containing 2 ng/ml IGF-I.
Figure 10 : Effect on proliferation on HSMM cells (A) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I.
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing medium only, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium only. The next three relate to IGF-I
(See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FBS, background staining and no cells respectively.
*
means P < 0.05 compared to medium only control.
(B) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 in combination with 2 ng/ml IGF-I were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I. BrdU incorporation was measured to assess the level of cell proliferation achieved. Controls containing medium supplemented with 2 ng/ml IGF-I, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium supplemented with 2 ng/ml IGF-I only. The next three relate to IGF-I (See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml.
The next three relate to controls containing 10% FBS, background staining and no cells respectively. * means P < 0.1 compared to medium control containing 2 ng/ml IGF-I.
Figure 11: Effect on proliferation on HSMM cells (A) Peptide A5: HSMM cells at 1000 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I.
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing medium only, no cells (BLk), background staining (BG) and 10% FCS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium only. The next three relate to IGF-I
(See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FCS, background staining and no cells respectively.
(B) Peptide A5: HSMM cells at 1000 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 in combination with 2 ng/ml IGF-I were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I. BrdU incorporation was measured to assess the level of cell proliferation achieved. Controls containing medium supplemented with 2 ng/ml IGF-I, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium supplemented with 2 ng/ml IGF-I only. The next three relate to IGF-I (See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml.
The next three relate to controls containing 10% FBS, background staining and no cells respectively. * means P < 0.1 compared to medium control containing 2 ng/ml IGF-I.
SEOUENCE INFORMATION
The DNA and amino acid sequences of human, rat and rabbit MGF DNA and are given in the sequence listing as SEQ ID NOS: 1/2, 3/4 and 5/6 respectively.
These are termed full-length MGF sequences in that they represent mature MGF encoded by exons 3/4/5/6 of the IGF-I gene, including the 49/52 base pair insert that changes the reading frame and creates the characteristic MGF C-terminus. Exons 1 and 2 are alternative leader sequences. For comparison, the corresponding DNA and amino acid sequences from human, rat and rabbit liver-type IGF-I are given as SEQ ID
NOS: 7/8, 9/10 and 11/12 respectively. A comparison of the six amino acid sequences, from the beginning of the sequence encoded by exon 4 onwards, is made in Figure 1.
The sequence of the native rat Eb peptide (25 amino acids; amino acids 87-111 of SEQ ID NO: 4) from the C-terminus of rat MGF is given as SEQ ID NO: 13.
The sequence of the native rabbit Eb peptide (25 amino acids; amino acids 87-111 of SEQ ID NO: 6) from the C-terminus of rabbit MGF is given as SEQ ID NO: 14.
The sequence of the native human Ec peptide (24 amino acids; amino acids 87-of SEQ ID NO: 2) from the C-terminus of human MGF is given as SEQ ID NO: 27.
Modified sequences derived from the peptide of SEQ ID NO: 27 are given as SEQ
ID NOS: 28 to 32.
In SEQ ID NO: 28, Serine is replaced with Alanine at position 5.
In SEQ ID NO: 29, Serine is replaced with Alanine at position 12.
In SEQ ID NO: 30, Serine is replaced with Alanine at position 18.
In SEQ ID NO: 31, Arginine is replaced with Alanine at position 14.
In SEQ ID NO: 32, Arginine is replaced with Alanine at position 14 and Arginine is also replaced with Alanine at position 15.
Native human Ec peptide has Arginine in its penultimate position. A variant of the native peptide with Histidine in the penultimate position has been synthesised and is shown in SEQ ID NO: 15. This peptide is also described as Peptide 1 in Figure 2.
SEQ ID NO: 26 represents the sequence of full-length human MGF incorporating Histidine in the penultimate position instead of Arginine. SEQ ID NO: 25 is a DNA
coding sequence for SEQ ID NO: 26, in which the Histidine in the penultimate position is encoded by CAC and the remaining sequence is the same as in SEQ ID
NO: 1.
Modified sequences derived from the peptide of SEQ ID NO: 15 are given as SEQ
ID NOS: 16 to 24. These are compared to peptide of SEQ ID NO: 15 and one another in Figure 2.
In Peptide 2 (SEQ ID NO: 16), Serine is replaced with Alanine at position 5.
In Peptide 3 (SEQ ID NO: 17), Serine is replaced with Alanine at position 12.
In Peptide 4 (SEQ ID NO: 18), Serine is replaced with Alanine at position 18.
In Peptide 5 (SEQ ID NO: 19), Arginine is replaced with Alanine at position 14.
In Peptide 6 (SEQ ID NO: 20), Arginine is replaced with Alanine at position 14 and Arginine is also replaced with Alanine at position 15.
In Short peptide 1(SEQ ID NO: 21), Arginine is replaced with Alanine at position 14 and the two C-terminal amino acids are removed.
In Short peptide 2 (SEQ ID NO: 22), Arginine is replaced with Alanine at position 14 and the four C-terminal amino acids are removed.
In Short peptide 3 (SEQ ID NO: 23), Arginine is replaced with Alanine at position 14 and the three N-terminal amino acids are removed.
In Short peptide 4 (SEQ ID NO: 24), Arginine is replaced with Alanine at position 14 and the five N-terminal amino acids are removed.
Four 8 amino acid peptide sequences are also included in the Sequence Listing.
SEQ ID NO: 33 is the 8 C-terminal amino acids of the variant sequence of SEQ
ID
NO:15, containing Histidine in the penultimate position.
SEQ ID NO: 34 is the 8 C-terminal amino acids of the native human MGF C-terminus of SEQ ID NO:27, containing Arginine in the penultimate position.
SEQ ID NO: 35 is the sequence of SEQ ID NO: 33 with Serine in position 2 substituted with Alanine. This therefore corresponds to the 8 C-terminal amino acids of SEQ ID NO: 18 (Peptide 4).
SEQ ID NO: 36 is the sequence of SEQ ID NO: 34 with Serine in position 2 substituted with Alanine. This therefore corresponds to the 8 C-terminal amino acids of SEQ ID NO: 30.
For ease of reference, these sequences are also described in the following Table.
and said polypeptide possessing biological activity.
The invention also provides use of a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I (IGF-I); or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide possessing biological activity in the manufacture of a medicament for use in the treatment of a neurological disorder or a disorder of cardiac muscle.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Sequence alignment, showing sequences encoded by part of the sequence of each of human, rat and rabbit MGF and human, rat and rabbit liver-type IGF-I
(Amino acids 26 to 110 of SEQ ID NO: 2 and to 26 to 111 of SEQ ID NOS: 4 and 6:
see below), and highlighting differences between MGF and liver-type IGF-I at C-terminus; created by 49 base pair insert in human MGF and 52 base pair insert in rat/rabbit MGF, leading to reading frame shift and divergence at C-terminus.
Figure 2: Effect of Alanine substitution and C-terniinal and N-terminal truncation on stability and biological activity - further sequence alignment, comparing modified sequences of Peptides 1-6 (SEQ ID NOS: 15-20) and Short peptides 1-4 (SEQ NOS: 21-24), and detailing impact of changes on stability as measured by incubation in human plasma and biological activity as measured by testing on muscle cell line (see Examples for details of test procedures).
In the Figure, the first two columns on the left hand side identify the peptides and give their sequences, identifying the changes made by way of substitution. The third column gives the results of the tests for stability (see Example 5 for details) and the final one on the right hand side gives the results of the tests for biological activity (again, see Example 5 for details).
Figure 3: Increase in strength of a murine dystrophic muscle following injection of stabilised peptide after 3 weeks -(A) percentage change in tetanic force in dystrophic muscle of mdx mice following injection of stabilised peptide (left hand column) and IGF (right hand column).
(B) percentage change in tetanic force in dystrophic muscle of mdx mice following injection of stabilised peptide (left hand column) and PBS vehicle control (right hand column).
Figure 4: Cardioprotection following adniinistration of stabilised peptide -comparison of ejection fractions achieved following administration to infarcted ovine heart of stabilised peptide (third column, referred to as "Ec domain"), full length MGF (fourth column), mature IGF-I (second column) and control preparation (first column).
Figure 5: Pressure/volume loop data showing preservation of function following myocardial in fraction (MI) - for normal (top left) and infarcted (MI) murine (top right) ventricle, and showing effect of stabilised peptide delivered systemically to the MI heart (bottom right, referred to as "MGF peptide") and the normal heart (bottom left). All panels show pressure (mmHg) on the Y-axis and Relative Volume Units on the X-axis.
Figure 6: Neuroprotective effects in rat brain slice system - from left to right, percentage of dead cells after treatment with stabilised peptide (referred to as "MGF"), IGF-I, TBH, TBH + stabilised peptide (24 hours), TBH + IGF-I (24 hours), TBH + stabilised peptide (48 hours), TBH + IGF-I (48 hours).
Figure 7: Western blots demonstrating the greater stability of the stabilised peptide that incorporates conversion of Arginine from L to D form and N-terminal PEGylation - the stability of the stabilised peptide compared to a corresponding one lacking the L to D form conversions and N-terminal PEGylation was investigated by incubation in fresh liuman plasma for a range of different time intervals. Western blotting was then used to assess the survival of each peptide over those time intervals: A = 0 minutes; B= 30 minutes; C = 2 hours; D = 24 hours.
The results for the peptide with L-D conversion and N-terminal PEGylation are shown on the right; those for the peptide lacking the L to D form conversions and N-terminal PEGylation are on the left.
Figure 8: Effect of.8 amino acid C-terminal peptides on proliferation of C2C12 muscle cells:
(A) DMGF and CMGF Peptides : C2C12 Cells were provided at 2000cell/well, in a medium containing DMEM (1000mg/L glucose), plus BSA(100ug/ml), plus IGF-I
(2ng per ml) and incubated for 36 hours. Cell proliferation was then assessed using an Alamar Blue assay. The left hand group of readings shows the results for experiments with concentrations of the DMGF peptide (See Example 1.3.1 for details) of 2, 5, 50 and 100 ng/ml. The middle group of readings shows the results for experiments with concentrations of the CMGF peptide (See Example 1.3.1 for details) of 2, 5, 50 and 100 ng/ml. The left hand group of readings shows the results for experiments with concentrations of IGF-I alone (See Example 1.5 for details) of 2, 5, 50 and 100 ng/ml. Y-axis values are fluorescence (wavelength of excitation 535nm, measurement at 590nm; mean plus standard error) in an Alamar Blue assay.
(B) Peptides A2, A4, A6 and A8: C2C12 muscle cells at a 500 cells/well.
Cultivation was carried out for 24 hours in 10% FBS, followed by starvation for 24 hours in 0.1% BSA, stimulation for 24 hours and then treatment with BrdU for 5 hours.
Concentrations of 0.1, 1, 10 and 100 ng/ml of peptides A2, A4, A6 and A8 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I (See the right-hand set of results).
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing no cells, medium only, 5% FBS and no BrdU were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first column on the left relates to a control in which no cells were present. The next four relate to peptide A2 at concentrations of 0.1, 1, 10 and 100 ng/ml. The next four relate to peptide A4 at concentrations of 0.1, 1, 10 and 100 ng/ml. The central three relate to controls containing medium only (med), 5% FBS) and no BrdU. The next four relate to peptide A6 at concentrations of 0.1, 1, 10 and 100 ng/ml. The next four relate to peptide A8 at concentrations of 0.1, 1, 10 and 100 ng/ml. The right-hand group of results relate to IGF-I (See Example 1.5) at concentrations of 0.1, 1, 10 and 100 ng/ml.
Figure 9 : Effect on proliferation on HSMM cells (A) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I.
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing medium only, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium only. The next three relate to IGF-I
(See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FBS, background staining and no cells respectively.
*
means P < 0.05 compared to medium only control.
(B) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 in combination with 2 ng/ml IGF-I were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I. BrdU incorporation was measured to assess the level of cell proliferation achieved. Controls containing medium supplemented with 2 ng/ml IGF-I, no cells (BLK), and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next three relate to IGF-I (See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FBS, medium supplemented with 2 ng/ml IGF-I and no cells respectively. *
means P < 0.01 and ** means P < 0.001 compared to medium control containing 2 ng/ml IGF-I.
Figure 10 : Effect on proliferation on HSMM cells (A) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I.
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing medium only, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium only. The next three relate to IGF-I
(See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FBS, background staining and no cells respectively.
*
means P < 0.05 compared to medium only control.
(B) Peptide A5: HSMM cells at 500 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 in combination with 2 ng/ml IGF-I were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I. BrdU incorporation was measured to assess the level of cell proliferation achieved. Controls containing medium supplemented with 2 ng/ml IGF-I, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium supplemented with 2 ng/ml IGF-I only. The next three relate to IGF-I (See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml.
The next three relate to controls containing 10% FBS, background staining and no cells respectively. * means P < 0.1 compared to medium control containing 2 ng/ml IGF-I.
Figure 11: Effect on proliferation on HSMM cells (A) Peptide A5: HSMM cells at 1000 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I.
BrdU incorporation was measured to assess the level of cell proliferation achieved.
Controls containing medium only, no cells (BLk), background staining (BG) and 10% FCS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium only. The next three relate to IGF-I
(See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml. The next three relate to controls containing 10% FCS, background staining and no cells respectively.
(B) Peptide A5: HSMM cells at 1000 cells/well. Cultivation was carried out for hours in 10% FCS, followed by two washes in serum free medium, stimulation for 48 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of peptide A5 in combination with 2 ng/ml IGF-I were tested, along with 0.1, 1, 10 and 100 ng/ml IGF-I. BrdU incorporation was measured to assess the level of cell proliferation achieved. Controls containing medium supplemented with 2 ng/ml IGF-I, no cells (BLK), background staining (BG) and 10% FBS were also provided. Values on the Y-axis are for fluorescence (absorbence at 370nm; mean plus standard error across 4 wells). The first five columns relate to peptide A5 at concentrations of 0.1, 1, 10, 100 and 500 ng/ml. The next column relates to the control containing medium supplemented with 2 ng/ml IGF-I only. The next three relate to IGF-I (See Example 1.5) alone at concentrations of 100, 10 and 0.1 ng/ml.
The next three relate to controls containing 10% FBS, background staining and no cells respectively. * means P < 0.1 compared to medium control containing 2 ng/ml IGF-I.
SEOUENCE INFORMATION
The DNA and amino acid sequences of human, rat and rabbit MGF DNA and are given in the sequence listing as SEQ ID NOS: 1/2, 3/4 and 5/6 respectively.
These are termed full-length MGF sequences in that they represent mature MGF encoded by exons 3/4/5/6 of the IGF-I gene, including the 49/52 base pair insert that changes the reading frame and creates the characteristic MGF C-terminus. Exons 1 and 2 are alternative leader sequences. For comparison, the corresponding DNA and amino acid sequences from human, rat and rabbit liver-type IGF-I are given as SEQ ID
NOS: 7/8, 9/10 and 11/12 respectively. A comparison of the six amino acid sequences, from the beginning of the sequence encoded by exon 4 onwards, is made in Figure 1.
The sequence of the native rat Eb peptide (25 amino acids; amino acids 87-111 of SEQ ID NO: 4) from the C-terminus of rat MGF is given as SEQ ID NO: 13.
The sequence of the native rabbit Eb peptide (25 amino acids; amino acids 87-111 of SEQ ID NO: 6) from the C-terminus of rabbit MGF is given as SEQ ID NO: 14.
The sequence of the native human Ec peptide (24 amino acids; amino acids 87-of SEQ ID NO: 2) from the C-terminus of human MGF is given as SEQ ID NO: 27.
Modified sequences derived from the peptide of SEQ ID NO: 27 are given as SEQ
ID NOS: 28 to 32.
In SEQ ID NO: 28, Serine is replaced with Alanine at position 5.
In SEQ ID NO: 29, Serine is replaced with Alanine at position 12.
In SEQ ID NO: 30, Serine is replaced with Alanine at position 18.
In SEQ ID NO: 31, Arginine is replaced with Alanine at position 14.
In SEQ ID NO: 32, Arginine is replaced with Alanine at position 14 and Arginine is also replaced with Alanine at position 15.
Native human Ec peptide has Arginine in its penultimate position. A variant of the native peptide with Histidine in the penultimate position has been synthesised and is shown in SEQ ID NO: 15. This peptide is also described as Peptide 1 in Figure 2.
SEQ ID NO: 26 represents the sequence of full-length human MGF incorporating Histidine in the penultimate position instead of Arginine. SEQ ID NO: 25 is a DNA
coding sequence for SEQ ID NO: 26, in which the Histidine in the penultimate position is encoded by CAC and the remaining sequence is the same as in SEQ ID
NO: 1.
Modified sequences derived from the peptide of SEQ ID NO: 15 are given as SEQ
ID NOS: 16 to 24. These are compared to peptide of SEQ ID NO: 15 and one another in Figure 2.
In Peptide 2 (SEQ ID NO: 16), Serine is replaced with Alanine at position 5.
In Peptide 3 (SEQ ID NO: 17), Serine is replaced with Alanine at position 12.
In Peptide 4 (SEQ ID NO: 18), Serine is replaced with Alanine at position 18.
In Peptide 5 (SEQ ID NO: 19), Arginine is replaced with Alanine at position 14.
In Peptide 6 (SEQ ID NO: 20), Arginine is replaced with Alanine at position 14 and Arginine is also replaced with Alanine at position 15.
In Short peptide 1(SEQ ID NO: 21), Arginine is replaced with Alanine at position 14 and the two C-terminal amino acids are removed.
In Short peptide 2 (SEQ ID NO: 22), Arginine is replaced with Alanine at position 14 and the four C-terminal amino acids are removed.
In Short peptide 3 (SEQ ID NO: 23), Arginine is replaced with Alanine at position 14 and the three N-terminal amino acids are removed.
In Short peptide 4 (SEQ ID NO: 24), Arginine is replaced with Alanine at position 14 and the five N-terminal amino acids are removed.
Four 8 amino acid peptide sequences are also included in the Sequence Listing.
SEQ ID NO: 33 is the 8 C-terminal amino acids of the variant sequence of SEQ
ID
NO:15, containing Histidine in the penultimate position.
SEQ ID NO: 34 is the 8 C-terminal amino acids of the native human MGF C-terminus of SEQ ID NO:27, containing Arginine in the penultimate position.
SEQ ID NO: 35 is the sequence of SEQ ID NO: 33 with Serine in position 2 substituted with Alanine. This therefore corresponds to the 8 C-terminal amino acids of SEQ ID NO: 18 (Peptide 4).
SEQ ID NO: 36 is the sequence of SEQ ID NO: 34 with Serine in position 2 substituted with Alanine. This therefore corresponds to the 8 C-terminal amino acids of SEQ ID NO: 30.
For ease of reference, these sequences are also described in the following Table.
SEQ ID Description NO: ("aa" denotes "amino acid") 1 Full length human IGF-1-Ec (= MGF) (Nucleotide and amino acid) 2 Full length human IGF-1-Ec (= MGF) Amino acid only) 3 Full length rat IGF-1-Eb (= rat MGF) (Nucleotide and amino acid) 4 Full length rat IGF-1-Eb (= rat MGF) (Amino acid only) Full length rabbit IGF-1-Eb (= rabbit MGF) (Nucleotide and amino acid) 6 Full length rabbit IGF-1-Eb rabbitMGF) (Amino acid only) 7 Full length human liver-type IGF-1 (Nucleotide and amino acid) 8 Full length human liver-type IGF-1 (Amino acid only) 9 Full length rat liver-type IGF-1 (Nucleotide and amino acid) Full length rat liver-type IGF-1 (Amino acid only) 11 Full length rabbit liver-type IGF-1 ( Nucleotide and amino acid) 12 Full length rabbit liver-type IGF-1 (Amino acid only) 13 Synthetic peptide corresponding to aa 87 - 111 of SEQ ID NO: 4 14 Synthetic peptide corresponding to aa 87 - 111 of SEQ ID NO: 6 Synthetic peptide corresponding to aa 87 - 110 of SEQ ID NO: 2 with Arg109->His (= Ar 23->His using SEQ ID NO: 15 numbering) 16 Peptide of SEQ ID NO: 15 with Ser5->Ala 17 Peptide of SEQ ID NO: 15 with Ser12--*Ala 18 Peptide of SEQ ID NO: 15 with Ser18-Ala 19 Peptide of SEQ ID NO: 15 with Arg14--+Ala Peptide of SEQ ID NO: 15 with Ar l4--->Ala , Ar 15-Ala 21 Synthetic peptide corresponding to aa 1-22 of SEQ ID NO: 15 with Arg14->Ala 22 Synthetic peptide corresponding to aa 1-20 of SEQ ID NO: 15 with Ar l4-->Ala 23 Synthetic peptide corresponding to aa 4- 24 of SEQ ID NO: 15 with Ar 14->Ala and Ar 23->His 24 Synthetic peptide corresponding to aa 6- 24 of SEQ ID NO: 2 with Ar 14-+Ala and Ar 23-aHis Se uence of SEQ ID NO: 1 with Ar 109-->His (Nucleotide and amino acid) 26 Sequence of SEQ ID NO: 2 with Arg109->His (Amino acid only) 27 Synthetic peptide corresponding to aa 87 - 110 of SEQ ID NO: 2 28 Peptide of SEQ ID NO: 27 with Ser5->Ala 29 Peptide of SEQ ID NO: 27 with Ser12--->Ala Peptide of SEQ ID NO: 27 with Serl 8->Ala 31 Peptide of SEQ ID NO: 27 with Ar 14-iAla 32 Peptide of SEQ ID NO: 27 with Arg14---- >Ala , Ar 15-->Ala 33 Peptide corresponding to the 8 C-terminal amino acids of SEQ ID NO: 15 34 Peptide corresponding to the 8 C-terminal amino acids of SEQ ID NO: 27 Peptide corres ondin to the 8 C-terminal amino acids of SEQ ID NO: 18 36 Peptide corresponding to the 8 C-terminal amino acids of SEQ ID NO: 30 DETAILED DESCRIPTION OF THE INVENTION
Polypeptides and Extended Polypeptides of the invention Polypeptides of the Invention Polypeptides of the invention are up to 50 amino acid residues in length. For example, they may be up to 10 amino acids in length, up to 30 amino acids in length, e.g. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids in length, or up to 35, 40, 45 or 50 amino acids in length.
Preferably, they are from 15 to 30 amino acids in length, more preferably 20 to 28, most preferably 22, 23, 24 or 25 amino acids in length. Also preferred are polypeptides of 5 to 10 amino acids in length, i.e. 5, 6, 7, 8, 9 or 10 amino acids in length, especially those of 8 amino acids in length.
A polypeptide of the invention comprises a sequence of amino acids derived from the C-terminal E peptide of an MGF isoform of IGF-I. An MGF isoform is, as discussed above, one in which alternative splicing introduces into the mRNA an insert which lengthens and changes the reading frame of the C-terminal E peptide found at the C-terminus of IGF-I to create an Ec or Eb peptide. An MGF isoform will typically have at least 80%, preferably 85% or 90% sequence identity to one of the MGFs of SEQ
ID NOS: 2, 4, or 6. In human MGF (SEQ ID NOS: 1 and 2), the insert is 49 base pairs and the C-terminal E peptide is known as an Ec peptide (SEQ ID NO: 27), which is 24 amino acids in length. In rat and rabbit MGF (SEQ ID NOS: 3-6), the insert is 49 base pairs and the C-terminal E peptides are known as Eb peptides, which are 25 amino acids in length (SEQ ID NOS: 13 and 14). The sequence of the invention may be derived from any of these MGF C-terminal E peptides or from any other C-terminal E peptide from the MGF of any other species.
The sequence comprised in the polypeptide of the invention and derived from the C-terminal E peptide of an MGF isoform may be derived from said C-terminal E
peptide in any way, as long as the requirements for biological activity and stability (see below) are met. In particular, the sequence may be derived from the MGF C-terminal E peptide in the sense that it has exactly the sequence of the C-terminal E
peptide (e.g. SEQ ID NO: 13, 14, 27 or 34) and is merely not present within a full-length MGF molecule. It may also be derived from the MGF C-terminal E peptide in the sense that its sequence is altered (see "Modifications" below), again as long as the requirements for biological activity and stability (see below) are met.
Up to the maximum length of 50 amino acids, the polypeptide may also comprise native MGF sequence N-terminal to the sequence derived from the C-terminal E
peptide. Alternatively, any additional sequence may be non-MGF-derived, i.e.
it may be any sequence, again as long as the requirements for biological activity and stability (see below) are met.
The sequence derived from the C-terminal MGF E peptide may include at least 10, at least 15 or at least 20 amino acids, e.g. 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 amino acids in the case of the human C-terminal MGF Ec peptide or 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids in the case of the rat or rabbit C-terminal MGF Eb peptide. Alternatively, it may include up to 10 ainino acids, preferably 5 to 10 amino acids, ie 5, 6, 7, 8, 9 or 10 amino acids, especially 8 amino acids.
Polypeptides or extended polypeptides of the invention can be assembled together to form larger structures containing two or more polypeptide of the invention, e.g.
multiple copies of the same polypeptide or extended polypeptides of the invention or a mixture of different ones. Depending on the nature of the polypeptides and in particular whether they contain any L-D conversions (see below), these structures may be made as fusion proteins, normally by recombinant expression by standard techniques from coding DNA, or assembled synthetically, or expressed as fusion proteins and then subjected to appropriate chemical modifications.
-1~-Extended Polypeptides of the Invention An extended polypeptide of the invention comprises a polypeptide of the invention, extended by non-wild-type sequence. By this is meant that any extension sequence is non-MGF sequence in that, if the N-terminus or C-terminus of the polypeptide of the invention represents native MGF sequence, then that sequence may not simply be joined to any sequence that it adjoins in native MGF. Apart from that, an extension may have any sequence. Thus, the polypeptides of the invention may be extended at either or both of the C- and N- termini by an amino acid sequence of any length. For example, an extension may comprise up to 5, up to 10, up to 20, up to 50, or up to 100 or 200 or more amino acids. Typically, any such extension will be short, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids in length. An extension may contain, or even consist entirely of D-form amino acids (see below), e.g. to reduce exopeptidase attack. For example, a polypeptide may be extended by 1 to 5 D-form amino acids at one or both ends. For example, in some embodiments an additional Cysteine residue may be incorporated at the C-terminus.
Modifications A polypeptide or extended polypeptide of the invention may be modified in any manner that increases its stability compared to the unmodified E peptide that they comprise a sequence derived from. Stability may be increased in various ways.
For example, it is envisaged that modifications (e.g. PEGylation or other chemical modifications or L-D form ainino acid conversions) to the C- and/or N-termini of the protein will protect it against exopeptidase attack, as will cyclisation, and that internal modifications (e.g. substitution, deletion, insertion and internal L-D form conversion will protect it against cleavage by endopeptidases by disrupting their cleavage sites.
For example, it may be PEGylated, preferably at the N-terminus to the extent that the location of the PEGylation can be controlled, though PEGylation at other sites, such as the C-terminus and between the C- and N-termini is also contemplated.
PEGylation involves the covalent attachment of PEG to the polypeptide. Any suitable type of PEG, e.g. any suitable molecular weight, may be used as long as the resultant PEGylated polypeptide satisfies the requirements for biological activity and stability (see below).
Whether to achieve stabilisation or otherwise, polypeptide of the invention may also incorporate other chemical modifications as well as, or instead of, PEGylation. Such modifications include glycosylation, sulphation, amidation and acetylation. In particular, polypeptides may be acetylated at the N-terminus are preferred or amidated at the C-terminus or both. Alternatively or additionally, one or more hexanoic or amino-hexanoic acid moieties may be added, preferably one hexanoic or amino-hexanoic acid moiety, normally at the N-terminus.
In addition or alternatively, the polypeptide or extended polypeptide may include one or more D-form amino acids. In nature, amino acids are in the L-form.
Inserting D-form amino acids can improve stability. Typically, a few, e.g. 1, 2, 3, 4 or 5, D-form amino acids may be used. However, more can also be used, e.g. 5 to 10, 10 to 15, 15 to 20 or 20 or more as long as the resultant PEGylated polypeptide satisfies the requirements for biological activity and stability (see below). If those requirements are satisfied, the entire polypeptide may even be synthesised using D-form amino acids.
D-form amino acids may be used at any position in the polypeptide. In the human MGF C-terminal E peptide of SEQ ID NO: 27, it is preferred to replace one or both of the Arginines at positions 14 and 15 with D-form amino acids. Corresponding changes are also preferred in the rat and rabbit sequences of SEQ ID NOS: 13 and 14 (positions 14, 15 and 16, as the rat/rabbit sequences comprise three Arginines in succession whereas the human one has only two) and in the variant sequence of SEQ
ID NO: 15.
Polypeptides and Extended Polypeptides of the invention Polypeptides of the Invention Polypeptides of the invention are up to 50 amino acid residues in length. For example, they may be up to 10 amino acids in length, up to 30 amino acids in length, e.g. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids in length, or up to 35, 40, 45 or 50 amino acids in length.
Preferably, they are from 15 to 30 amino acids in length, more preferably 20 to 28, most preferably 22, 23, 24 or 25 amino acids in length. Also preferred are polypeptides of 5 to 10 amino acids in length, i.e. 5, 6, 7, 8, 9 or 10 amino acids in length, especially those of 8 amino acids in length.
A polypeptide of the invention comprises a sequence of amino acids derived from the C-terminal E peptide of an MGF isoform of IGF-I. An MGF isoform is, as discussed above, one in which alternative splicing introduces into the mRNA an insert which lengthens and changes the reading frame of the C-terminal E peptide found at the C-terminus of IGF-I to create an Ec or Eb peptide. An MGF isoform will typically have at least 80%, preferably 85% or 90% sequence identity to one of the MGFs of SEQ
ID NOS: 2, 4, or 6. In human MGF (SEQ ID NOS: 1 and 2), the insert is 49 base pairs and the C-terminal E peptide is known as an Ec peptide (SEQ ID NO: 27), which is 24 amino acids in length. In rat and rabbit MGF (SEQ ID NOS: 3-6), the insert is 49 base pairs and the C-terminal E peptides are known as Eb peptides, which are 25 amino acids in length (SEQ ID NOS: 13 and 14). The sequence of the invention may be derived from any of these MGF C-terminal E peptides or from any other C-terminal E peptide from the MGF of any other species.
The sequence comprised in the polypeptide of the invention and derived from the C-terminal E peptide of an MGF isoform may be derived from said C-terminal E
peptide in any way, as long as the requirements for biological activity and stability (see below) are met. In particular, the sequence may be derived from the MGF C-terminal E peptide in the sense that it has exactly the sequence of the C-terminal E
peptide (e.g. SEQ ID NO: 13, 14, 27 or 34) and is merely not present within a full-length MGF molecule. It may also be derived from the MGF C-terminal E peptide in the sense that its sequence is altered (see "Modifications" below), again as long as the requirements for biological activity and stability (see below) are met.
Up to the maximum length of 50 amino acids, the polypeptide may also comprise native MGF sequence N-terminal to the sequence derived from the C-terminal E
peptide. Alternatively, any additional sequence may be non-MGF-derived, i.e.
it may be any sequence, again as long as the requirements for biological activity and stability (see below) are met.
The sequence derived from the C-terminal MGF E peptide may include at least 10, at least 15 or at least 20 amino acids, e.g. 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 amino acids in the case of the human C-terminal MGF Ec peptide or 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids in the case of the rat or rabbit C-terminal MGF Eb peptide. Alternatively, it may include up to 10 ainino acids, preferably 5 to 10 amino acids, ie 5, 6, 7, 8, 9 or 10 amino acids, especially 8 amino acids.
Polypeptides or extended polypeptides of the invention can be assembled together to form larger structures containing two or more polypeptide of the invention, e.g.
multiple copies of the same polypeptide or extended polypeptides of the invention or a mixture of different ones. Depending on the nature of the polypeptides and in particular whether they contain any L-D conversions (see below), these structures may be made as fusion proteins, normally by recombinant expression by standard techniques from coding DNA, or assembled synthetically, or expressed as fusion proteins and then subjected to appropriate chemical modifications.
-1~-Extended Polypeptides of the Invention An extended polypeptide of the invention comprises a polypeptide of the invention, extended by non-wild-type sequence. By this is meant that any extension sequence is non-MGF sequence in that, if the N-terminus or C-terminus of the polypeptide of the invention represents native MGF sequence, then that sequence may not simply be joined to any sequence that it adjoins in native MGF. Apart from that, an extension may have any sequence. Thus, the polypeptides of the invention may be extended at either or both of the C- and N- termini by an amino acid sequence of any length. For example, an extension may comprise up to 5, up to 10, up to 20, up to 50, or up to 100 or 200 or more amino acids. Typically, any such extension will be short, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids in length. An extension may contain, or even consist entirely of D-form amino acids (see below), e.g. to reduce exopeptidase attack. For example, a polypeptide may be extended by 1 to 5 D-form amino acids at one or both ends. For example, in some embodiments an additional Cysteine residue may be incorporated at the C-terminus.
Modifications A polypeptide or extended polypeptide of the invention may be modified in any manner that increases its stability compared to the unmodified E peptide that they comprise a sequence derived from. Stability may be increased in various ways.
For example, it is envisaged that modifications (e.g. PEGylation or other chemical modifications or L-D form ainino acid conversions) to the C- and/or N-termini of the protein will protect it against exopeptidase attack, as will cyclisation, and that internal modifications (e.g. substitution, deletion, insertion and internal L-D form conversion will protect it against cleavage by endopeptidases by disrupting their cleavage sites.
For example, it may be PEGylated, preferably at the N-terminus to the extent that the location of the PEGylation can be controlled, though PEGylation at other sites, such as the C-terminus and between the C- and N-termini is also contemplated.
PEGylation involves the covalent attachment of PEG to the polypeptide. Any suitable type of PEG, e.g. any suitable molecular weight, may be used as long as the resultant PEGylated polypeptide satisfies the requirements for biological activity and stability (see below).
Whether to achieve stabilisation or otherwise, polypeptide of the invention may also incorporate other chemical modifications as well as, or instead of, PEGylation. Such modifications include glycosylation, sulphation, amidation and acetylation. In particular, polypeptides may be acetylated at the N-terminus are preferred or amidated at the C-terminus or both. Alternatively or additionally, one or more hexanoic or amino-hexanoic acid moieties may be added, preferably one hexanoic or amino-hexanoic acid moiety, normally at the N-terminus.
In addition or alternatively, the polypeptide or extended polypeptide may include one or more D-form amino acids. In nature, amino acids are in the L-form.
Inserting D-form amino acids can improve stability. Typically, a few, e.g. 1, 2, 3, 4 or 5, D-form amino acids may be used. However, more can also be used, e.g. 5 to 10, 10 to 15, 15 to 20 or 20 or more as long as the resultant PEGylated polypeptide satisfies the requirements for biological activity and stability (see below). If those requirements are satisfied, the entire polypeptide may even be synthesised using D-form amino acids.
D-form amino acids may be used at any position in the polypeptide. In the human MGF C-terminal E peptide of SEQ ID NO: 27, it is preferred to replace one or both of the Arginines at positions 14 and 15 with D-form amino acids. Corresponding changes are also preferred in the rat and rabbit sequences of SEQ ID NOS: 13 and 14 (positions 14, 15 and 16, as the rat/rabbit sequences comprise three Arginines in succession whereas the human one has only two) and in the variant sequence of SEQ
ID NO: 15.
Stereochemical and/or directional peptide isomers may also be used. For example, Retro (RE) peptides may be used, in which the sequence of the invention is assembled from L-amino acids but in reversed order. Alternatively, Retro-inverso (RI) peptides may be used, in which the sequence is reversed and synthesised from D-amino acids.
Additionally or alternatively, D-form amino acids may be included at one end or the other, or both, of the polypeptide. It is envisaged that this will help to protect against exopeptidase attack. This may be achieved by converting the terminal amino acids, e.g. the terminal 1, 2, 3, 4 or 5 amino acids at one or both ends, of the sequence derived from the MGF C-terminal E peptide to D-form. Alternatively or additionally, it may be achieved by adding 1, 2, 3, 4 or 5 further D-form amino acids at one or both ends of the polypeptide. Such further amino acids may or may not correspond to those that adjoin the sequence derived from the MGF C-terminal E peptide in native MGF. Such further amino acids may be any amino acids. One possible amino acid for addition in D-form in this way is Arginine. For example, a D-form Arginine residue may be added at the N-terminus, the C-terminus or both.
In one embodiment, the sequence of the native human MGF C-terminal E peptide of SEQ ID NO: 27 is retained but the Arginines at positions 14 and 15 of SEQ ID
NO:
27are converted to the D-form and N-terminal PEGylation is provided. C-terminal amidation may also be provided.
In another embodiment, the sequence of the human MGF C-terminal E peptide variant of SEQ ID NO: 15 is retained but Arginines 14 and 15 in SEQ ID NO: 15 are converted to the D-form and N-terminal PEGylation is provided.
In some further embodiments, the sequence of the 8 C-terminal amino acids from SEQ ID NO: 15 or 27, ie the sequence of SEQ ID NO: 33 or 34, is used and N-terminal PEGylation is provided or a hexanoic or amino-hexanoic acid moiety is added at the C-terminus. C-terminal amidation may also be provided.
Additionally or alternatively, D-form amino acids may be included at one end or the other, or both, of the polypeptide. It is envisaged that this will help to protect against exopeptidase attack. This may be achieved by converting the terminal amino acids, e.g. the terminal 1, 2, 3, 4 or 5 amino acids at one or both ends, of the sequence derived from the MGF C-terminal E peptide to D-form. Alternatively or additionally, it may be achieved by adding 1, 2, 3, 4 or 5 further D-form amino acids at one or both ends of the polypeptide. Such further amino acids may or may not correspond to those that adjoin the sequence derived from the MGF C-terminal E peptide in native MGF. Such further amino acids may be any amino acids. One possible amino acid for addition in D-form in this way is Arginine. For example, a D-form Arginine residue may be added at the N-terminus, the C-terminus or both.
In one embodiment, the sequence of the native human MGF C-terminal E peptide of SEQ ID NO: 27 is retained but the Arginines at positions 14 and 15 of SEQ ID
NO:
27are converted to the D-form and N-terminal PEGylation is provided. C-terminal amidation may also be provided.
In another embodiment, the sequence of the human MGF C-terminal E peptide variant of SEQ ID NO: 15 is retained but Arginines 14 and 15 in SEQ ID NO: 15 are converted to the D-form and N-terminal PEGylation is provided.
In some further embodiments, the sequence of the 8 C-terminal amino acids from SEQ ID NO: 15 or 27, ie the sequence of SEQ ID NO: 33 or 34, is used and N-terminal PEGylation is provided or a hexanoic or amino-hexanoic acid moiety is added at the C-terminus. C-terminal amidation may also be provided.
Alternatively or additionally, polypeptides of the invention may also incorporate other modifications, for example truncation, insertion, internal deletion or substitution.
As to truncation, it has has also been found that shorter peptides, based on the C-terminal eight amino acids of SEQ ID NO: 15 are active. However, the results in Example 5 below suggest that the activity of longer peptides related to the MGF C-terminus can be quite sensitive to truncation, particularly of the N-terminus of the peptides. At the N-terminus of the peptide of SEQ ID NO: 15, truncation by 3 amino acids led to loss of activity in the muscle cell model used in Example 5. At the C-terminus of the peptide of SEQ ID NO: 15, truncation by four amino acids led to loss of activity in the muscle cell model, though truncation by two did not. In the case of the native human, rat and rabbit E peptide sequences, and in the variant one of SEQ
ID NO: 15 and other peptides of the invention that have lengths comparable to those of the native peptides (eg 18 or more amino acids), it is therefore envisaged that it will be possible to truncate by 1, 2 or 3 amino acids at the C-terminus without loss of activity. It is also envisaged that it will be possible to truncate by 1 or 2 amino acids at the N-terminus without loss of activity.
As to insertion, short stretches of amino acids may be inserted into the sequence derived from that of human C-terminal MGF E peptide, as long as the resultant polypeptide satisfies the requirements for biological activity and stability (see below) and comprises less than 50 amino acids. Each insertion may comprise, for example 1, 2, 3, 4 or 5 amino acids. There may be one or more, e.g. 2, 3, 4 or 5 such insertions.
As to internal deletion, short stretches of amino acids may be deleted from the internal sequence derived from that of human C-terminal MGF E peptide, as long as the resultant polypeptide satisfies the requirements for biological activity and stability (see below). One or more such deletions, e.g. 1, 2, 3, 4 or 5 deletions, may be made, up to a total of, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids.
As to truncation, it has has also been found that shorter peptides, based on the C-terminal eight amino acids of SEQ ID NO: 15 are active. However, the results in Example 5 below suggest that the activity of longer peptides related to the MGF C-terminus can be quite sensitive to truncation, particularly of the N-terminus of the peptides. At the N-terminus of the peptide of SEQ ID NO: 15, truncation by 3 amino acids led to loss of activity in the muscle cell model used in Example 5. At the C-terminus of the peptide of SEQ ID NO: 15, truncation by four amino acids led to loss of activity in the muscle cell model, though truncation by two did not. In the case of the native human, rat and rabbit E peptide sequences, and in the variant one of SEQ
ID NO: 15 and other peptides of the invention that have lengths comparable to those of the native peptides (eg 18 or more amino acids), it is therefore envisaged that it will be possible to truncate by 1, 2 or 3 amino acids at the C-terminus without loss of activity. It is also envisaged that it will be possible to truncate by 1 or 2 amino acids at the N-terminus without loss of activity.
As to insertion, short stretches of amino acids may be inserted into the sequence derived from that of human C-terminal MGF E peptide, as long as the resultant polypeptide satisfies the requirements for biological activity and stability (see below) and comprises less than 50 amino acids. Each insertion may comprise, for example 1, 2, 3, 4 or 5 amino acids. There may be one or more, e.g. 2, 3, 4 or 5 such insertions.
As to internal deletion, short stretches of amino acids may be deleted from the internal sequence derived from that of human C-terminal MGF E peptide, as long as the resultant polypeptide satisfies the requirements for biological activity and stability (see below). One or more such deletions, e.g. 1, 2, 3, 4 or 5 deletions, may be made, up to a total of, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids.
As to substitution, any amino acids in the polypeptide may in principle be substituted by any other amino acid, as, as long as the resultant polypeptide satisfies the requirements for biological activity and stability (see below). One or more such substitutions may be made, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15 or up to 20 substitutions in total. Preferably, in the sequence derived from the MGF C-terminal E
peptide, no more than 10 substitutions will be made, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 substitutions. Preferably, in the in the sequence derived from the MGF C-terminal E
peptide, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the amino acid residues will be the same as in the native MGF C-terminal E peptide from which the sequence is derived. In one preferred approach, residues at one or both ends of the polypeptide (terminal residues) are substituted. It is envisaged that this will protect against exopeptidase attack. Thus, for example, it may be preferred to substitute residues in the N-terminal and for C-terminal positions, or in the positions immediated adjacent to the terminal ones, or up to 3, 4 or 5 positions from one or both ends.
Substitutions may increase stability or biological activity. For example, the results discussed in Example 5 and Figure 2 below indicate that substitution at one or more of positions 5, 12, 14 and 18 of the peptide of SEQ ID NO: 15 can increase stability.
The same results show that substitutions at positions 12, 14 and 18 can also increase biological activity. Substitutions in positions 5, 12, 14 and 18 of the peptides of SEQ
ID NOS: 27 and 15, and in position 2 of SEQ ID NOS 33 and 34 (which corresponds to position 18 of SEQ ID NOS: a5 and 27), are therefore preferred.
Corresponding substitutions into positions 5, 12, 15 and 19 of rat/rabbit MGF C-terminal E
peptides of SEQ ID NOS: 13 and 14 are also preferred.
Whether in positions 5, 12, 14 or 18 of SEQ ID NOS: 27 or 15, position 2 of SEQ ID
NOS: 33 and 34, positions 5, 12, 15 and 19 of SEQ ID NOS: 13 and 14, or elsewhere, substitution of the native amino acid with Alanine is one preferred option, as shown in Example 5 and Figure 2. However, other amino acids may equally be used.
Alternatively or additionally, the polypeptide may include substitutions that do not have a significant effect on stability or biological activity. These will typically be conservative substitutions. Conservative substitutions may be made, for example according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.
ALIPHATIC Non-polar G A P
ILV
Polar-uncharged C S T M
NQ
Polar-charged D E
KR
AROMATIC H F W Y
Typically, amino acid sequence modifications such as L-D conversions, substitutions, insertions and deletions, in the polypeptides of the invention will be found in the sequence of amino acids that is derived from the MGF C-terminal E
peptide. However, where the polypeptide contains additional MGF sequence, they may alternatively or additionally be found in that additional sequence. For example, if a polypeptide of the invention contains further MGF sequence that is N-terminal to the sequence of the E peptide (e.g. SEQ ID NO: 13, 14 or 27) in native MGF, modifications may be found in that sequence.
Alternatively or additionally, stability can also be increased by cyclisation of the polypeptides or extended polypeptides of the invention. It is envisaged that this will protect against exopeptidase attack.
peptide, no more than 10 substitutions will be made, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 substitutions. Preferably, in the in the sequence derived from the MGF C-terminal E
peptide, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the amino acid residues will be the same as in the native MGF C-terminal E peptide from which the sequence is derived. In one preferred approach, residues at one or both ends of the polypeptide (terminal residues) are substituted. It is envisaged that this will protect against exopeptidase attack. Thus, for example, it may be preferred to substitute residues in the N-terminal and for C-terminal positions, or in the positions immediated adjacent to the terminal ones, or up to 3, 4 or 5 positions from one or both ends.
Substitutions may increase stability or biological activity. For example, the results discussed in Example 5 and Figure 2 below indicate that substitution at one or more of positions 5, 12, 14 and 18 of the peptide of SEQ ID NO: 15 can increase stability.
The same results show that substitutions at positions 12, 14 and 18 can also increase biological activity. Substitutions in positions 5, 12, 14 and 18 of the peptides of SEQ
ID NOS: 27 and 15, and in position 2 of SEQ ID NOS 33 and 34 (which corresponds to position 18 of SEQ ID NOS: a5 and 27), are therefore preferred.
Corresponding substitutions into positions 5, 12, 15 and 19 of rat/rabbit MGF C-terminal E
peptides of SEQ ID NOS: 13 and 14 are also preferred.
Whether in positions 5, 12, 14 or 18 of SEQ ID NOS: 27 or 15, position 2 of SEQ ID
NOS: 33 and 34, positions 5, 12, 15 and 19 of SEQ ID NOS: 13 and 14, or elsewhere, substitution of the native amino acid with Alanine is one preferred option, as shown in Example 5 and Figure 2. However, other amino acids may equally be used.
Alternatively or additionally, the polypeptide may include substitutions that do not have a significant effect on stability or biological activity. These will typically be conservative substitutions. Conservative substitutions may be made, for example according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.
ALIPHATIC Non-polar G A P
ILV
Polar-uncharged C S T M
NQ
Polar-charged D E
KR
AROMATIC H F W Y
Typically, amino acid sequence modifications such as L-D conversions, substitutions, insertions and deletions, in the polypeptides of the invention will be found in the sequence of amino acids that is derived from the MGF C-terminal E
peptide. However, where the polypeptide contains additional MGF sequence, they may alternatively or additionally be found in that additional sequence. For example, if a polypeptide of the invention contains further MGF sequence that is N-terminal to the sequence of the E peptide (e.g. SEQ ID NO: 13, 14 or 27) in native MGF, modifications may be found in that sequence.
Alternatively or additionally, stability can also be increased by cyclisation of the polypeptides or extended polypeptides of the invention. It is envisaged that this will protect against exopeptidase attack.
Preferred polypeptides of the invention include the following.
(i) A peptide which is 24 amino acids in length and has the sequence of SEQ ID
NO: 15 but is stabilised by converting the two Arginines of SEQ ID NO 15 (positions 14 and 15) from L-form to D-form and by N-terminal PEGylation.
(ii) A peptide as in (i) above but lacking PEGylation, ie having the sequence of SEQ ID NO: 15 but stabilised by converting the two Arginines of SEQ ID
NO 15 (positions 14 and 15) from L-form to D-form.
(iii) The peptides described in Example 5 and Figure 2 as Peptides 2, 3, 4 and (SEQ ID NOS: 16 to 19).
(iv) The peptide described in Example 5 and Figure 2 as Short peptide 1(SEQ ID
NO: 21), which has the sequence of SEQ ID NO: 19 (in which Arginine at position 14 is replaced by Alanine) but is truncated by 2 amino acids at the C-terminus.
(v) A peptide corresponding to that of (i) above but based on the native huinan C-terminal peptide of SEQ ID NO: 27, which contains Arginine rather than Histidine in the penultimate position, ie a peptide having the sequence of SEQ ID NO: 27 but stabilised by converting the two Arginines at positions 14 and 15 of SEQ ID NO 27 from L-form to D-form and by N-terminal PEGylation.
(vi) A peptide as in (v) above but lacking PEGylation, ie having the sequence of of SEQ ID NO: 27 but stabilised by converting the two Arginines at positions 14 and 15 of SEQ ID NO 27 from L-form to D-form.
(vii) Peptides corresponding to those of (iii) above but based on the native human C-terminal peptide of SEQ ID NO: 27, which contains Arginine rather than Histidine in the penultimate position; shown herein as SEQ ID NOS: 28 to 31.
(viii) Peptides of any of SEQ ID NOS 33-36 with N-terminal PEGylation or the attachment of an N-terminal hexanoic or amino-hexanoic acid moiety.
(ix) Any of the peptides of (i), (ii), (iii), (iv), (v), (vi), (vii), or (vii) above with C-terminal amidation, notably the peptides of (ii) and (vi) above with C-terminal amidation, i.e. peptides having the sequences of SEQ ID NOS: 15 and 27, with conversion of L-Arginine to D-Arginine at positions 14 and 15 and C-terminal amidation, but lacking PEGylation.
(x) Any of the peptides of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) or (ix) above with an additional Cysteine residue at the C-terminus.
(xi) Any of the peptides of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) or (ix) above with an additional D-form Arginine residue at the N-terminus.
Modifications according to the invention may confer additional advantages as well as increased stability. For example, they may confer increased therapeutic activity or be advantageous from an immunological standpoint (eg via reduced immunogenicity).
This applies in particular to modifications that involve L-D conversion and/or stereochemical and/or directional isomerism (see above).
Biological Activity Polypeptides and extended polypeptides of the invention have biological activity.
This activity may be selected from the following.
The ability to increase muscle strength in dystrophic and/or non-dystrophic skeletal muscle in mice, humans or other mammals (cf. Example 2 below). Preferably, a polypeptide or extended peptide of the invention will be able to increase muscle strength (e.g. as measured by maximum attainable tetanic force) by at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 50%, at least 75% or at least 100% in dystrophic and/or non-dystrophic muscle.
Cardioprotective ability in sheep, mice, humans or other mammals (cf. Example below). Preferably, a polypeptide or extended polypeptide of the invention will have the ability to prevent or limit myocardial damage in an infarcted or mechanically overloaded heart. This can be measured by pressure/volume loops or by reference to the ability to increase ejection fraction compared to an infracted heart to which no polypeptide or extended polypeptide of the invention is administered.
Preferably a polypeptide or extended polypeptide of the invention will have the ability to increase ejection fraction by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9% or by at least 10% or more.
Neuroprotective ability in vitro or in vivo in mice, gerbils, humans or other mammals (cf. Example 4 below). Preferably, a polypeptide or extended polypeptide of the invention will have the ability to reduce cell death in rat organotypic hippocampal cultures and/or other similar in vitro models. Preferably, following exposure to TBH
or other another agent that induces oxidative stress or causes damage in other ways, a polypeptide or extended polypeptide of the invention will have the ability to reduce cell death in such models by at least 20%, at least 25%, at least 30%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or more. Alternatively or additionally, polypeptides or extended polypeptides of the invention may have neuroprotective ability Furthermore, the polypeptides or extended polypeptides of the invention may have one or more biological properties characteristic of full-length MGF (e.g. of SEQ ID
NOS: 2, 4 or 6). For example, polypeptides or extended polypeptides of the invention may have the functional properties of MGF identified in W097/33997. In particular, they may have the ability to induce growth of skeletal muscle tissue.
Similarly, as discussed herein, they may have the ability to upregulate protein synthesis needed for skeletal muscle repair and/or to activate satellite (stem) cells in skeletal muscle.
In this regard, one method of assessing biological activity is the Alamar Blue method as discussed in Example 5.2.2. This involves contacting a polypeptide with mononucleated myoblast cells and assessing the extent to which it causes them to proliferate. This can be scored in any suitable way, e.g. on a scale of 0 to 3 as discussed in the Examples. Activity may also be measured via cyclins, such as cyclin 1D, which are early markers of cell division. Activity may also be measured via the use of bromodeoxy uridine (BrdU). BrdU will substitute itself for thymidine during DNA replication and hence can be used to identify cells whose DNA is undergoing replication and to measure how much replication and cell division is taking place.
Alternatively or additionally, polypeptides or extended polypeptides of the invention may have the neurological properties previously identified in WO01/136483.
Thus, they may have the capacity to effect motoneurone rescue. In particular, they may be able to reduce motoneurone loss following nerve avulsion by up to 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100% in a treated subject compared to an equivalent situation in a non-treated subject. Reduction of motoneurone loss by 70% or more, or 80%
more (i.e. to 30% or less or 20% or less) is preferred. The degree of rescue may be calculated using any suitable technique, e.g. a known technique such as Stereology.
As a specific test, the techniques used in WO01/136483, which rely on measuring motoneurone rescue in response to facial nerve avulsion in rats, may be used.
Alternatively or additionally, polypeptides or extended polypeptides of the invention may have the properties identified in W003/060882, which is to say the ability to prevent or limit myocardial damage following ischemia or mechanical overload by preventing cell death, or apoptosis, of the muscle cells of the myocardium.
Preferably, a polypeptide or extended polypeptide of the invention will have the ability to completely prevent apoptosis in the area of cardiac muscle to which it is applied. However, apoptosis may also be only partially prevented, i.e.
limited.
Damage is limited if any reduction of damage is achieved compared to that which would have taken place without a treatment of the invention, e.g. if damage is reduced by 1% or more, 5% or more, 10% or more, 20% or more, 3 0% or more, 50%
or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more, or 99% or more, as measured by the number or proportion of cells which die, or by the size of the area of muscle that loses function, or by the overall ability of the heart to pump blood.
In particular, reduction of damage can be estimated in vivo by determining cardiac output, ejection fraction etc using minimally invasive methods. Markers such as creatine kinase and troponin T in the serum can also be assayed. These are the parameters used in clinical, situations to determine the extent damage to the cardiac muscle following injury.
The ability to prevent apoptosis may be measured by any suitable technique.
For example, with reference to Example 4 and Figures 3 and 6, it may be measured by the ability to prevent apoptosis in a cardiac muscle cell or cardiac-like cell line, as indicated by DNA fragmentation. The ability to prevent apoptosis, as indicated by DNA fragmentation, may be tested by treating the cells with sorbitol or another agent that places the cells under osmotic stress for up to, e.g. 1, 2, 4, 6, 12, 24 or 48 hours, preferably 12 to 24 hours, more preferably 24 hours, and investigating whether the pattern of fragmentation associated with apoptosis can be observed. An MGF
polypeptide of the invention expressed in this way will typically reduce, preferably eliminate, DNA fragmentation under these conditions, as compared to an untreated cell) after 6, 12 or 24 hours' sorbitol treatment.
The absence of expression, or low expression, of genes that act as markers for apoptosis can also act as an indication of prevention of apoptosis. One suitable marker is the Bax gene. Similarly, increased expression of anti-apoptotic markers in MGF-transfected cells under apoptotic conditions can be taken as a sign that the polypeptide of the invention is preventing apoptosis. One suitable anti-apoptotic marker gene is Bc12. The ability to prevent apoptosis may also be measured by reference to an MGF polypeptide's ability to prevent a reduction in cell number in myocyte cells in vitro.
Another preferred property of polypeptides and extended polypeptides of the invention is the ability to induce a hypertrophic phenotype in cardiac muscle cells.
In particular, this may be tested by assessing the ability to induce a hypertrophic phenotype in primary cardiac myocyte cultures in vitro. A preferred method for determining this is to test for an increase in expression of ANF (Atrial Natriuretic Factor) and/or bMHC (Beta Myosin Heavy Chain). ANF is an embryonic marker gene that is upregulated in hypertrophic conditions, bMHC is an important contractile protein in muscle.
Stability of Polypeptides and Extended Polypeptides of the Invention Polypeptides and extended polypeptides of the invention have increased stability compared to the native C-terminal MGF E peptides that they contain sequences derived from. Such comparisons are made between the polypeptide or extended polypeptide of the invention and the native C-terminal MGF E peptide in its isolated, unmodified form (e.g. an unmodified form of SEQ ID NO: 13, 14, 27, or 34, separated from the remainder of the MGF molecule and in isolated form as a 24-mer (SEQ ID NO: 27), 25-mer (SEQ ID NOS 13/14) or 8-mer (SEQ ID NO 34) ).
Comparisons may also be made with the Histidine-containing sequences of SEQ ID
NO: 15 and 33. Stability may be increased by any degree via the modifications discussed herein.
Stability may be assessed in terms of half-life in human plasma or by any other suitable technique. In particular, stability can be measured by assessing peptides' susceptibility to proteolytic cleavage in fresh human plasma according to the technique of Example 5.1 below, in which the plasma was stored until used at -70 C, l0 g of peptide was added to 2m1 of plasma, plus 7 ml of PBS and the mixture was incubated at 37 C for different time intervals. Western blotting was then used to detect each peptide over those time intervals. (In Figure 7: A= 0 minutes; B=
minutes; C = 2 hours; D = 24 hours. The results for the peptide with L-D
conversion and N-terminal PEGylation are shown on the right; those for the peptide lacking the L to D form conversions and N-terminal PEGylation are on the left.) Relatively little of the peptide lacking L-D conversion and PEGylation could be detected after minutes, very little after 2 hours and none or almost none after 24 hours. In contrast, the peptide with L-D conversion and PEGylation could be detected in much greater abundance and 2 hours and 24 hours.
Other measures of stability can be based on determining the loss of biological activity over time. This can be done by any suitable method, e.g. via an in vitro assay for any of the measures of biological activity discussed herein.
Quantitatively, in relative terms, preferred polypeptides or extended polypeptides of the invention may have half-lives that are increased by at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, at least 80%, at least 100%, at least 200% or at least 500% or more compared to the corresponding unmodified MGF C-terminal E
peptide.
Quantitatively, in absolute terms, preferred polypeptides or extended polypeptides of the invention may have half-lives of at least 1 hour, at least 2 hours, at least 4 hours, at least 8 hours, at last 12 hours, at least 24 hours or at least 48 hours or more.
Alternatively, qualitative or semi-quantitative measurements of stability may be used, as in Example 5 and Figure 2, for example by scoring the stability of polypeptides or extended polypeptides on a scale from 0 to 3. On that scale, the polypeptide of SEQ ID NO: 15 scored 1. Certain other modified polypeptides of the invention scored 2 or 3. A polypeptide or extended polypeptide of the invention will generally score more highly on such a scale than the corresponding native MGF
C-terminal E peptide.
Further Peptides of the Invention Whilst many of the peptides of the invention will be stabilised, as discussed above, it may under certain circumstances be possible to make use of unstabilised polypeptides, including the native polypeptides of SEQ ID NOS: 13, 14 27 and 34 or the histidine-containing variant of SEQ ID NO: 15 and 33. In the treatment of neurological and cardiac disorders according to the invention, it may be desirable for the polypeptide or extended polypeptide of the invention to be degraded relatively rapidly, i.e. to exert its effect for a relatively short period of time.
Therefore, stabilisation will not necessarily be required in the context of such treatments.
Where stabilisation is not required, it is preferred to use the native polypeptides of SEQ ID NOS: 13, 14, 27 and 34 or the Histidine-containing variant of SEQ ID
NO:
15 or 33 without stabilising modifications. However, modified polypeptides may also be used. Any of the modifications discussed herein may be applied except that, in this aspect, it is not required that those modifications result in increased stability.
Treatments According to the Invention Polypeptides and extended polypeptides of the invention can be used to treat a number of conditions. Broadly, these break down into three areas: disorders of skeletal muscle, disorders of cardiac muscle and neurological disorders.
However, because nerve and muscle function are inter-dependent, there may be some overlap between these categories, e.g. in the area of neuromuscular disorders.
Neurological disorders may generally be divided into two categories, neurogenic disorders where the fault lies in the nervous system itself and myogenic or muscle-related neurological disorders. Both can be treated according to the invention.
(i) A peptide which is 24 amino acids in length and has the sequence of SEQ ID
NO: 15 but is stabilised by converting the two Arginines of SEQ ID NO 15 (positions 14 and 15) from L-form to D-form and by N-terminal PEGylation.
(ii) A peptide as in (i) above but lacking PEGylation, ie having the sequence of SEQ ID NO: 15 but stabilised by converting the two Arginines of SEQ ID
NO 15 (positions 14 and 15) from L-form to D-form.
(iii) The peptides described in Example 5 and Figure 2 as Peptides 2, 3, 4 and (SEQ ID NOS: 16 to 19).
(iv) The peptide described in Example 5 and Figure 2 as Short peptide 1(SEQ ID
NO: 21), which has the sequence of SEQ ID NO: 19 (in which Arginine at position 14 is replaced by Alanine) but is truncated by 2 amino acids at the C-terminus.
(v) A peptide corresponding to that of (i) above but based on the native huinan C-terminal peptide of SEQ ID NO: 27, which contains Arginine rather than Histidine in the penultimate position, ie a peptide having the sequence of SEQ ID NO: 27 but stabilised by converting the two Arginines at positions 14 and 15 of SEQ ID NO 27 from L-form to D-form and by N-terminal PEGylation.
(vi) A peptide as in (v) above but lacking PEGylation, ie having the sequence of of SEQ ID NO: 27 but stabilised by converting the two Arginines at positions 14 and 15 of SEQ ID NO 27 from L-form to D-form.
(vii) Peptides corresponding to those of (iii) above but based on the native human C-terminal peptide of SEQ ID NO: 27, which contains Arginine rather than Histidine in the penultimate position; shown herein as SEQ ID NOS: 28 to 31.
(viii) Peptides of any of SEQ ID NOS 33-36 with N-terminal PEGylation or the attachment of an N-terminal hexanoic or amino-hexanoic acid moiety.
(ix) Any of the peptides of (i), (ii), (iii), (iv), (v), (vi), (vii), or (vii) above with C-terminal amidation, notably the peptides of (ii) and (vi) above with C-terminal amidation, i.e. peptides having the sequences of SEQ ID NOS: 15 and 27, with conversion of L-Arginine to D-Arginine at positions 14 and 15 and C-terminal amidation, but lacking PEGylation.
(x) Any of the peptides of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) or (ix) above with an additional Cysteine residue at the C-terminus.
(xi) Any of the peptides of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii) or (ix) above with an additional D-form Arginine residue at the N-terminus.
Modifications according to the invention may confer additional advantages as well as increased stability. For example, they may confer increased therapeutic activity or be advantageous from an immunological standpoint (eg via reduced immunogenicity).
This applies in particular to modifications that involve L-D conversion and/or stereochemical and/or directional isomerism (see above).
Biological Activity Polypeptides and extended polypeptides of the invention have biological activity.
This activity may be selected from the following.
The ability to increase muscle strength in dystrophic and/or non-dystrophic skeletal muscle in mice, humans or other mammals (cf. Example 2 below). Preferably, a polypeptide or extended peptide of the invention will be able to increase muscle strength (e.g. as measured by maximum attainable tetanic force) by at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 50%, at least 75% or at least 100% in dystrophic and/or non-dystrophic muscle.
Cardioprotective ability in sheep, mice, humans or other mammals (cf. Example below). Preferably, a polypeptide or extended polypeptide of the invention will have the ability to prevent or limit myocardial damage in an infarcted or mechanically overloaded heart. This can be measured by pressure/volume loops or by reference to the ability to increase ejection fraction compared to an infracted heart to which no polypeptide or extended polypeptide of the invention is administered.
Preferably a polypeptide or extended polypeptide of the invention will have the ability to increase ejection fraction by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9% or by at least 10% or more.
Neuroprotective ability in vitro or in vivo in mice, gerbils, humans or other mammals (cf. Example 4 below). Preferably, a polypeptide or extended polypeptide of the invention will have the ability to reduce cell death in rat organotypic hippocampal cultures and/or other similar in vitro models. Preferably, following exposure to TBH
or other another agent that induces oxidative stress or causes damage in other ways, a polypeptide or extended polypeptide of the invention will have the ability to reduce cell death in such models by at least 20%, at least 25%, at least 30%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% or more. Alternatively or additionally, polypeptides or extended polypeptides of the invention may have neuroprotective ability Furthermore, the polypeptides or extended polypeptides of the invention may have one or more biological properties characteristic of full-length MGF (e.g. of SEQ ID
NOS: 2, 4 or 6). For example, polypeptides or extended polypeptides of the invention may have the functional properties of MGF identified in W097/33997. In particular, they may have the ability to induce growth of skeletal muscle tissue.
Similarly, as discussed herein, they may have the ability to upregulate protein synthesis needed for skeletal muscle repair and/or to activate satellite (stem) cells in skeletal muscle.
In this regard, one method of assessing biological activity is the Alamar Blue method as discussed in Example 5.2.2. This involves contacting a polypeptide with mononucleated myoblast cells and assessing the extent to which it causes them to proliferate. This can be scored in any suitable way, e.g. on a scale of 0 to 3 as discussed in the Examples. Activity may also be measured via cyclins, such as cyclin 1D, which are early markers of cell division. Activity may also be measured via the use of bromodeoxy uridine (BrdU). BrdU will substitute itself for thymidine during DNA replication and hence can be used to identify cells whose DNA is undergoing replication and to measure how much replication and cell division is taking place.
Alternatively or additionally, polypeptides or extended polypeptides of the invention may have the neurological properties previously identified in WO01/136483.
Thus, they may have the capacity to effect motoneurone rescue. In particular, they may be able to reduce motoneurone loss following nerve avulsion by up to 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100% in a treated subject compared to an equivalent situation in a non-treated subject. Reduction of motoneurone loss by 70% or more, or 80%
more (i.e. to 30% or less or 20% or less) is preferred. The degree of rescue may be calculated using any suitable technique, e.g. a known technique such as Stereology.
As a specific test, the techniques used in WO01/136483, which rely on measuring motoneurone rescue in response to facial nerve avulsion in rats, may be used.
Alternatively or additionally, polypeptides or extended polypeptides of the invention may have the properties identified in W003/060882, which is to say the ability to prevent or limit myocardial damage following ischemia or mechanical overload by preventing cell death, or apoptosis, of the muscle cells of the myocardium.
Preferably, a polypeptide or extended polypeptide of the invention will have the ability to completely prevent apoptosis in the area of cardiac muscle to which it is applied. However, apoptosis may also be only partially prevented, i.e.
limited.
Damage is limited if any reduction of damage is achieved compared to that which would have taken place without a treatment of the invention, e.g. if damage is reduced by 1% or more, 5% or more, 10% or more, 20% or more, 3 0% or more, 50%
or more, 70% or more, 80% or more, 90% or more, 95% or more, 98% or more, or 99% or more, as measured by the number or proportion of cells which die, or by the size of the area of muscle that loses function, or by the overall ability of the heart to pump blood.
In particular, reduction of damage can be estimated in vivo by determining cardiac output, ejection fraction etc using minimally invasive methods. Markers such as creatine kinase and troponin T in the serum can also be assayed. These are the parameters used in clinical, situations to determine the extent damage to the cardiac muscle following injury.
The ability to prevent apoptosis may be measured by any suitable technique.
For example, with reference to Example 4 and Figures 3 and 6, it may be measured by the ability to prevent apoptosis in a cardiac muscle cell or cardiac-like cell line, as indicated by DNA fragmentation. The ability to prevent apoptosis, as indicated by DNA fragmentation, may be tested by treating the cells with sorbitol or another agent that places the cells under osmotic stress for up to, e.g. 1, 2, 4, 6, 12, 24 or 48 hours, preferably 12 to 24 hours, more preferably 24 hours, and investigating whether the pattern of fragmentation associated with apoptosis can be observed. An MGF
polypeptide of the invention expressed in this way will typically reduce, preferably eliminate, DNA fragmentation under these conditions, as compared to an untreated cell) after 6, 12 or 24 hours' sorbitol treatment.
The absence of expression, or low expression, of genes that act as markers for apoptosis can also act as an indication of prevention of apoptosis. One suitable marker is the Bax gene. Similarly, increased expression of anti-apoptotic markers in MGF-transfected cells under apoptotic conditions can be taken as a sign that the polypeptide of the invention is preventing apoptosis. One suitable anti-apoptotic marker gene is Bc12. The ability to prevent apoptosis may also be measured by reference to an MGF polypeptide's ability to prevent a reduction in cell number in myocyte cells in vitro.
Another preferred property of polypeptides and extended polypeptides of the invention is the ability to induce a hypertrophic phenotype in cardiac muscle cells.
In particular, this may be tested by assessing the ability to induce a hypertrophic phenotype in primary cardiac myocyte cultures in vitro. A preferred method for determining this is to test for an increase in expression of ANF (Atrial Natriuretic Factor) and/or bMHC (Beta Myosin Heavy Chain). ANF is an embryonic marker gene that is upregulated in hypertrophic conditions, bMHC is an important contractile protein in muscle.
Stability of Polypeptides and Extended Polypeptides of the Invention Polypeptides and extended polypeptides of the invention have increased stability compared to the native C-terminal MGF E peptides that they contain sequences derived from. Such comparisons are made between the polypeptide or extended polypeptide of the invention and the native C-terminal MGF E peptide in its isolated, unmodified form (e.g. an unmodified form of SEQ ID NO: 13, 14, 27, or 34, separated from the remainder of the MGF molecule and in isolated form as a 24-mer (SEQ ID NO: 27), 25-mer (SEQ ID NOS 13/14) or 8-mer (SEQ ID NO 34) ).
Comparisons may also be made with the Histidine-containing sequences of SEQ ID
NO: 15 and 33. Stability may be increased by any degree via the modifications discussed herein.
Stability may be assessed in terms of half-life in human plasma or by any other suitable technique. In particular, stability can be measured by assessing peptides' susceptibility to proteolytic cleavage in fresh human plasma according to the technique of Example 5.1 below, in which the plasma was stored until used at -70 C, l0 g of peptide was added to 2m1 of plasma, plus 7 ml of PBS and the mixture was incubated at 37 C for different time intervals. Western blotting was then used to detect each peptide over those time intervals. (In Figure 7: A= 0 minutes; B=
minutes; C = 2 hours; D = 24 hours. The results for the peptide with L-D
conversion and N-terminal PEGylation are shown on the right; those for the peptide lacking the L to D form conversions and N-terminal PEGylation are on the left.) Relatively little of the peptide lacking L-D conversion and PEGylation could be detected after minutes, very little after 2 hours and none or almost none after 24 hours. In contrast, the peptide with L-D conversion and PEGylation could be detected in much greater abundance and 2 hours and 24 hours.
Other measures of stability can be based on determining the loss of biological activity over time. This can be done by any suitable method, e.g. via an in vitro assay for any of the measures of biological activity discussed herein.
Quantitatively, in relative terms, preferred polypeptides or extended polypeptides of the invention may have half-lives that are increased by at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, at least 80%, at least 100%, at least 200% or at least 500% or more compared to the corresponding unmodified MGF C-terminal E
peptide.
Quantitatively, in absolute terms, preferred polypeptides or extended polypeptides of the invention may have half-lives of at least 1 hour, at least 2 hours, at least 4 hours, at least 8 hours, at last 12 hours, at least 24 hours or at least 48 hours or more.
Alternatively, qualitative or semi-quantitative measurements of stability may be used, as in Example 5 and Figure 2, for example by scoring the stability of polypeptides or extended polypeptides on a scale from 0 to 3. On that scale, the polypeptide of SEQ ID NO: 15 scored 1. Certain other modified polypeptides of the invention scored 2 or 3. A polypeptide or extended polypeptide of the invention will generally score more highly on such a scale than the corresponding native MGF
C-terminal E peptide.
Further Peptides of the Invention Whilst many of the peptides of the invention will be stabilised, as discussed above, it may under certain circumstances be possible to make use of unstabilised polypeptides, including the native polypeptides of SEQ ID NOS: 13, 14 27 and 34 or the histidine-containing variant of SEQ ID NO: 15 and 33. In the treatment of neurological and cardiac disorders according to the invention, it may be desirable for the polypeptide or extended polypeptide of the invention to be degraded relatively rapidly, i.e. to exert its effect for a relatively short period of time.
Therefore, stabilisation will not necessarily be required in the context of such treatments.
Where stabilisation is not required, it is preferred to use the native polypeptides of SEQ ID NOS: 13, 14, 27 and 34 or the Histidine-containing variant of SEQ ID
NO:
15 or 33 without stabilising modifications. However, modified polypeptides may also be used. Any of the modifications discussed herein may be applied except that, in this aspect, it is not required that those modifications result in increased stability.
Treatments According to the Invention Polypeptides and extended polypeptides of the invention can be used to treat a number of conditions. Broadly, these break down into three areas: disorders of skeletal muscle, disorders of cardiac muscle and neurological disorders.
However, because nerve and muscle function are inter-dependent, there may be some overlap between these categories, e.g. in the area of neuromuscular disorders.
Neurological disorders may generally be divided into two categories, neurogenic disorders where the fault lies in the nervous system itself and myogenic or muscle-related neurological disorders. Both can be treated according to the invention.
Disorders of skeletal muscle that are susceptible to treatment according to the invention include: muscular dystrophy, including but not limited to Duchenne or Becker muscular dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), congenital muscular dystrophy (CMD) and autosomal dystrophies, and related progressive skeletal muscle weakness and wasting; muscle atrophy, including but not limited to disuse atrophy, glucocorticoid-induced atrophy, muscle atrophy in ageing humans and muscle atrophy induced by spinal cord injuries or neuromuscular diseases; cachexia, for example cachexia associated with, cancers, AIDS, Chronic Obstructive Pulmonary Disease (COPD), chronic inflammatory diseases, burns injury etc; muscle weakness, especially in certain muscles such as the urinary sphincter, anal sphincter and pelvic floor muscles; sarcopenia and frailty in the elderly. The invention also fmds application in muscle repair following trauma.
So far as neurological disorders are concerned, treatment of neurodegenerative disorders is one possibility. Treatment of motoneurone disorders, especially neurodegenerative disorders of motoneurones is also a possibility.
Examples of neurological (including neuromuscular) disorders include amyotrophic lateral sclerosis; spinal muscular atrophy; progressive spinal muscular atrophy;
infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome;
a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; and motoneurone loss associated with ageing; and autosomal as well as sex-linked muscular dystroplzy;
Alzheimer's disease; Parkinson's disease; diabetic neuropathy; peripheral neuropathies; embolic and haemorrhagic stroke; and alcohol-related brain damage.
Polypeptides and extended polypeptides of the invention may also be used for maintenance of the central nervous system (CNS). The invention also finds application in nerve repair following trauma.
Nerve damage may also be treated according to the invention. In this embodiment, the polypeptide or extended polypeptide will typically be localised around the sites of such damage to effect repair, e.g. by means of the placement of a conduit around the two ends of a severed peripheral nerve (cf. WO01/85781).
As to cardiac disorders, there may be mentioned diseases where promotion of cardiac muscle protein synthesis is a beneficial treatment, cardiomyopathies; acute heart failure or acute insult including myocarditis or myocardial infarction;
pathological heart hypertrophy; and congestive heart failure. Polypeptides and extended polypeptides of the invention may also be used for improving cardiac output by increasing heart stroke volume. In particular, polypeptides and extended polypeptides of the invention may be used for prevention of myocardial damage following ischemia and/or mechanical overload.
In this case, they will generally be administered as rapidly as possible after the onset of the ischemia or mechanical overload to the heart, for example as soon as a heart attack resulting from ischemia has been diagnosed. Preferably, they will be administered within 5, 10, 15, 30 or 60 minutes, or within 2 or 5 hours.
Preferably, the ischemia or mechanical overload in response to which the MGF polypeptide or polynucleotide is administered is a temporary condition. In a particularly preferred embodiment, the polypeptide or extended polypeptide of the invention is administered in response to a heart attack. Treatments of the invention will be particularly effective in helping heart attack sufferers make a good recovery;
and to return to a normal, active lifestyle.
Under somce circumstances, it may be desirable to use polypeptides and extended polypeptides of the invention in combination with other pharmaceutically active agents. For example, polypeptides and extended polypeptides of the invention may be used together with IGF-I (see Examples 1.5, 7 and 8). Such combined uses may involve coadministration of the polypeptides or extended polypeptides of the invention in a single pharmaceutically acceptable carrier or excipient with the other pharmaceutically active agent or agents, or they may involve separate, sequential or simultaneous injection, at the same site or at different sites.
So far as neurological disorders are concerned, treatment of neurodegenerative disorders is one possibility. Treatment of motoneurone disorders, especially neurodegenerative disorders of motoneurones is also a possibility.
Examples of neurological (including neuromuscular) disorders include amyotrophic lateral sclerosis; spinal muscular atrophy; progressive spinal muscular atrophy;
infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome;
a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; and motoneurone loss associated with ageing; and autosomal as well as sex-linked muscular dystroplzy;
Alzheimer's disease; Parkinson's disease; diabetic neuropathy; peripheral neuropathies; embolic and haemorrhagic stroke; and alcohol-related brain damage.
Polypeptides and extended polypeptides of the invention may also be used for maintenance of the central nervous system (CNS). The invention also finds application in nerve repair following trauma.
Nerve damage may also be treated according to the invention. In this embodiment, the polypeptide or extended polypeptide will typically be localised around the sites of such damage to effect repair, e.g. by means of the placement of a conduit around the two ends of a severed peripheral nerve (cf. WO01/85781).
As to cardiac disorders, there may be mentioned diseases where promotion of cardiac muscle protein synthesis is a beneficial treatment, cardiomyopathies; acute heart failure or acute insult including myocarditis or myocardial infarction;
pathological heart hypertrophy; and congestive heart failure. Polypeptides and extended polypeptides of the invention may also be used for improving cardiac output by increasing heart stroke volume. In particular, polypeptides and extended polypeptides of the invention may be used for prevention of myocardial damage following ischemia and/or mechanical overload.
In this case, they will generally be administered as rapidly as possible after the onset of the ischemia or mechanical overload to the heart, for example as soon as a heart attack resulting from ischemia has been diagnosed. Preferably, they will be administered within 5, 10, 15, 30 or 60 minutes, or within 2 or 5 hours.
Preferably, the ischemia or mechanical overload in response to which the MGF polypeptide or polynucleotide is administered is a temporary condition. In a particularly preferred embodiment, the polypeptide or extended polypeptide of the invention is administered in response to a heart attack. Treatments of the invention will be particularly effective in helping heart attack sufferers make a good recovery;
and to return to a normal, active lifestyle.
Under somce circumstances, it may be desirable to use polypeptides and extended polypeptides of the invention in combination with other pharmaceutically active agents. For example, polypeptides and extended polypeptides of the invention may be used together with IGF-I (see Examples 1.5, 7 and 8). Such combined uses may involve coadministration of the polypeptides or extended polypeptides of the invention in a single pharmaceutically acceptable carrier or excipient with the other pharmaceutically active agent or agents, or they may involve separate, sequential or simultaneous injection, at the same site or at different sites.
Production of Polypeptides and Extended Polypeptides of the Invention Polypeptides and extended polypeptides of the invention may be produced by standard techniques. Typically, they will be obtained by standard techniques of peptide synthesis, plus appropriate chemical modifications (e.g. PEGylation) to the resulting amino acid sequence if necessary. Where there are no D-form amino acids, polypeptides and extended polypeptides may instead be obtained via recombinant expression in a host cell from the appropriate coding DNA, again by standard techniques.
Isolation and purification to any desired degree may also be carried out by standard techniques. Polypeptides and extended polypeptides according to the invention will generally be isolated or purified, either completely or partially. A
preparation of an isolated polypeptide or extended polypeptide is any preparation that contains the polypeptide or extended polypeptide at a higher concentration than the preparation in which it was produced. In particular, where the polypeptide or extended polypeptide is obtained recombinantly, the polypeptide or extended polypeptide will typically have been extracted from the host cell and the major cellular components removed.
A polypeptide or extended polypeptide in purified form will generally form part of a preparation in which more than 90%, for example up to 95%, up to 98% or up to 99% of the polypeptide material in the preparation is that of the invention.
Isolated and purified preparations will often be aqueous solutions containing the polypeptide or extended polypeptide of the invention. However, the polypeptide or extended polypeptide of the invention may be purified or isolated in other forms, e.g.
as crystals or other dry preparations.
Compositions, Formulations, Administration and Dosages The polypeptides and extended polypeptides of the invention are preferably provided in the form of compositions comprising the polypeptide or extended polypeptide and a carrier. In particular, such a composition may be a pharmaceutical composition comprising the polypeptide or extended polypeptides and a pharmaceutically acceptable carrier or diluent. Any suitable phannaceutical formulation may be used.
For example, suitable formulations may include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials, and may be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question. Sterile, pyrogen-free aqueous and non-aqueous solutions are preferred.
Formulations will generally be tailored, by standard formulation techniques, to the modes of administration discussed below.
The polypeptide of the invention may be administered by any suitable route tailored to the condition to be treated, for example topical, cutaneous, parenteral, intramuscular, subcutaneous or transdermal administration; or by direct injection into the bloodstream or direct application to mucosal tissues.
Injection is likely to be the preferred route under many circumstances, for example subcutaneous, parenteral intramuscular or intravenous injection. Intravenous injection will often be preferred under many clinical circumstances. So-called "needle-less" injection or transcutaneous administration may be possible under some circumstances.
In the treatment of skeletal muscle disorders, intravenous and intramuscular injection are preferred routes. Topical administration is also envisaged, e.g. via patches , to strengthen the muscles of the abdomen or for other purposes.
In the treatment of cardiac muscle disorders, delivery will generally be intravenous.
Under appropriate clinical circumstances (e.g. in specialist cardiac units) direct delivery to the heart may also be possible, e.g. using a so-called "needle-less"
injection system for delivery the polypeptide to the heart.
The polypeptides and extended polypeptides of the invention may be delivered in any suitable dosage, and using any suitable dosage regime. Persons of skill in the art will appreciate that the dosage amount'and regime may be adapted to ensure optimal treatment of the particular condition to be treated, depending on numerous factors.
Some such factors may be the age, sex and clinical condition of the subject to be treated.
Based on the Inventors' experience, it is envisaged that doses in the region of 0.2 to 10 mg will be effective, for example 0.2 to 0.8 mg, preferably about 0.5 mg.
For example, a solution containing the polypeptide or extended polypeptide at a concentration of 1 mg/ml may be used in an amount of 0.1 to 1 ml. Single or multiple doses may be given, depending on the application in question and the clinical circumstances.
The following Examples illustrate the invention.
Isolation and purification to any desired degree may also be carried out by standard techniques. Polypeptides and extended polypeptides according to the invention will generally be isolated or purified, either completely or partially. A
preparation of an isolated polypeptide or extended polypeptide is any preparation that contains the polypeptide or extended polypeptide at a higher concentration than the preparation in which it was produced. In particular, where the polypeptide or extended polypeptide is obtained recombinantly, the polypeptide or extended polypeptide will typically have been extracted from the host cell and the major cellular components removed.
A polypeptide or extended polypeptide in purified form will generally form part of a preparation in which more than 90%, for example up to 95%, up to 98% or up to 99% of the polypeptide material in the preparation is that of the invention.
Isolated and purified preparations will often be aqueous solutions containing the polypeptide or extended polypeptide of the invention. However, the polypeptide or extended polypeptide of the invention may be purified or isolated in other forms, e.g.
as crystals or other dry preparations.
Compositions, Formulations, Administration and Dosages The polypeptides and extended polypeptides of the invention are preferably provided in the form of compositions comprising the polypeptide or extended polypeptide and a carrier. In particular, such a composition may be a pharmaceutical composition comprising the polypeptide or extended polypeptides and a pharmaceutically acceptable carrier or diluent. Any suitable phannaceutical formulation may be used.
For example, suitable formulations may include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials, and may be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question. Sterile, pyrogen-free aqueous and non-aqueous solutions are preferred.
Formulations will generally be tailored, by standard formulation techniques, to the modes of administration discussed below.
The polypeptide of the invention may be administered by any suitable route tailored to the condition to be treated, for example topical, cutaneous, parenteral, intramuscular, subcutaneous or transdermal administration; or by direct injection into the bloodstream or direct application to mucosal tissues.
Injection is likely to be the preferred route under many circumstances, for example subcutaneous, parenteral intramuscular or intravenous injection. Intravenous injection will often be preferred under many clinical circumstances. So-called "needle-less" injection or transcutaneous administration may be possible under some circumstances.
In the treatment of skeletal muscle disorders, intravenous and intramuscular injection are preferred routes. Topical administration is also envisaged, e.g. via patches , to strengthen the muscles of the abdomen or for other purposes.
In the treatment of cardiac muscle disorders, delivery will generally be intravenous.
Under appropriate clinical circumstances (e.g. in specialist cardiac units) direct delivery to the heart may also be possible, e.g. using a so-called "needle-less"
injection system for delivery the polypeptide to the heart.
The polypeptides and extended polypeptides of the invention may be delivered in any suitable dosage, and using any suitable dosage regime. Persons of skill in the art will appreciate that the dosage amount'and regime may be adapted to ensure optimal treatment of the particular condition to be treated, depending on numerous factors.
Some such factors may be the age, sex and clinical condition of the subject to be treated.
Based on the Inventors' experience, it is envisaged that doses in the region of 0.2 to 10 mg will be effective, for example 0.2 to 0.8 mg, preferably about 0.5 mg.
For example, a solution containing the polypeptide or extended polypeptide at a concentration of 1 mg/ml may be used in an amount of 0.1 to 1 ml. Single or multiple doses may be given, depending on the application in question and the clinical circumstances.
The following Examples illustrate the invention.
EXAMPLES
1. Peptides 1.1 Peptides of Examples 2, 3, 4 and 6 The peptide used in Examples 2, 3, 4 and 6 had the sequence of SEQ ID NO: 15), in which the penultimate Arginine of the native sequence (See SEQ ID NOS: 1, 2 and 27) is replaced by Histidine, stabilised by the use of the D form of Arginine instead of the naturally occurring L-form at positions 14 and 15 and the covalent attachment of the N-terminus to a polyethylene glycol (PEG) derivative (0'O-bis(2aminopropyl)polyethylene glyclol 1900) (Jeffamine) via a succinic acid bridge, and amidated at the C-terminus.
1.2 Peptides of Exatnple 5 The peptides of Example 5 were obtained from Alta Biosciences, Birmingham, UK, having been synthesised via standard techniques using a peptide synthesiser.
These peptides are unPEGylated and free from L-D conversion and C-terminal amidation.
Also, a peptide corresponding to that of 1.1 above, with the same L-D
conversions, but without PEGylation, has also been tested for stability (see 5.2.3 below).
This peptide was synthesised via standard techniques using a peptide synthesiser.
The product was purified by HPLC and analyzed by MALDI-MS.
1.3 Peptides of Example 7 1.3.1 Peptides of Exaynple 7.1 The peptides of Example 7.1 had the 8 amino acid sequence Gly-Ser-Thr-Phe-Glu-Glu-His-Lys (SEQ ID NO:33), plus modifications to improve stability. In the peptide referred to as DMGF in Figure 8, stabilisation was achieved via N-terminal PEGylation as in 1.1 above. In the peptide referred to as CMGF in Figure 8, stabilisation was achieved via N-terminal attachment of hexanoic acid acid. Both DMGF and CMGF were also amidated at the C-terminal end.
1. 3.2 Peptides of Example 7.2 In Example 7.2, peptides A2, A4 and A6 had the sequence Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys (SEQ ID NO:34). Peptides A2, A4 and A6 were amidated at the C-terminus. Peptide A2 was unmodified at the N-terminus. Peptide A4 had a hexanoic acid moiety attached at the N-terminus. Peptide A6 had an amino-hexanoic acid moiety attached at the N-terminus.
Peptide A8 had the sequence Gly-Ser-Thr-Phe-Glu-Glu-His-Lys (SEQ ID NO:33), amidated at the C-terminus and with hexanoic acid attached at the N-terminus.
1. 4 Peptide of Example 8 The peptide used in Example 8 had the sequence of SEQ ID NO: 15, in which the penultimate Arginine of the native sequence (See SEQ ID NOS: 1, 2 and 27) is replaced by Histidine, stabilised by the use of the D form of Arginine instead of the naturally occurring L-form at positions 14 and 15 and amidated at the C-terminus.
The peptide used in Example 8 was not pegylated.
1.5 IGF-I Peptide For comparison, IGF-I peptide has been used. This is the IGF-I receptor binding domain encoded by Exons 3 and 4 that is common to all splice variants and is approximately 70 amino acids in length. In Examples 1-4, this was obtained from PeproTech, EC, UK. In Example 6, it was obtained from Sigma - Aldrich (ER2 IGF-I). IGF-I peptide was also used in Example 7.
1. Peptides 1.1 Peptides of Examples 2, 3, 4 and 6 The peptide used in Examples 2, 3, 4 and 6 had the sequence of SEQ ID NO: 15), in which the penultimate Arginine of the native sequence (See SEQ ID NOS: 1, 2 and 27) is replaced by Histidine, stabilised by the use of the D form of Arginine instead of the naturally occurring L-form at positions 14 and 15 and the covalent attachment of the N-terminus to a polyethylene glycol (PEG) derivative (0'O-bis(2aminopropyl)polyethylene glyclol 1900) (Jeffamine) via a succinic acid bridge, and amidated at the C-terminus.
1.2 Peptides of Exatnple 5 The peptides of Example 5 were obtained from Alta Biosciences, Birmingham, UK, having been synthesised via standard techniques using a peptide synthesiser.
These peptides are unPEGylated and free from L-D conversion and C-terminal amidation.
Also, a peptide corresponding to that of 1.1 above, with the same L-D
conversions, but without PEGylation, has also been tested for stability (see 5.2.3 below).
This peptide was synthesised via standard techniques using a peptide synthesiser.
The product was purified by HPLC and analyzed by MALDI-MS.
1.3 Peptides of Example 7 1.3.1 Peptides of Exaynple 7.1 The peptides of Example 7.1 had the 8 amino acid sequence Gly-Ser-Thr-Phe-Glu-Glu-His-Lys (SEQ ID NO:33), plus modifications to improve stability. In the peptide referred to as DMGF in Figure 8, stabilisation was achieved via N-terminal PEGylation as in 1.1 above. In the peptide referred to as CMGF in Figure 8, stabilisation was achieved via N-terminal attachment of hexanoic acid acid. Both DMGF and CMGF were also amidated at the C-terminal end.
1. 3.2 Peptides of Example 7.2 In Example 7.2, peptides A2, A4 and A6 had the sequence Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys (SEQ ID NO:34). Peptides A2, A4 and A6 were amidated at the C-terminus. Peptide A2 was unmodified at the N-terminus. Peptide A4 had a hexanoic acid moiety attached at the N-terminus. Peptide A6 had an amino-hexanoic acid moiety attached at the N-terminus.
Peptide A8 had the sequence Gly-Ser-Thr-Phe-Glu-Glu-His-Lys (SEQ ID NO:33), amidated at the C-terminus and with hexanoic acid attached at the N-terminus.
1. 4 Peptide of Example 8 The peptide used in Example 8 had the sequence of SEQ ID NO: 15, in which the penultimate Arginine of the native sequence (See SEQ ID NOS: 1, 2 and 27) is replaced by Histidine, stabilised by the use of the D form of Arginine instead of the naturally occurring L-form at positions 14 and 15 and amidated at the C-terminus.
The peptide used in Example 8 was not pegylated.
1.5 IGF-I Peptide For comparison, IGF-I peptide has been used. This is the IGF-I receptor binding domain encoded by Exons 3 and 4 that is common to all splice variants and is approximately 70 amino acids in length. In Examples 1-4, this was obtained from PeproTech, EC, UK. In Example 6, it was obtained from Sigma - Aldrich (ER2 IGF-I). IGF-I peptide was also used in Example 7.
2. Injection of Stabilised Peptide into Dystrophic Muscle Using intramuscular injections (twice weekly injections of 25 1 containing 17 g of the chemically stabilised peptide), muscle strength was increased by more than 25%
within a few weeks in the tibialis anterior muscle of non-dystrophic miceThis muscle is not diseased like the muscle of mdx mice (see below), although it is possible that it was physically damaged by the repeated injections.
Greater increases, of up to around 35% (Figures 3A, 3B), were recorded for intramuscular injections (two per week for three weeks) in the dystrophic muscles of the mdx mouse, which has the same type of mutation as that in human Duchenne muscular dystrophy. Injections of IGF-I led only to an increase of around 5%, as shown in Figure 3A On the same basis, the results of a comparison between the stabilised peptide and a PBS vehicle-only control are shown in Figure 3B.
These data relating to muscle protection and repair show that the stabilised peptide is effective in increasing the strength of dystrophic and non-dystrophic muscle.
3. Cardioprotection and Myocardial Repair by Stabilised Peptide A myocardial infarction (MI) was induced in ovine hearts by catheterising a marginal branch of the circumflex coronary artery and injecting a small bolus of microspheres to induce localised ischemia. Full-length MGF (native C-terminal peptide plus sequence encoded by exons 3 and 4 and common to MGF and liver-type IGF-I) or stabilised peptide was injected (200nm, intracoronary) 15 minutes later using the same catheter whilst the animal was still under the anaesthetic. As a control, mature liver-type IGF-I was used. The use of the stabilised peptide alone was found to markedly increase the percentage of viable myocardium and the ejection fraction as measured by echocardiography and computerised analysis of the ejection function following the MI. Full-length MGF also had a significant, though smaller effect.
within a few weeks in the tibialis anterior muscle of non-dystrophic miceThis muscle is not diseased like the muscle of mdx mice (see below), although it is possible that it was physically damaged by the repeated injections.
Greater increases, of up to around 35% (Figures 3A, 3B), were recorded for intramuscular injections (two per week for three weeks) in the dystrophic muscles of the mdx mouse, which has the same type of mutation as that in human Duchenne muscular dystrophy. Injections of IGF-I led only to an increase of around 5%, as shown in Figure 3A On the same basis, the results of a comparison between the stabilised peptide and a PBS vehicle-only control are shown in Figure 3B.
These data relating to muscle protection and repair show that the stabilised peptide is effective in increasing the strength of dystrophic and non-dystrophic muscle.
3. Cardioprotection and Myocardial Repair by Stabilised Peptide A myocardial infarction (MI) was induced in ovine hearts by catheterising a marginal branch of the circumflex coronary artery and injecting a small bolus of microspheres to induce localised ischemia. Full-length MGF (native C-terminal peptide plus sequence encoded by exons 3 and 4 and common to MGF and liver-type IGF-I) or stabilised peptide was injected (200nm, intracoronary) 15 minutes later using the same catheter whilst the animal was still under the anaesthetic. As a control, mature liver-type IGF-I was used. The use of the stabilised peptide alone was found to markedly increase the percentage of viable myocardium and the ejection fraction as measured by echocardiography and computerised analysis of the ejection function following the MI. Full-length MGF also had a significant, though smaller effect.
Mature liver-type IGF-I had a much smaller effect. The results are given in Figure 4, which shows percentage change in ejection fraction on day 6 as compared to ejection fraction on day 1 before the procedure was carried out. Thus, the stabilised peptide was very effective in protecting the myocardium from ischemic damage.
Additional experiments were carried out on mice. In these studies the MI was produced by ligating the left anterior descending (LAD) coronary artery of the murine heart. This causes dilation of the left ventricle, the progression of which leads to heart failure. Stabilised peptide administered systemically markedly improved the strength and function of the heart as measured by the pressure/volume loops (Figure 5) that demonstrate the ability of the heart to pump blood and the dilation that results when the damaged heart can no longer cope with the venous return. This is markedly improved by the systemic administration of the stabilised peptide, through which the myocardial wall muscle is protected and increased in thickness. Therefore there is considerable potential for treatment of patients immediately following a heart attack.
4. Neuroprotection by Stabilised Peptide Following Ischemia and General Damage 4.1 Neuroprotective Effect In Vitro The neuroprotective effect of the stabilised peptide was demonstrated in vitro using the well-characterised model of selective neuronal death in rat organotypic hippocampal cultures.
Hippocampal slices were prepared from 7-10 days old Wistar rats according to the method of Stoppini et al (1991) with minor modifications according to Sarnowska (2002). Briefly, rats were anaesthetised with Vetbutal, ice-cooled and decapitated.
Brains were quickly removed to ice-cold working solution pH 7.2: 96% of HBSS/HEPES- (Ca2+ and Mg2+ free) containing 2mmol/L L-glutamine, 5 mg/ml glucose, 1% amphotericine B, 0,4% penicillin-streptomycin. Hippocampi were separated and cut into 400 m slices using McIlwain tissue chopper. Millicell-CM
membranes (Millipore) in 6-well plates were pre-equilibrated with 1 ml of culture medium pH 7.2: 50% DMEM, 25% HBSS/HEPES, 25% HS, 2 mmol/L L-glutamine, 5 mg/ml glucose, 1% amphotericine B, 0.4% penicillin-streptamycine in a moist atmosphere of air and 5% CO2 at 32 C for 30 minutes. Four selected slices were settled on each membrane. Slices were cultivated for two weeks at 32 C in 5%
atmosphere of 100% humidity. The viability of the slices was checked daily under the light microscopy and evaluated additionally on the day of experiment by propidium iodide staining and observed under fluorescent microscope (Zeiss Axiovert 25) with MC-10095 camera (Carl Zeiss Jena GmbH) in order to record initial PI uptake (Sarnowska, 2002).
Oxidative stress was induced after 14 days in culture by adding 30 mM TBH
(tert-butyl peroxide) for 3 hours. After that time the slices were transferred to the fresh culture medium. Resulting cell death was assessed 24 and 48 h after the beginning of the experiment.
Stabilised peptide or, for the purpose of comparison, recombinant IGF-1 was added to the culture medium to the final concentration of 100 ng/ml at the beginning of the experiment and was continuously present in the medium.
In order to investigate a pathway in which the MGF acts, a specific anti-IGF-1 receptor (AB-1) blocking antibody (Oncogene) was included in the medium 1 hour before the slices were exposed to TBH and MGF or IGF-1 peptide. The concentration of the antibody (1000 ng/ml) was used according to the manufacturer's recommendation.
To obtain detailed images of the slices, a confocal laser scanning microscope (Zeiss LSM 510) was used. A helium-neon laser (543 nm) was used for the excitation of propidium iodide (PI). Following acquisition, images were processed using the Zeiss LSM 510 software package v. 2.8. Quantitative measurement of tissue deterioration was performed using image analyser KS 300 (Carl Zeiss Jena GmbH).
Cell damage was quantified on fluorescence images of PI-stained cultures 24 and 48 hours after TBH challenge. The relative extent of cell death was calculated from each standardized CAl region as follows: % of dead cells = (experimental fluorescent intensity (FI)- background FI) / (maximal Fl- background FI) x 100, where maximal FI was obtained by killing all cells with exposure to 100 mM glutamate.
All the measureinents were repeated for 5 independent culture preparations and slices were used for each experimental condition. Statistical significance of the differences between the results was calculated using one-way Anova followed by Dunnet's test, (GraphPad Prism 3.02).
Rat brain slices were isolated following induction of localized damage by TBH
(tert-butyl hydroperoxide) as discussed above. The resulting cell death in treated and non-treated brain slices was determined. This is illustrated in Figure 6. In the absence of treatment peptide, TBH caused about 60% of the cells to die within 24 hours but, following treatment with the stabilised peptide (100ng/ml), 85% protection was observed. The IGF-I receptor domain peptide (rIGF-I), which is also part of full length MGF was also neuroprotective (as previously reported). However, this was to a lesser degree (72%) and the protective effect of IGF-1 was only noticeable for up to 24 hours, whereas the stabilised peptide functioned for significantly longer as its neuroprotective effect was still clearly observed after 48 hours.
4.2 Neuroprotective Effect in Gerbil Model Other experiments were carried out using a Gerbil model of brain ischemia. To assess neuroprotection, confocal microscopy was carried out on the brain after administration of the stabilised peptide or the IGF-I receptor binding domain.
Additional experiments were carried out on mice. In these studies the MI was produced by ligating the left anterior descending (LAD) coronary artery of the murine heart. This causes dilation of the left ventricle, the progression of which leads to heart failure. Stabilised peptide administered systemically markedly improved the strength and function of the heart as measured by the pressure/volume loops (Figure 5) that demonstrate the ability of the heart to pump blood and the dilation that results when the damaged heart can no longer cope with the venous return. This is markedly improved by the systemic administration of the stabilised peptide, through which the myocardial wall muscle is protected and increased in thickness. Therefore there is considerable potential for treatment of patients immediately following a heart attack.
4. Neuroprotection by Stabilised Peptide Following Ischemia and General Damage 4.1 Neuroprotective Effect In Vitro The neuroprotective effect of the stabilised peptide was demonstrated in vitro using the well-characterised model of selective neuronal death in rat organotypic hippocampal cultures.
Hippocampal slices were prepared from 7-10 days old Wistar rats according to the method of Stoppini et al (1991) with minor modifications according to Sarnowska (2002). Briefly, rats were anaesthetised with Vetbutal, ice-cooled and decapitated.
Brains were quickly removed to ice-cold working solution pH 7.2: 96% of HBSS/HEPES- (Ca2+ and Mg2+ free) containing 2mmol/L L-glutamine, 5 mg/ml glucose, 1% amphotericine B, 0,4% penicillin-streptomycin. Hippocampi were separated and cut into 400 m slices using McIlwain tissue chopper. Millicell-CM
membranes (Millipore) in 6-well plates were pre-equilibrated with 1 ml of culture medium pH 7.2: 50% DMEM, 25% HBSS/HEPES, 25% HS, 2 mmol/L L-glutamine, 5 mg/ml glucose, 1% amphotericine B, 0.4% penicillin-streptamycine in a moist atmosphere of air and 5% CO2 at 32 C for 30 minutes. Four selected slices were settled on each membrane. Slices were cultivated for two weeks at 32 C in 5%
atmosphere of 100% humidity. The viability of the slices was checked daily under the light microscopy and evaluated additionally on the day of experiment by propidium iodide staining and observed under fluorescent microscope (Zeiss Axiovert 25) with MC-10095 camera (Carl Zeiss Jena GmbH) in order to record initial PI uptake (Sarnowska, 2002).
Oxidative stress was induced after 14 days in culture by adding 30 mM TBH
(tert-butyl peroxide) for 3 hours. After that time the slices were transferred to the fresh culture medium. Resulting cell death was assessed 24 and 48 h after the beginning of the experiment.
Stabilised peptide or, for the purpose of comparison, recombinant IGF-1 was added to the culture medium to the final concentration of 100 ng/ml at the beginning of the experiment and was continuously present in the medium.
In order to investigate a pathway in which the MGF acts, a specific anti-IGF-1 receptor (AB-1) blocking antibody (Oncogene) was included in the medium 1 hour before the slices were exposed to TBH and MGF or IGF-1 peptide. The concentration of the antibody (1000 ng/ml) was used according to the manufacturer's recommendation.
To obtain detailed images of the slices, a confocal laser scanning microscope (Zeiss LSM 510) was used. A helium-neon laser (543 nm) was used for the excitation of propidium iodide (PI). Following acquisition, images were processed using the Zeiss LSM 510 software package v. 2.8. Quantitative measurement of tissue deterioration was performed using image analyser KS 300 (Carl Zeiss Jena GmbH).
Cell damage was quantified on fluorescence images of PI-stained cultures 24 and 48 hours after TBH challenge. The relative extent of cell death was calculated from each standardized CAl region as follows: % of dead cells = (experimental fluorescent intensity (FI)- background FI) / (maximal Fl- background FI) x 100, where maximal FI was obtained by killing all cells with exposure to 100 mM glutamate.
All the measureinents were repeated for 5 independent culture preparations and slices were used for each experimental condition. Statistical significance of the differences between the results was calculated using one-way Anova followed by Dunnet's test, (GraphPad Prism 3.02).
Rat brain slices were isolated following induction of localized damage by TBH
(tert-butyl hydroperoxide) as discussed above. The resulting cell death in treated and non-treated brain slices was determined. This is illustrated in Figure 6. In the absence of treatment peptide, TBH caused about 60% of the cells to die within 24 hours but, following treatment with the stabilised peptide (100ng/ml), 85% protection was observed. The IGF-I receptor domain peptide (rIGF-I), which is also part of full length MGF was also neuroprotective (as previously reported). However, this was to a lesser degree (72%) and the protective effect of IGF-1 was only noticeable for up to 24 hours, whereas the stabilised peptide functioned for significantly longer as its neuroprotective effect was still clearly observed after 48 hours.
4.2 Neuroprotective Effect in Gerbil Model Other experiments were carried out using a Gerbil model of brain ischemia. To assess neuroprotection, confocal microscopy was carried out on the brain after administration of the stabilised peptide or the IGF-I receptor binding domain.
In the gerbil brain, bilateral ligation of the common carotid arteries invariably produces specific hippocampal lesions: in the CAl region, pyramidal neurones start to die 3-4 days after ischemia.
Male Mongolian gerbils weighing 50-60 g were used. The ischemic insult was performed by 5 min. ligation of the common carotid arteries under halotane in N20:02 (70:30) anaesthesia in strictly controlled normothermic conditions as previously described (Domanska-Janik et al., 2004). The cerebral blood flow was continuously monitored by laser Doppler flowmetry (Muro, Inc.). A group of animals received stabilised peptide or IGF-1 (1 g/ l in PBS) by injection at a dose of 25 g directly to the left carotid artery immediately upon the reperfusion.
Sham operated animals were injected with the same dose of the peptide.
Usually, 10 - 15 minutes after the procedure, treated animals were standing up on their legs and behaving as untreated ones. The animals were allowed a recovery period of one week, then were perfused with ice-cold 4% paraformaldehyde in PBS
under pentobarbital anaesthesia. The histological evaluation was performed on paraffin-embedded and fixed, 10 mm-thick sections stained by hematoxylline/eosine.
The extent of cell damage in the CA1 hippocampal region was quantified, under a Zeiss Axioscop 2, as the mean number of the persisted, intact neurons in the coronal sections. At least three defined 300 m fields of the CAl region were captured using a MC 10095 camera (Carl Zeiss Jena GmbH) and counted in a computer-assisted image analysis system (KS 300, Carl Zeiss Jena GmbH).
In control animals, the mean number of morphologically intact neurones per 300 m length scored in the CAl region was 121.25 + 12.5 (mean + SD, n=5). In contrast to the untreated animals, where only about 12% (15.2 5, n=7) of neurones survived the ischemic episode, injection (single bolus of 25 g) of the stabilised MGF
C-terminal peptide into the left carotid artery, immediately after re-perfusion, provided a very significant neuroprotection. 83.2 25 (n=10) neurones were scored on the injected side (74.5 % of non-operated control value) and 65.8 30 (n=10) on the contralateral side (54 % of non-operated control value). Thus, treatment with the stabilised MGF C-terminal peptide enabled a high proportion of the CA1 hippocampal neurones to survive the ischemic insult. In most animals, the protective effect was noticeable bilaterally while in a minority it was mostly evident on the injected (left) side.
In contrast, similar injection of 25 g of IGF-1 peptide had little influence on the postischemic survival of CAl neurones; 7 days after the insult there were 19.2 7.3 neurones (n=5) left, which is only 15.8 % of the control neuronal cell number and not significantly different from the untreated postischemic group.
5. Biological Activity and Stability of Modified Peptides 5.1 Peptide Stabilised by L-D Conversion and N-terminal PEGylation The peptide used in Examples 2, 3 and 4 above had the sequence of SEQ ID NO:
(which corresponds to that of the the lluman Ec peptide of MGF (SEQ ID NO:
27), except that Arginine in the penultimate position is replaced by Histidine ) stabilised by the use of the D form of Arginine at positions 14 and 15 instead of the naturally occurring L-form and the covalent attachment of the N-terminus to polyethylene glycol (PEG), and amidated at the C-terminus.
The biological activity of this peptide is confirmed in Examples 2, 3 and 4.
Its stability is demonstrated by Figure 7. Stability of the peptides with and without PEGylation and L-D conversion of Arginine at positions 14 and 15 was investigated by assessing the peptides' susceptibility to proteolytic cleavage in fresh human plasma.
The plasma was stored until used at -70 C. 10 g of peptide were added to 2m1 of plasma, plus 7 ml of PBS. This mixture was incubated at 37 C for different time intervals. Western blotting with a polyclonal antibody having specificity to peptides with the amino acid sequence of SEQ ID NO : 15 was then used to detect each peptide over those time intervals. (In Figure 7: A = 0 minutes; B = 30 minutes; C = 2 hours; D = 24 hours. The results for the peptide with L-D conversion and N-terminal PEGylation are shown on the right; those for the peptide lacking the L to D
form conversions and N-terminal PEGylation are on the left.). Relatively little of the peptide lacking L-D conversion and PEGylation could be detected after 30 minutes, very little after 2 hours and none or almost none after 24 hours. In contrast, the peptide with L-D conversion and PEGylation could be detected in abundance even after 24 hours.
5.2 Further Peptides - Replacement of Serine or Arginine with Alanine and C-ternzinal and N-terminal Truncation 5.2.1 Further Peptides Herein, the sequence of the native human Ec peptide from the C-terminus of human MGF is given as SEQ ID NO: 27. In the peptide of SEQ ID NO: 15, the penultimate amino acid, which is Arginine in the native peptide (See SEQ ID NOS 2 and 27) is replaced with Histidine. The peptide of SEQ ID NO: 15 is described as Peptide 1 in Figure 2.
Further modified sequences derived from the sequence of SEQ ID NO: 15 are given as SEQ ID NOS: 16 to 24 and compared to that of SEQ ID NO: 15 in Figure 2, where they are referred to as Peptides 2-6 and Short peptides 1-4.
In Peptide 2 (SEQ ID NO: 16), Serine is replaced with Alanine at position 5.
In Peptide 3 (SEQ ID NO: 17), Serine is replaced with Alanine at position 12. In Peptide 4 (SEQ ID NO: 18), Serine is replaced with Alanine at position 18. In Peptide 5 (SEQ ID NO: 19), Arginine is replaced with Alanine at position 14.
In Peptide 6 (SEQ ID NO: 20), Arginine is replaced with Alanine at position 14 and Arginine is also replaced with Alanine at position 15. In Short peptide 1(SEQ
ID
NO: 21), Arginine is replaced with Alanine at position 14 and the two C-terminal amino acids are removed. In Short peptide 2 (SEQ ID NO: 22), Arginine is replaced with Alanine at position 14 and the four C-terminal amino acids are removed.
In Short peptide 3 (SEQ ID NO: 23), Arginine is replaced with Alanine at position and the three N-terminal amino acids are removed. In Short peptide 4 (SEQ ID
NO:
24), Arginine is replaced with Alanine at position 14 and the five N-terminal amino acids are removed.
5.2.2 Biological Activity of Further Peptides Biological activity was determined using an in vitro system by measuring the ability of the C terminal peptides to induce mononucleated myoblasts (satellite cells) to replicate. Cell number was determined using the Alamar Blue metliod. This was assessed on a scale of 0 to 3 and the results are shown in Figure 2.
0= no measureable increase in cell number at 6h.
1= significant increase in cell number at 4h.
2= significant increase in cell number at 2h.
3 = significant increase in cell number at 1 h.
Significance was at the level of P>0.05 using the T test.
The peptide (Peptide 1) of SEQ ID NO: 15 showed little or no activity owing to its short half-life. Peptide 2 (SEQ ID NO: 16) and Short Peptide 1(SEQ ID NO: 21) scored 1 on the activity scale. Peptides 4 and 5 (SEQ ID NOS: 18 and 19) scored 2 on the activity scale. Peptide 3 (SEQ ID NO: 17) scored 3 on the activity scale.
Peptide 6 (SEQ ID NO: 20) and Short peptides 2, 3 and 4 (SEQ ID NOS: 22, 23 and 24) exhibited no measurable activity (zero score).
5.2.3 Stability of Furtlaef= Peptides The stability of each peptide was determined by introducing it into fresh human plasma and using Western blotting as discussed in Example 5.1 above. Like biological activity, stability was scored on a scale of 0 to 3. The results are shown in Figure 2.
Stability was determined as the amount of the peptide that remained intact and bound to the specific antibody in the following way:
1= marked loss of detectable antibody binding by %Z hours.
2 = marked loss of detectable binding by 2 hours.
3 = no marked loss of antibody binding by 24 hours.
The peptide (Peptide 1) of SEQ ID NO: 15 scored 1. Peptide 6 (SEQ ID NO: 20) also scored 1. Peptides 3 and 4 (SEQ ID NOS: 17 and 18) scored 2. Peptides 2 and 5 (SEQ ID NOS: 16 and 19) scored 3.
The peptide of Examples 1-4 also scored 3 on this scale. The same peptide, but lacking PEGylation, also scored 3 on this scale. Short peptides 1-4 have not yet been tested, though Short peptides 2 to 4 appear to lack biological activity anyway.
6. Effects of Stabilised Peptide on Muscle Satellite Cell Proliferation in Dystrophic, ALS and Healthy Human Muscle The stabilised peptide of 1.1 above was used in these experiments. Comparisons were made with the IGF-I peptide of 1.3 above.
6.1 Sufninary Primary human muscle cell cultures were derived from biopsies of congenital muscular dystrophy (CMD), facioscapulohumeral dystrophy (FSHD) and motor neurone disease or amyotrophic lateral sclerosis (ALS) patients as well as from healthy muscle using proliferation/differentiation assays. Cell cultures were treated with the two peptides and immunocytochemistry techniques were used to detect cells expressing the differentiation marker desmin, and total number of nuclei using DAPI.
Creatine phosphokinase (CPK) and protein assays were used to determine myogenic differentiation following peptide treatment. The stabilised peptide considerably increased stem (desmin positive) cell proliferation for normal (non-diseased) muscle (from 38.4zL2.5% to 57.9 3.2% in normal (non-diseased) limb and from 49.8 2.4%
to 68.8+3.9% for normal (non-diseased) craniofacial muscle biopsies). Although the initial muscle stem cell numbers were lower in patients with muscle wasting, the stabilised peptide still induced an increase (CMD 10.4d:1.7% to 17.5 1.6%;
FSHD
11.7 1.3% to 20.4- 2.1% and ALS 4.811.1% to 7.2 0.8%). The results also confirmed that the stabilised peptide had no effect on myotube formation but that it increases myoblast progenitor cell proliferation, whilst mature IGF-I enhanced differentiation.
6.2 Isolation of Human Muscle-Derived Cells Human primary muscle cell cultures were isolated as previously described [Lewis et al., 2000; Sinanan et al., 2004]. Briefly, following informed consent, craniofacial (masseter) muscle biopsies were obtained from healthy adult and CMD patients during elective surgery at the Eastman and Middlesex Hospitals, London, UK.
Human lower limb (vastus lateralis) muscle samples were obtained from consenting, adult healthy, FSHD and ALS patients by needle biopsy under local anaesthesia at the Royal Free Hospital, London, UK. Biopsies were pooled from several patients with the same disorder to obtain sufficient cell numbers in the primary cultures.
These were washed with antibiotic (penicillin, 100U/ml; streptomycin, 100 g/ml;
fungizone, 2.5 g/ml; Invitrogen) supplemented DMEM (high glucose; Invitrogen), scissor-minced and tissue fragments plated into 0.2% gelatin-coated (Sigma-Aldrich) T150cm2 culture flasks (Helena Biosciences). Explant cultures were incubated in serum-containing Growth Media (sGM), composed of DMEM, 20% FCS (PAA
Male Mongolian gerbils weighing 50-60 g were used. The ischemic insult was performed by 5 min. ligation of the common carotid arteries under halotane in N20:02 (70:30) anaesthesia in strictly controlled normothermic conditions as previously described (Domanska-Janik et al., 2004). The cerebral blood flow was continuously monitored by laser Doppler flowmetry (Muro, Inc.). A group of animals received stabilised peptide or IGF-1 (1 g/ l in PBS) by injection at a dose of 25 g directly to the left carotid artery immediately upon the reperfusion.
Sham operated animals were injected with the same dose of the peptide.
Usually, 10 - 15 minutes after the procedure, treated animals were standing up on their legs and behaving as untreated ones. The animals were allowed a recovery period of one week, then were perfused with ice-cold 4% paraformaldehyde in PBS
under pentobarbital anaesthesia. The histological evaluation was performed on paraffin-embedded and fixed, 10 mm-thick sections stained by hematoxylline/eosine.
The extent of cell damage in the CA1 hippocampal region was quantified, under a Zeiss Axioscop 2, as the mean number of the persisted, intact neurons in the coronal sections. At least three defined 300 m fields of the CAl region were captured using a MC 10095 camera (Carl Zeiss Jena GmbH) and counted in a computer-assisted image analysis system (KS 300, Carl Zeiss Jena GmbH).
In control animals, the mean number of morphologically intact neurones per 300 m length scored in the CAl region was 121.25 + 12.5 (mean + SD, n=5). In contrast to the untreated animals, where only about 12% (15.2 5, n=7) of neurones survived the ischemic episode, injection (single bolus of 25 g) of the stabilised MGF
C-terminal peptide into the left carotid artery, immediately after re-perfusion, provided a very significant neuroprotection. 83.2 25 (n=10) neurones were scored on the injected side (74.5 % of non-operated control value) and 65.8 30 (n=10) on the contralateral side (54 % of non-operated control value). Thus, treatment with the stabilised MGF C-terminal peptide enabled a high proportion of the CA1 hippocampal neurones to survive the ischemic insult. In most animals, the protective effect was noticeable bilaterally while in a minority it was mostly evident on the injected (left) side.
In contrast, similar injection of 25 g of IGF-1 peptide had little influence on the postischemic survival of CAl neurones; 7 days after the insult there were 19.2 7.3 neurones (n=5) left, which is only 15.8 % of the control neuronal cell number and not significantly different from the untreated postischemic group.
5. Biological Activity and Stability of Modified Peptides 5.1 Peptide Stabilised by L-D Conversion and N-terminal PEGylation The peptide used in Examples 2, 3 and 4 above had the sequence of SEQ ID NO:
(which corresponds to that of the the lluman Ec peptide of MGF (SEQ ID NO:
27), except that Arginine in the penultimate position is replaced by Histidine ) stabilised by the use of the D form of Arginine at positions 14 and 15 instead of the naturally occurring L-form and the covalent attachment of the N-terminus to polyethylene glycol (PEG), and amidated at the C-terminus.
The biological activity of this peptide is confirmed in Examples 2, 3 and 4.
Its stability is demonstrated by Figure 7. Stability of the peptides with and without PEGylation and L-D conversion of Arginine at positions 14 and 15 was investigated by assessing the peptides' susceptibility to proteolytic cleavage in fresh human plasma.
The plasma was stored until used at -70 C. 10 g of peptide were added to 2m1 of plasma, plus 7 ml of PBS. This mixture was incubated at 37 C for different time intervals. Western blotting with a polyclonal antibody having specificity to peptides with the amino acid sequence of SEQ ID NO : 15 was then used to detect each peptide over those time intervals. (In Figure 7: A = 0 minutes; B = 30 minutes; C = 2 hours; D = 24 hours. The results for the peptide with L-D conversion and N-terminal PEGylation are shown on the right; those for the peptide lacking the L to D
form conversions and N-terminal PEGylation are on the left.). Relatively little of the peptide lacking L-D conversion and PEGylation could be detected after 30 minutes, very little after 2 hours and none or almost none after 24 hours. In contrast, the peptide with L-D conversion and PEGylation could be detected in abundance even after 24 hours.
5.2 Further Peptides - Replacement of Serine or Arginine with Alanine and C-ternzinal and N-terminal Truncation 5.2.1 Further Peptides Herein, the sequence of the native human Ec peptide from the C-terminus of human MGF is given as SEQ ID NO: 27. In the peptide of SEQ ID NO: 15, the penultimate amino acid, which is Arginine in the native peptide (See SEQ ID NOS 2 and 27) is replaced with Histidine. The peptide of SEQ ID NO: 15 is described as Peptide 1 in Figure 2.
Further modified sequences derived from the sequence of SEQ ID NO: 15 are given as SEQ ID NOS: 16 to 24 and compared to that of SEQ ID NO: 15 in Figure 2, where they are referred to as Peptides 2-6 and Short peptides 1-4.
In Peptide 2 (SEQ ID NO: 16), Serine is replaced with Alanine at position 5.
In Peptide 3 (SEQ ID NO: 17), Serine is replaced with Alanine at position 12. In Peptide 4 (SEQ ID NO: 18), Serine is replaced with Alanine at position 18. In Peptide 5 (SEQ ID NO: 19), Arginine is replaced with Alanine at position 14.
In Peptide 6 (SEQ ID NO: 20), Arginine is replaced with Alanine at position 14 and Arginine is also replaced with Alanine at position 15. In Short peptide 1(SEQ
ID
NO: 21), Arginine is replaced with Alanine at position 14 and the two C-terminal amino acids are removed. In Short peptide 2 (SEQ ID NO: 22), Arginine is replaced with Alanine at position 14 and the four C-terminal amino acids are removed.
In Short peptide 3 (SEQ ID NO: 23), Arginine is replaced with Alanine at position and the three N-terminal amino acids are removed. In Short peptide 4 (SEQ ID
NO:
24), Arginine is replaced with Alanine at position 14 and the five N-terminal amino acids are removed.
5.2.2 Biological Activity of Further Peptides Biological activity was determined using an in vitro system by measuring the ability of the C terminal peptides to induce mononucleated myoblasts (satellite cells) to replicate. Cell number was determined using the Alamar Blue metliod. This was assessed on a scale of 0 to 3 and the results are shown in Figure 2.
0= no measureable increase in cell number at 6h.
1= significant increase in cell number at 4h.
2= significant increase in cell number at 2h.
3 = significant increase in cell number at 1 h.
Significance was at the level of P>0.05 using the T test.
The peptide (Peptide 1) of SEQ ID NO: 15 showed little or no activity owing to its short half-life. Peptide 2 (SEQ ID NO: 16) and Short Peptide 1(SEQ ID NO: 21) scored 1 on the activity scale. Peptides 4 and 5 (SEQ ID NOS: 18 and 19) scored 2 on the activity scale. Peptide 3 (SEQ ID NO: 17) scored 3 on the activity scale.
Peptide 6 (SEQ ID NO: 20) and Short peptides 2, 3 and 4 (SEQ ID NOS: 22, 23 and 24) exhibited no measurable activity (zero score).
5.2.3 Stability of Furtlaef= Peptides The stability of each peptide was determined by introducing it into fresh human plasma and using Western blotting as discussed in Example 5.1 above. Like biological activity, stability was scored on a scale of 0 to 3. The results are shown in Figure 2.
Stability was determined as the amount of the peptide that remained intact and bound to the specific antibody in the following way:
1= marked loss of detectable antibody binding by %Z hours.
2 = marked loss of detectable binding by 2 hours.
3 = no marked loss of antibody binding by 24 hours.
The peptide (Peptide 1) of SEQ ID NO: 15 scored 1. Peptide 6 (SEQ ID NO: 20) also scored 1. Peptides 3 and 4 (SEQ ID NOS: 17 and 18) scored 2. Peptides 2 and 5 (SEQ ID NOS: 16 and 19) scored 3.
The peptide of Examples 1-4 also scored 3 on this scale. The same peptide, but lacking PEGylation, also scored 3 on this scale. Short peptides 1-4 have not yet been tested, though Short peptides 2 to 4 appear to lack biological activity anyway.
6. Effects of Stabilised Peptide on Muscle Satellite Cell Proliferation in Dystrophic, ALS and Healthy Human Muscle The stabilised peptide of 1.1 above was used in these experiments. Comparisons were made with the IGF-I peptide of 1.3 above.
6.1 Sufninary Primary human muscle cell cultures were derived from biopsies of congenital muscular dystrophy (CMD), facioscapulohumeral dystrophy (FSHD) and motor neurone disease or amyotrophic lateral sclerosis (ALS) patients as well as from healthy muscle using proliferation/differentiation assays. Cell cultures were treated with the two peptides and immunocytochemistry techniques were used to detect cells expressing the differentiation marker desmin, and total number of nuclei using DAPI.
Creatine phosphokinase (CPK) and protein assays were used to determine myogenic differentiation following peptide treatment. The stabilised peptide considerably increased stem (desmin positive) cell proliferation for normal (non-diseased) muscle (from 38.4zL2.5% to 57.9 3.2% in normal (non-diseased) limb and from 49.8 2.4%
to 68.8+3.9% for normal (non-diseased) craniofacial muscle biopsies). Although the initial muscle stem cell numbers were lower in patients with muscle wasting, the stabilised peptide still induced an increase (CMD 10.4d:1.7% to 17.5 1.6%;
FSHD
11.7 1.3% to 20.4- 2.1% and ALS 4.811.1% to 7.2 0.8%). The results also confirmed that the stabilised peptide had no effect on myotube formation but that it increases myoblast progenitor cell proliferation, whilst mature IGF-I enhanced differentiation.
6.2 Isolation of Human Muscle-Derived Cells Human primary muscle cell cultures were isolated as previously described [Lewis et al., 2000; Sinanan et al., 2004]. Briefly, following informed consent, craniofacial (masseter) muscle biopsies were obtained from healthy adult and CMD patients during elective surgery at the Eastman and Middlesex Hospitals, London, UK.
Human lower limb (vastus lateralis) muscle samples were obtained from consenting, adult healthy, FSHD and ALS patients by needle biopsy under local anaesthesia at the Royal Free Hospital, London, UK. Biopsies were pooled from several patients with the same disorder to obtain sufficient cell numbers in the primary cultures.
These were washed with antibiotic (penicillin, 100U/ml; streptomycin, 100 g/ml;
fungizone, 2.5 g/ml; Invitrogen) supplemented DMEM (high glucose; Invitrogen), scissor-minced and tissue fragments plated into 0.2% gelatin-coated (Sigma-Aldrich) T150cm2 culture flasks (Helena Biosciences). Explant cultures were incubated in serum-containing Growth Media (sGM), composed of DMEM, 20% FCS (PAA
Laboratories), penicillin (100U/ml) and streptomycin (100 g/ml) (Invitrogen), and maintained at 37 C in humidified 95% air with 5% CO2. The first wave of migration of mononuclear cells from the explant was designated the ~-wave and this population was used throughout this study. Migratory human muscle cell were enzymatically harvested using trypsin-EDTA (Invitrogen) and subcultured in sGM
unti170-80% confluency. Passage number x(PX), was defined as the xth sequential harvest of subconfluent cells. All experiments were performed using P3_5 cohorts.
The expanded cells were then stored under cryogenic conditions until they were used in the experiments described below. At least 6 runs were made for each of the treatments used for each diseased muscle culture as well as for the two types of healthy muscle.
6.3 Determination of the myogenic progenitor (stent) cell population in vitro Assessment of the number of myogenic precursors was performed as described previously (Sinanan et al., 2004). Cells were re-plated on gelatin-coated (0.2%) 13mm coverslips at an initial density of 4.5x 103 cells cm 2. To avoid confounding effects of IGF and related protein in FCS, cells were cultured in a serum-free, defined media (dGM); DMEM supplemented with EGF (10ng/ml), bFGF (2ng/ml), insulin (5ng/ml), holo-transferrin (5 g/ml), sodium selenite (5ng/ml), dexamethasone (390ng/ml), vitamin C (50 ghnl), vitamin H (D-biotin; 250ng/ml), Vitamin E
(Trolox; 25 g/ml) (Sigma-Aldrich), albumax-1 (0.5mg/ml) (Invitrogen), fetuin (500gg/ml) (Clonetics/BioWhittaker), penicillin (100U/ml) and streptomycin (100 g/ml) (Invitrogen). After allowing 24 hours for adherence, the stabilised peptide (10ng/ml) with and without rIGF-I, (10ng/ml) and with and without monoclonal IGF-I receptor antibody (Ab-1, 100 g/ml, Oncogene) were added in dGM as appropriate. The peptides used were (see 1.1 and 1.3 above) the stabilised peptide related to the E domain of MGF / IGF-IEc peptide [24 amino acid residues]
synthesized as described previously [Dluzniewska et al, 2005] and human IGF-I
peptide [70 amino acid residues] (Sigma - Aldrich ER2 IGF-I). All media were replaced every 2-3 days. The cultures were sampled at various time-points for immunocytochemical analyses.
6.4 Ina mu n o cyto ch ena istry At the appropriate time-points, cells were fixed with methanol for 10 min (-20 C), followed by detergent permeabilization with 0.5% Triton-X100 for 10-15 min.
Cells were then incubated for 60 min with an anti-desmin (1:100; clone D33, DAKO, Glostrup, Denmark) antibody, diluted in antibody diluting solution (ADS; PBS
p1us10% FCS, 0.025% sodium azide, 0.1M lysine). A class specific anti-mouse IgG
antibody conjugated to FITC (1:200; Jackson ImmunoResearch Laboratories/Stratech Scientific) was used to visualize. Nuclei were identified by introducing the fluorescent minor-groove DNA-binding probe, DAPI (1.0 ng/ml;
Sigma-Aldrich), into the final antibody incubation step. Coverslips were mounted with the glycerol-based anti-fade agent, Citifluor (Citifluor Ltd), and sealed with clear nail varnish. Cell-associated fluorescence and morphology, were visualized by epi-fluorescence and Leica Modulation Contrast (LMC) microscopy respectively, using an inverted Leica DMIRB microscope equipped with Leica FW4000 image processing software. For the proliferation assay, all blue and green fluorescent positive cells were counted in a field. At least 30 fields in each coverslip were counted in a systematic manner; at least 100 cells were therefore counted on each coverslip. The number of cells was compared as the percentage of desmin positive cells to the total number of DAPI positive cells.
6.5 Creatine phosphokitaase (CPK) assay This assay was performed using previously published protocols [Auluck et al., 2005].
Measurement of CPK allows for the quantitative comparison of myogenesis [Goto et al., 1999], as it is a marker of myotube formation. The enzyme CPK catalyzes the reversible phosphorylation of adenosine-5-diphosphate (ADP) to form adenosine-triphosphate (ATP) and free creatine. The reaction may be followed in either direction by measuring the formation of inorganic phosphorus, an end-product of the reaction which is proportional to CPK activity. This was measured using the colorimetric method based on the generation of inorganic phosphate [Fiske and Subbarow, 1925] procedure. This was then expressed in terms of the protein content of the culture.
Previously expanded primary human muscle cell cultures were re-plated at 10x104 cells/well in 0.2% gelatin coated 96 well plates. Cells were cultured unti170/80%
confluent in sGM then the medium changed to differentiation medium (DM; DMEM, 2% FCS, penicillin (100U/ml) and streptomycin (100 g/ml)) containing the stabilised peptide [24 amino acid residues] synthesized as previously described [Dluzniewska et al, 2005] and/or human IGF-I peptide [70 amino acid residues]
(Sigma - Aldrich IGF-I ER2). After 48 hours, cells were washed twice with ice cold PBS and then stored frozen in 0.5 mM glycine buffer (pH 6.75) at -70 C. Fixed cells were lysed by rapid thawing and CPK assay kit used according to manufacturers instructions (Sigma-Aldrich). The protein concentration of each sample was determined against an albumin standard curve using the Pierce Micro BCA Kit (PerBio Science, UK Ltd., Northumberland, UK).
6.6 Statistical analysis 1-way ANOVA test was applied using StatView 4.51 (SAS Institute Inc., Cherwell Scientific Publishing Ltd, Oxford, UK) followed by the Fisher's PLSD post hoc test.
p<0.05 was considered significant. Data were pooled for all runs (minimum of 6) for the 4 types of experiments for each condition including the two types of healthy muscle and presented as mean s.d.
6.7 The proportion of tnyogenic precuf-sors in hunaan inuscle primary cultures The percentage of myogenic (desmin positive) cells was determined from all of the muscles tested (See Table below). Normal (non-diseased) muscle contained a significant proportion of desmin positive cells whereas diseased muscle contained a much lower proportion of myogenic cells.
Table - Human primary muscle cultures derived from different nzuscle sources that contain differing proportions of nzyogenic (desmin positive) cells before addition ofpeptides Muscle Type Desmin positive cells as percentage of total cells in primary culture.
Normal (non-diseased) 49.8 2.4%
Craniofacial Normal (non-diseased) Limb 38.4L2.5%
CMD Limb 10.4~:1.7%
ALS Limb 4.8 1.1 %
FSHD Limb 11.7 1.3%
6.8 Effect on normal (non-diseased) human primary muscle progenitor cells The stabilised peptide increased proliferation (changes in the proportion of desmin-associated nuclei to total nuclei) significantly in normal craniofacial (masseter) primary cultures from 49.8 2.4% to 68.8 3.9%; p<0.0001). IGF-I also induced a moderate increase (from 49.8 2.4% to 58.4 4.2%; p<0.0001). Interestingly, it was found that the effect of the stabilised peptide on desmin positive cell proliferation ratio was inhibited when IGF-I was added (from 68.8 3.9% to 59.5f4.2%;
p<0.0001). The effect seen in normal lower limb (quadriceps) primary cultures was similar to that seen with craniofacial muscle. The stabilised peptide increased muscle progenitor cell proliferation significantly (from 38.4 2.5% to 57.9 3.2%;
p<0.0001).
IGF-I had only a minor effect on proliferation (from 38.4-L-2.5% to 47.1 3.5%;
p<0.0001) but IGF-I completely abrogated the response to the stabilised peptide when the two peptides were added in combination (from 57.9 3.2% to 38.8 0.6%;
p<0.0001).
6.9 Effect on disease-state human primary muscle derived cell proliferation Following the observation that the stabilised peptide could reproducibly and significantly increase the number of desmin positive cells in normal muscle, the effect on disease-state muscle was investigated. In primary cultures derived from congenital muscular dystrophy (CMD), the stabilised peptide significantly increased muscle progenitor cell proliferation (from 10.4 1.7% to 17.5 1.6%; p<0.0001), whilst IGF-I had a small effect (10.4 1.7% to 13.2 1.7%; p=0.005). When combining both peptides the inhibiting effect was again as observed as for normal inuscle, with effect of the stabilised peptide being reduced to control levels (from 17.5 1.6% to 13.1+1.2%; p=0.0001). The effects of the stabilised peptide on cellular proliferation of muscle cells from amyotrophic lateral sclerosis - (ALS) and FSHD
(produced similar results. The stabilised peptide increased the numbers of desmin expressing cells markedly in these disorders (ALS from 4.8 1.1% to 7.2 0.8%;
p=0.0002, FSHD from 11.7 1.3% to 20.412.1%; p<0.0001). As was the case for normal muscle, IGF-I again had a negligible effect (ALS from 4.8 1.1 % to 4.7 1.4%; p=0.7719, FSHD from 11.7 1.3% to 14.1 1.6%; p=0.0107)). When both isoforms were used together, MGF-induced desmin expressing increase was again inhibited (ALS from 7.2 0.8% to 5.3 1.0%; p=0.0024, FSHD from 20.412.1% to 14.5+1.4%; p<0.0001).
6.10 Increased progenitor cell pf=olifet=ation by MGF E domain in relation to the IGF-I receptor In normal muscle, the increase in proliferation induced by the stabilised peptide was not inhibited by the presence of an anti-IGFIR antibody (68.8 3.9% in MGF
treated and 71.1 6.2% in MGF plus Ab-I treated cells; p=0.2472). The same effect was also observed for both CMD and ALS muscle (17.5 1.6% vs. 16.7--I= 1.8% p=0.4589 for CMD; 7.2 0.8% vs. 6.5 0.8%,p=0.2933 for ALS). This indicates that the action of the MGF E domain does not involve the IGF-I receptor.
6.11 Effects of MGF E domain on preventitag terminal differentiation.
In the CPK assays of 6.4 above, the stabilised peptide did not facilitate primary myoblast differentiation and myotube formation. In contrast, IGF-I at a concentration of 10 ng/ml apparently stimulates myotube formation as the numbers of cells expressing desmin is decreased by the addition of IGF-I on this stage of myogenesis. Indeed, in the presence of l Ong/ml IGF-I, the stabilised peptide acted as an agonist and, in a dose-dependent manner, prevented differentiation to the myoblast fusion competent stage. The decrease of 100 ng/ml of the stabilised peptide with 10 ng/ml of systemic IGF-I was lower than 10 ng/ml of MGF with the same dose of IGF-I.
6.12 Conclusions The stabilised peptide induced progenitor cell proliferation significantly in primary muscle culture from patients with CMD, FSHD and ALS as well as healthy individuals. The stabilised peptide did not affect myotube formation, a process that IGF-I accelerates significantly. This demonstrates that the biologically active MGF
E domain has a distinct activity compared to mature IGF-I.Our findings indicate that the different actions of IGF-I isoforms are probably mediated via different receptors.
The blocking of the IGF-I receptor provides evidence that MGF E domain increases satellite cell proliferation via a different signalling pathway to IGF-I, and that the initial satellite cell activation is a separate process from that which is influenced by mature IGF-I.
It has been proposed that muscle wasting in neurological conditions and ageing is due to a loss of satellite cells. We have demonstrated that the ratio of progenitor (desmin positive) cells to total myoblasts from the patients with CMD, FSHD
and ALS is low compared to the ratio of myoblasts from healthy individuals. Thus it is debatable whether muscles degenerate because of lack of satellite cells or because of inability to express some factor for satellite cell activation. We have previously demonstrated that elderly people are unable to express MGF at the levels required to maintain muscle [Hameed et al., 2004], with similar findings for FSHD and ALS
patients (unpublished findings).
Muscle wasting is one of the main causes of death in patients with certain neuromuscular diseases. Muscle loss can be linked to the inability to express MGF, and that muscles of the mdx dystrophic mouse, a model for human Duchenne Muscular Dystrophy, are unable to produce MGF even during mechanical stimuli [Goldspink et al., 1996]. De Bari et al found that when mesenchyrnal stem cells were introduced into dystrophic muscles of mdx mouse, the sarcolemmal expression of dystrophin and also MGF expression was restored [De Bari et al., 2003].
Therefore, the production of MGF may depend on the compliance of the cell membrane and possibly involve some type of mechanotransduction mechanism e.g.
the dystrophin complex It has been known for some time that IGF-I is a neurotrophic factor, and possesses potential clinical applications for neurodegenerative disorders, particularly ALS.
Using animal models, systemic delivery of human recombinant IGF-I (mature IGF-I) has been used in animal models and to treat ALS patients. Most recently, it was reported that exercise, when combined with IGF-I gene therapy by AAV2 vector, has some synergistic effects in treatment of an animal model of ALS [Kaspar et al., 2005].
However, the data presented here indicate it is the activity of MGF, not that of ordinary IGF-I, that will be most for use in the treatment of muscle wasting, because it offers an effective method of replenishing the muscle satellite (stem) cell pool that is required for muscle maintenance and repair. This supports the use of peptides of the invention as therapeutic agents for muscle degeneration in disorders such as CMD, FSHD and ALS in which there is an apparent impairment in expressing the MGF splice variant. There is also the potential for using peptides of the invention to multiply the muscle satellite cells in culture for cell therapy purposes.
7. Cell Proliferation Assays with 8 Amino Acid Peptides 7.1 DMGF and CMGFpeptides The 8 amino acid peptides described in 1.3.1 above and referred to in Figure 8A as DMGF and CMGF were tested for the ability to induce proliferation of C2C12 muscle cells at a density of 2000 cells per well in a medium containing DMEM
(1000mg/L glucose), BSA (100ug/ml) and IGF-I (2ng per ml). Concentrations of 2, 5, 50 and 100 ng/ml of DMGF and CMGF were tested (See the left-hand and middle sets of results in Figure 8), along with 2, 5, 50 and 100 ng/ml IGF-I alone (See the right-hand set of results in Figure 8). After 36 hours incubation, an Alamar Blue assay was used to assess the level of cell proliferation achieved. A control containing only the medium was also provided.
Both DMGF and CMGF induced cell proliferation. The results are shown in Figure 8A in terms of fluorescence in the Alamar Blue Assay. All values for DMGF and CMGF, and those for IGF-I alone, were statistically different to the control value for the medium only. Increasing levels of proliferation were observed with increasing concentration of DMGF/CMGF.
7.2 Peptides A2, A4, A6 a:ad A8 The 8 amino acid peptides described in 1.3.2 above and referred to in Figure 8B as A2, A4, A6 and A8 were tested for the ability to induce proliferation of C2C
muscle cells at a density of 500 cells per well. Cultivation was carried out foir 24 hours in 10% FBS, followed by starvation for 24 hours in 0.1% BSA, stimulation for 24 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10 and 100 ng/ml of peptides A2, A4, A6 and A8 were tested, along with 0.1, 1, 10 and ng/ml IGF-I (See the right-hand set of results in Figure 8B). Incorporation of BrdU
was measured to assess the level of cell proliferation achieved. Controls containing no cells, medium only, 5% FBS and no BrdU were also provided.
Peptides A2, A4, A6 and A8 induced cell proliferation. The results are shown in Figure 8 in terms of fluorescence (absorbence at 370nm; mean plus standard error across 4 wells).
8. Cell Proliferation Assays with Human primary cells (HSMM) The 24 amino acid peptide described in 1.4 above and referred to in Figures 9-11 as A5 was tested for the ability to induce proliferation of human muscle progenitor cells (Cambrex). These are commercially available primary human muscle cells, ie human muscle stem (progenitor) cells. They are also sometimes known as Human Skeletal Muscle Myoblasts (HSMM). Cells were obtained from a 39 year old male subject.
Cultivation was carried out for 24 hours in 200 1 of SkGM2 medium supplemented with hEGF, L-Glut, dexametllasone, antibiotics and 10% FCS. The cultivation medium was then removed and the cells were washed twice in serum free medium.
A5 was tested for the ability to induce proliferation of Cambrex HSMM at a density of 500 (Figures 9 and 10) or 1000 (Figure 11) cells per well in Cambrex SkGM2 medium supplemented with hEGF, L-Glut, dexamethasone and antibiotics.
Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of A5 were tested (See the left-hand sets of results in Figures 9A, 10A and 11A), along with 0.1, 10 and 100 ng/ml IGF-I
alone (See results in Figures 9A, 10A and 11 A). Concentrations of 0.1, 1, 10, and 500 ng/ml of A5 were also tested in the presence of 2 ng/ml IGF-I (See the left-hand set of results in Figures 9B, 10B and 11B). After 48 hours incubation, the cells were treated with BrdU for 5 hours. Incorporation of BrdU was measured to assess the level of cell proliferation achieved. Controls containing no cells, medium only, 5% FBS and no BrdU were also provided.
unti170-80% confluency. Passage number x(PX), was defined as the xth sequential harvest of subconfluent cells. All experiments were performed using P3_5 cohorts.
The expanded cells were then stored under cryogenic conditions until they were used in the experiments described below. At least 6 runs were made for each of the treatments used for each diseased muscle culture as well as for the two types of healthy muscle.
6.3 Determination of the myogenic progenitor (stent) cell population in vitro Assessment of the number of myogenic precursors was performed as described previously (Sinanan et al., 2004). Cells were re-plated on gelatin-coated (0.2%) 13mm coverslips at an initial density of 4.5x 103 cells cm 2. To avoid confounding effects of IGF and related protein in FCS, cells were cultured in a serum-free, defined media (dGM); DMEM supplemented with EGF (10ng/ml), bFGF (2ng/ml), insulin (5ng/ml), holo-transferrin (5 g/ml), sodium selenite (5ng/ml), dexamethasone (390ng/ml), vitamin C (50 ghnl), vitamin H (D-biotin; 250ng/ml), Vitamin E
(Trolox; 25 g/ml) (Sigma-Aldrich), albumax-1 (0.5mg/ml) (Invitrogen), fetuin (500gg/ml) (Clonetics/BioWhittaker), penicillin (100U/ml) and streptomycin (100 g/ml) (Invitrogen). After allowing 24 hours for adherence, the stabilised peptide (10ng/ml) with and without rIGF-I, (10ng/ml) and with and without monoclonal IGF-I receptor antibody (Ab-1, 100 g/ml, Oncogene) were added in dGM as appropriate. The peptides used were (see 1.1 and 1.3 above) the stabilised peptide related to the E domain of MGF / IGF-IEc peptide [24 amino acid residues]
synthesized as described previously [Dluzniewska et al, 2005] and human IGF-I
peptide [70 amino acid residues] (Sigma - Aldrich ER2 IGF-I). All media were replaced every 2-3 days. The cultures were sampled at various time-points for immunocytochemical analyses.
6.4 Ina mu n o cyto ch ena istry At the appropriate time-points, cells were fixed with methanol for 10 min (-20 C), followed by detergent permeabilization with 0.5% Triton-X100 for 10-15 min.
Cells were then incubated for 60 min with an anti-desmin (1:100; clone D33, DAKO, Glostrup, Denmark) antibody, diluted in antibody diluting solution (ADS; PBS
p1us10% FCS, 0.025% sodium azide, 0.1M lysine). A class specific anti-mouse IgG
antibody conjugated to FITC (1:200; Jackson ImmunoResearch Laboratories/Stratech Scientific) was used to visualize. Nuclei were identified by introducing the fluorescent minor-groove DNA-binding probe, DAPI (1.0 ng/ml;
Sigma-Aldrich), into the final antibody incubation step. Coverslips were mounted with the glycerol-based anti-fade agent, Citifluor (Citifluor Ltd), and sealed with clear nail varnish. Cell-associated fluorescence and morphology, were visualized by epi-fluorescence and Leica Modulation Contrast (LMC) microscopy respectively, using an inverted Leica DMIRB microscope equipped with Leica FW4000 image processing software. For the proliferation assay, all blue and green fluorescent positive cells were counted in a field. At least 30 fields in each coverslip were counted in a systematic manner; at least 100 cells were therefore counted on each coverslip. The number of cells was compared as the percentage of desmin positive cells to the total number of DAPI positive cells.
6.5 Creatine phosphokitaase (CPK) assay This assay was performed using previously published protocols [Auluck et al., 2005].
Measurement of CPK allows for the quantitative comparison of myogenesis [Goto et al., 1999], as it is a marker of myotube formation. The enzyme CPK catalyzes the reversible phosphorylation of adenosine-5-diphosphate (ADP) to form adenosine-triphosphate (ATP) and free creatine. The reaction may be followed in either direction by measuring the formation of inorganic phosphorus, an end-product of the reaction which is proportional to CPK activity. This was measured using the colorimetric method based on the generation of inorganic phosphate [Fiske and Subbarow, 1925] procedure. This was then expressed in terms of the protein content of the culture.
Previously expanded primary human muscle cell cultures were re-plated at 10x104 cells/well in 0.2% gelatin coated 96 well plates. Cells were cultured unti170/80%
confluent in sGM then the medium changed to differentiation medium (DM; DMEM, 2% FCS, penicillin (100U/ml) and streptomycin (100 g/ml)) containing the stabilised peptide [24 amino acid residues] synthesized as previously described [Dluzniewska et al, 2005] and/or human IGF-I peptide [70 amino acid residues]
(Sigma - Aldrich IGF-I ER2). After 48 hours, cells were washed twice with ice cold PBS and then stored frozen in 0.5 mM glycine buffer (pH 6.75) at -70 C. Fixed cells were lysed by rapid thawing and CPK assay kit used according to manufacturers instructions (Sigma-Aldrich). The protein concentration of each sample was determined against an albumin standard curve using the Pierce Micro BCA Kit (PerBio Science, UK Ltd., Northumberland, UK).
6.6 Statistical analysis 1-way ANOVA test was applied using StatView 4.51 (SAS Institute Inc., Cherwell Scientific Publishing Ltd, Oxford, UK) followed by the Fisher's PLSD post hoc test.
p<0.05 was considered significant. Data were pooled for all runs (minimum of 6) for the 4 types of experiments for each condition including the two types of healthy muscle and presented as mean s.d.
6.7 The proportion of tnyogenic precuf-sors in hunaan inuscle primary cultures The percentage of myogenic (desmin positive) cells was determined from all of the muscles tested (See Table below). Normal (non-diseased) muscle contained a significant proportion of desmin positive cells whereas diseased muscle contained a much lower proportion of myogenic cells.
Table - Human primary muscle cultures derived from different nzuscle sources that contain differing proportions of nzyogenic (desmin positive) cells before addition ofpeptides Muscle Type Desmin positive cells as percentage of total cells in primary culture.
Normal (non-diseased) 49.8 2.4%
Craniofacial Normal (non-diseased) Limb 38.4L2.5%
CMD Limb 10.4~:1.7%
ALS Limb 4.8 1.1 %
FSHD Limb 11.7 1.3%
6.8 Effect on normal (non-diseased) human primary muscle progenitor cells The stabilised peptide increased proliferation (changes in the proportion of desmin-associated nuclei to total nuclei) significantly in normal craniofacial (masseter) primary cultures from 49.8 2.4% to 68.8 3.9%; p<0.0001). IGF-I also induced a moderate increase (from 49.8 2.4% to 58.4 4.2%; p<0.0001). Interestingly, it was found that the effect of the stabilised peptide on desmin positive cell proliferation ratio was inhibited when IGF-I was added (from 68.8 3.9% to 59.5f4.2%;
p<0.0001). The effect seen in normal lower limb (quadriceps) primary cultures was similar to that seen with craniofacial muscle. The stabilised peptide increased muscle progenitor cell proliferation significantly (from 38.4 2.5% to 57.9 3.2%;
p<0.0001).
IGF-I had only a minor effect on proliferation (from 38.4-L-2.5% to 47.1 3.5%;
p<0.0001) but IGF-I completely abrogated the response to the stabilised peptide when the two peptides were added in combination (from 57.9 3.2% to 38.8 0.6%;
p<0.0001).
6.9 Effect on disease-state human primary muscle derived cell proliferation Following the observation that the stabilised peptide could reproducibly and significantly increase the number of desmin positive cells in normal muscle, the effect on disease-state muscle was investigated. In primary cultures derived from congenital muscular dystrophy (CMD), the stabilised peptide significantly increased muscle progenitor cell proliferation (from 10.4 1.7% to 17.5 1.6%; p<0.0001), whilst IGF-I had a small effect (10.4 1.7% to 13.2 1.7%; p=0.005). When combining both peptides the inhibiting effect was again as observed as for normal inuscle, with effect of the stabilised peptide being reduced to control levels (from 17.5 1.6% to 13.1+1.2%; p=0.0001). The effects of the stabilised peptide on cellular proliferation of muscle cells from amyotrophic lateral sclerosis - (ALS) and FSHD
(produced similar results. The stabilised peptide increased the numbers of desmin expressing cells markedly in these disorders (ALS from 4.8 1.1% to 7.2 0.8%;
p=0.0002, FSHD from 11.7 1.3% to 20.412.1%; p<0.0001). As was the case for normal muscle, IGF-I again had a negligible effect (ALS from 4.8 1.1 % to 4.7 1.4%; p=0.7719, FSHD from 11.7 1.3% to 14.1 1.6%; p=0.0107)). When both isoforms were used together, MGF-induced desmin expressing increase was again inhibited (ALS from 7.2 0.8% to 5.3 1.0%; p=0.0024, FSHD from 20.412.1% to 14.5+1.4%; p<0.0001).
6.10 Increased progenitor cell pf=olifet=ation by MGF E domain in relation to the IGF-I receptor In normal muscle, the increase in proliferation induced by the stabilised peptide was not inhibited by the presence of an anti-IGFIR antibody (68.8 3.9% in MGF
treated and 71.1 6.2% in MGF plus Ab-I treated cells; p=0.2472). The same effect was also observed for both CMD and ALS muscle (17.5 1.6% vs. 16.7--I= 1.8% p=0.4589 for CMD; 7.2 0.8% vs. 6.5 0.8%,p=0.2933 for ALS). This indicates that the action of the MGF E domain does not involve the IGF-I receptor.
6.11 Effects of MGF E domain on preventitag terminal differentiation.
In the CPK assays of 6.4 above, the stabilised peptide did not facilitate primary myoblast differentiation and myotube formation. In contrast, IGF-I at a concentration of 10 ng/ml apparently stimulates myotube formation as the numbers of cells expressing desmin is decreased by the addition of IGF-I on this stage of myogenesis. Indeed, in the presence of l Ong/ml IGF-I, the stabilised peptide acted as an agonist and, in a dose-dependent manner, prevented differentiation to the myoblast fusion competent stage. The decrease of 100 ng/ml of the stabilised peptide with 10 ng/ml of systemic IGF-I was lower than 10 ng/ml of MGF with the same dose of IGF-I.
6.12 Conclusions The stabilised peptide induced progenitor cell proliferation significantly in primary muscle culture from patients with CMD, FSHD and ALS as well as healthy individuals. The stabilised peptide did not affect myotube formation, a process that IGF-I accelerates significantly. This demonstrates that the biologically active MGF
E domain has a distinct activity compared to mature IGF-I.Our findings indicate that the different actions of IGF-I isoforms are probably mediated via different receptors.
The blocking of the IGF-I receptor provides evidence that MGF E domain increases satellite cell proliferation via a different signalling pathway to IGF-I, and that the initial satellite cell activation is a separate process from that which is influenced by mature IGF-I.
It has been proposed that muscle wasting in neurological conditions and ageing is due to a loss of satellite cells. We have demonstrated that the ratio of progenitor (desmin positive) cells to total myoblasts from the patients with CMD, FSHD
and ALS is low compared to the ratio of myoblasts from healthy individuals. Thus it is debatable whether muscles degenerate because of lack of satellite cells or because of inability to express some factor for satellite cell activation. We have previously demonstrated that elderly people are unable to express MGF at the levels required to maintain muscle [Hameed et al., 2004], with similar findings for FSHD and ALS
patients (unpublished findings).
Muscle wasting is one of the main causes of death in patients with certain neuromuscular diseases. Muscle loss can be linked to the inability to express MGF, and that muscles of the mdx dystrophic mouse, a model for human Duchenne Muscular Dystrophy, are unable to produce MGF even during mechanical stimuli [Goldspink et al., 1996]. De Bari et al found that when mesenchyrnal stem cells were introduced into dystrophic muscles of mdx mouse, the sarcolemmal expression of dystrophin and also MGF expression was restored [De Bari et al., 2003].
Therefore, the production of MGF may depend on the compliance of the cell membrane and possibly involve some type of mechanotransduction mechanism e.g.
the dystrophin complex It has been known for some time that IGF-I is a neurotrophic factor, and possesses potential clinical applications for neurodegenerative disorders, particularly ALS.
Using animal models, systemic delivery of human recombinant IGF-I (mature IGF-I) has been used in animal models and to treat ALS patients. Most recently, it was reported that exercise, when combined with IGF-I gene therapy by AAV2 vector, has some synergistic effects in treatment of an animal model of ALS [Kaspar et al., 2005].
However, the data presented here indicate it is the activity of MGF, not that of ordinary IGF-I, that will be most for use in the treatment of muscle wasting, because it offers an effective method of replenishing the muscle satellite (stem) cell pool that is required for muscle maintenance and repair. This supports the use of peptides of the invention as therapeutic agents for muscle degeneration in disorders such as CMD, FSHD and ALS in which there is an apparent impairment in expressing the MGF splice variant. There is also the potential for using peptides of the invention to multiply the muscle satellite cells in culture for cell therapy purposes.
7. Cell Proliferation Assays with 8 Amino Acid Peptides 7.1 DMGF and CMGFpeptides The 8 amino acid peptides described in 1.3.1 above and referred to in Figure 8A as DMGF and CMGF were tested for the ability to induce proliferation of C2C12 muscle cells at a density of 2000 cells per well in a medium containing DMEM
(1000mg/L glucose), BSA (100ug/ml) and IGF-I (2ng per ml). Concentrations of 2, 5, 50 and 100 ng/ml of DMGF and CMGF were tested (See the left-hand and middle sets of results in Figure 8), along with 2, 5, 50 and 100 ng/ml IGF-I alone (See the right-hand set of results in Figure 8). After 36 hours incubation, an Alamar Blue assay was used to assess the level of cell proliferation achieved. A control containing only the medium was also provided.
Both DMGF and CMGF induced cell proliferation. The results are shown in Figure 8A in terms of fluorescence in the Alamar Blue Assay. All values for DMGF and CMGF, and those for IGF-I alone, were statistically different to the control value for the medium only. Increasing levels of proliferation were observed with increasing concentration of DMGF/CMGF.
7.2 Peptides A2, A4, A6 a:ad A8 The 8 amino acid peptides described in 1.3.2 above and referred to in Figure 8B as A2, A4, A6 and A8 were tested for the ability to induce proliferation of C2C
muscle cells at a density of 500 cells per well. Cultivation was carried out foir 24 hours in 10% FBS, followed by starvation for 24 hours in 0.1% BSA, stimulation for 24 hours and then treatment with BrdU for 5 hours. Concentrations of 0.1, 1, 10 and 100 ng/ml of peptides A2, A4, A6 and A8 were tested, along with 0.1, 1, 10 and ng/ml IGF-I (See the right-hand set of results in Figure 8B). Incorporation of BrdU
was measured to assess the level of cell proliferation achieved. Controls containing no cells, medium only, 5% FBS and no BrdU were also provided.
Peptides A2, A4, A6 and A8 induced cell proliferation. The results are shown in Figure 8 in terms of fluorescence (absorbence at 370nm; mean plus standard error across 4 wells).
8. Cell Proliferation Assays with Human primary cells (HSMM) The 24 amino acid peptide described in 1.4 above and referred to in Figures 9-11 as A5 was tested for the ability to induce proliferation of human muscle progenitor cells (Cambrex). These are commercially available primary human muscle cells, ie human muscle stem (progenitor) cells. They are also sometimes known as Human Skeletal Muscle Myoblasts (HSMM). Cells were obtained from a 39 year old male subject.
Cultivation was carried out for 24 hours in 200 1 of SkGM2 medium supplemented with hEGF, L-Glut, dexametllasone, antibiotics and 10% FCS. The cultivation medium was then removed and the cells were washed twice in serum free medium.
A5 was tested for the ability to induce proliferation of Cambrex HSMM at a density of 500 (Figures 9 and 10) or 1000 (Figure 11) cells per well in Cambrex SkGM2 medium supplemented with hEGF, L-Glut, dexamethasone and antibiotics.
Concentrations of 0.1, 1, 10, 100 and 500 ng/ml of A5 were tested (See the left-hand sets of results in Figures 9A, 10A and 11A), along with 0.1, 10 and 100 ng/ml IGF-I
alone (See results in Figures 9A, 10A and 11 A). Concentrations of 0.1, 1, 10, and 500 ng/ml of A5 were also tested in the presence of 2 ng/ml IGF-I (See the left-hand set of results in Figures 9B, 10B and 11B). After 48 hours incubation, the cells were treated with BrdU for 5 hours. Incorporation of BrdU was measured to assess the level of cell proliferation achieved. Controls containing no cells, medium only, 5% FBS and no BrdU were also provided.
IGF-I alone had no significant effect on the proliferation of HSMM at any dose (see Figures 9-11). After 48 hours, the A5 peptide had a significant effect (P <
0.1) on the proliferation of HSMM when used in isolation at doses of l Ong/ml and below (Figures 9A and 10A). Addition of 2ng/ml IGF-I to the medium in combination with A5 resulted in a significant effect on the proliferation of HSMM at a higher confidence level (P < 0.001 ; Figures 9B, 10B and 11 B). As the cells are comparatively slow growing, it is recommended to increase incubation period with peptide to 72 hours. Secondly, the signal would be enhanced by increasing the BrdU
exposure time.
REFERENCES
- Domanska-Janik et al. Brain Res. Mol. Brain Res. 121, 50-59 (2004) - Hill and Goldspink, J. Physiol. 549.2, 409-418 (2003) - McKoy et al, J. Physiol. 516.2, 573-592 (1999) - Sarnowska, Folia Neuropathol. 40[2], 101-106 (2002) - Stoppini, et al, J. Neurosci Methods 37, 173-182 (1991) - Yang et al, J. Muscle Res. Cell Motil. 17, 487-495 (1996) - Yang and Goldspink, FEBS Letts. 522, 156-160 (2002) - Auluck et al, Euro. J. Oral Sci. 113: 218-244 (2005) - De Bari et al, J. Cell Biol. 60: 909-918 (2003) - Dluzniewska et al, FASEB J. 19: 1896-1898 (2005) - Fiske and Subbarow, J. Biol. Chem. 66: 375-400 (1925) - Goldspink et al, J. Physiol. 495P: 162-163P (1996).
- Goto et al, Anal. Biochem. 272: 135-142 (1999) - Hameed et al, J Physiol. 555: 231-240 (2004) - Kaspar et al, Ann. Neurol. 57: 649-655 (2005) - Lewis et al, Muscle Res. Cel. Motil. 21: 223-233 (2000) - Sinanan et al, Biotechnol. Appl. Biochem. 40:25-34 (2004) DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
0.1) on the proliferation of HSMM when used in isolation at doses of l Ong/ml and below (Figures 9A and 10A). Addition of 2ng/ml IGF-I to the medium in combination with A5 resulted in a significant effect on the proliferation of HSMM at a higher confidence level (P < 0.001 ; Figures 9B, 10B and 11 B). As the cells are comparatively slow growing, it is recommended to increase incubation period with peptide to 72 hours. Secondly, the signal would be enhanced by increasing the BrdU
exposure time.
REFERENCES
- Domanska-Janik et al. Brain Res. Mol. Brain Res. 121, 50-59 (2004) - Hill and Goldspink, J. Physiol. 549.2, 409-418 (2003) - McKoy et al, J. Physiol. 516.2, 573-592 (1999) - Sarnowska, Folia Neuropathol. 40[2], 101-106 (2002) - Stoppini, et al, J. Neurosci Methods 37, 173-182 (1991) - Yang et al, J. Muscle Res. Cell Motil. 17, 487-495 (1996) - Yang and Goldspink, FEBS Letts. 522, 156-160 (2002) - Auluck et al, Euro. J. Oral Sci. 113: 218-244 (2005) - De Bari et al, J. Cell Biol. 60: 909-918 (2003) - Dluzniewska et al, FASEB J. 19: 1896-1898 (2005) - Fiske and Subbarow, J. Biol. Chem. 66: 375-400 (1925) - Goldspink et al, J. Physiol. 495P: 162-163P (1996).
- Goto et al, Anal. Biochem. 272: 135-142 (1999) - Hameed et al, J Physiol. 555: 231-240 (2004) - Kaspar et al, Ann. Neurol. 57: 649-655 (2005) - Lewis et al, Muscle Res. Cel. Motil. 21: 223-233 (2000) - Sinanan et al, Biotechnol. Appl. Biochem. 40:25-34 (2004) DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.
NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME
NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:
NOTE POUR LE TOME / VOLUME NOTE:
Claims (89)
1. A polypeptide comprising up to 50 amino acid residues;
said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I (IGF-I);
said polypeptide incorporating one or more modifications that give it increased stability compared to the unmodified MGF E peptide;
and said polypeptide possessing biological activity.
said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I (IGF-I);
said polypeptide incorporating one or more modifications that give it increased stability compared to the unmodified MGF E peptide;
and said polypeptide possessing biological activity.
2. A polypeptide of claim 1 wherein said biological activity is selected from the ability to increase muscle strength, cardioprotective ability and neuroprotective ability.
3. A polypeptide of claim 1 or 2 wherein at least one of said modifications is to said sequence of amino acids that is derived from said C-terminal E peptide.
4. A polypeptide of any one of the preceding claims wherein said modifications include one or more conversions of an L-form amino acid to the corresponding D-form amino acid.
5. A polypeptide of any one of the preceding claims wherein said modifications include PEGylation or the addition of a hexanoic or amino-hexanoic acid moiety
6. A polypeptide of claim 5 wherein said PEGylation or addition of a hexanoic or amino-hexanoic acid moiety is at the N-terminal.
7. A polypeptide of any one of the preceding claims wherein said modifications include cyclisation of the polypeptide.
8. A polypeptide of any one of the preceding claims wherein said modifications include the substitution of one or more amino acids.
9. A polypeptide of claim 8 wherein said substitution includes the replacement with Alanine of an amino acid other than Alanine.
10. A polypeptide of any one of the preceding claims wherein said C-terminal E
peptide is the Rat Eb peptide of SEQ ID NO: 13 or the Rabbit Eb peptide of SEQ
ID NO: 14.
peptide is the Rat Eb peptide of SEQ ID NO: 13 or the Rabbit Eb peptide of SEQ
ID NO: 14.
11. A polypeptide of any one of claims 1 to 9 wherein said C-terminal E
peptide is the human Ec peptide of SEQ ID NO: 27 or the peptide of SEQ ID NO: 15.
peptide is the human Ec peptide of SEQ ID NO: 27 or the peptide of SEQ ID NO: 15.
12. A polypeptide of claim 11 wherein the modifications include PEGylation or the addition of a hexanoic or amino-hexanoic acid moiety.
13. A polypeptide of claim 12 wherein said PEGylation or addition of a hexanoic or amino-hexanoic acid moiety is at the N-terminal..
14. A polypeptide of claim 11 wherein said modifications include one or more conversions of an L-form amino acid to the corresponding D-form amino acid.
15. A polypeptide of claim 14 wherein one or both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 27 or 15 is in the D-form.
16. A polypeptide of claim 15 wherein both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 27 or 15 are in the D-form.
17. A polypeptide of claim 11 wherein said modifications include the substitution of one or more amino acids.
18. A polypeptide of claim 17 wherein said substitution is at position 5, 12,14 or 18.
19. A polypeptide of claim 18 wherein said substitution includes the replacement with Alanine of an amino acid other than Alanine.
20. A polypeptide of claim 19 wherein said Alanine substitution is one or more of (a) Serine to Alanine at position 5, (b) Serine to Alanine at position 12, (c) Arginine to Alanine at position 14 and (d) Serine to Alanine at position 18 of SEQ ID
NO:
15 or 27.
NO:
15 or 27.
21. A polypeptide of any one of claims 1 to 9 wherein said C-terminal peptide is the polypeptide of SEQ ID NO: 33 or 34.
22. A polypeptide of claim 21 wherein the modifications include PEGylation or the addition of a hexanoic or amino-hexanoic acid moiety.
23. A polypeptide of claim 12 wherein said PEGylation or addition of a hexanoic or amino-hexanoic acid moiety is at the N-terminal.
24. A polypeptide of claim 20 wherein said modifications include the substitution of one or more amino acids.
25. A polypeptide of claim 17 wherein said substitution is at position 2.
26. A polypeptide of claim 25 wherein said substitution includes the replacement with Alanine of an amino acid other than Alanine.
27. A polypeptide of claim 26 wherein said Alanine substitution is one or more of (a) Serine to Alanine at position 2.
28. A polypeptide of claim 21 whose sequence is that of SEQ ID NO: 33, 34, 35 or 36.
29. A polypeptide of any one of the preceding claims wherein said modifications include the truncation by one or two amino acids of the C-terminus of said sequence of amino acids that is derived from said C-terminal E peptide.
30. A polypeptide of claim 29 whose sequence is that of the polypeptide of SEQ
ID
NO: 21.
ID
NO: 21.
31. A polypeptide of claim 11 whose sequence is that of the polypeptide of SEQ
ID
NO: 16, 17, 18 19, 28, 29, 30 or 31.
ID
NO: 16, 17, 18 19, 28, 29, 30 or 31.
32. A polypeptide of claim 11 whose sequence is that of SEQ ID NO: 15 or 27 but which is PEGylated at the N-terminus and wherein both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 15 or 27 are in the D-form.
33. A polypeptide of claim 11 whose sequence is that of SEQ ID NO: 15 or 27, wherein both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 15 or 27 are in the D-form, and which is not PEGylated.
34. A polypeptide of any one of the preceding claims which is amidated at the C-terminus.
35. An extended polypeptide comprising a polypeptide of any one of the preceding claims, extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide of claim 1.
36. An extended polypeptide of claim 35, wherein said extension comprises a Cysteine residue at the C-terminus and/or a D-Arginine residue at the N-terminus.
37. A polypeptide or extended polypeptide of any one of the preceding claims whose stability, as measured by half-life in human plasma, is at least 10% greater than that of the unmodified E peptide.
38. A polypeptide or extended polypeptide of claim 37 whose stability, as measured by half-life in human plasma, is at least 50% greater than that of the unmodified E peptide.
39. A polypeptide or extended polypeptide of claim 38 whose stability, as measured by half-life in human plasma, is at least 100% or more greater than that of the unmodified E peptide.
40. A polypeptide or extended polypeptide of any one of the preceding claims whose half-life in human plasma is at least 2 hours.
41. A polypeptide or extended polypeptide of claim 32 whose half-life in human plasma is at least 12 hours or at least 24 hours.
42. A composition comprising a polypeptide or extended polypeptide of any one of the preceding claims and a carrier.
43. A pharmaceutical composition comprising a polypeptide or extended polypeptide of any one of claims 1 to 41 and a pharmaceutically acceptable carrier.
44. A polypeptide or extended polypeptide of any one of claims 1 to 41 for use in a method of treatment of the human or animal body.
45. A method of treating a muscular disorder by administering to a patient in need thereof an effective amount of a polypeptide or extended polypeptide of any one of claims 1 to 41.
46. A method of claim 45 wherein said muscular disorder is a disorder of skeletal muscle.
47. A method of claim 46 wherein said muscular disorder is muscular dystrophy or related progressive skeletal muscle weakness or wasting, muscle atrophy, cachexia, muscle weakness; sarcopenia or frailty in an elderly subject; or wherein said polypeptide or extended polypeptide is administered for the purpose of muscle repair following trauma.
48. A method of claim 47 wherein said muscular dystrophy is Duchenne or Becker muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD) or congenital muscular dystrophy (CMD); said muscle atrophy is disuse atrophy, glucocorticoid-induced atrophy, muscle atrophy in an ageing subject or muscle atrophy induced by spinal cord injury or neuromuscular disease; said cachexia is associated with, cancer, AIDS, Chronic Obstructive Pulmonary Disease (COPD), a chronic inflammatory disease or bums injury; or said muscle weakness is in the urinary sphincter, anal sphincter or pelvic floor muscles.
49. A method of claim 45 wherein said muscular disorder is a disorder of cardiac muscle.
50. A method according to claim 49 wherein said polypeptide or extended polypeptide is administered for the purpose of prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart;
to promote cardiac muscle synthesis; to improve cardiac output by increasing heart stroke volume; to treat a cardiomyopathy; in response to an acute heart failure or acute insult to the heart; to treat pathological heart hypertrophy;
or to treat congestive heart failure.
to promote cardiac muscle synthesis; to improve cardiac output by increasing heart stroke volume; to treat a cardiomyopathy; in response to an acute heart failure or acute insult to the heart; to treat pathological heart hypertrophy;
or to treat congestive heart failure.
51. A method accoding to claim 50 wherein said acute heart failure or acute insult comprises myocarditis or myocardial infarction.
52. A method of treating a neurological disorder by administering to a patient in need thereof an effective amount of a polypeptide or extended polypeptide of any one of claims 1 to 41.
53. A method according to claim 52 wherein said polypeptide or extended polypeptide is administered for the purpose of prevention of neuronal loss associated with a disorder of, damage to, the nervous system, or for maintenance of the central nervous system (CNS).
54. A method of claim 53 wherein said neuronal loss is associated with a neurodegenerative disorder, nerve damage or ischemia.
55. A method according to claim 54 wherein said disorder is amyotrophic lateral sclerosis; spinal muscular atrophy; progressive spinal muscular atrophy;
infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome; a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; motoneurone loss associated with ageing; autosomal or sex-linked muscular dystrophy; Alzheimer's disease;
Parkinson's disease; diabetic neuropathy; a peripheral neuropathy; an embolic or haemorrhagic stroke; alcohol-related brain damage; or wherein said polypeptide or extended polypeptide is administered for the purpose of nerve repair following trauma.
infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome; a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; motoneurone loss associated with ageing; autosomal or sex-linked muscular dystrophy; Alzheimer's disease;
Parkinson's disease; diabetic neuropathy; a peripheral neuropathy; an embolic or haemorrhagic stroke; alcohol-related brain damage; or wherein said polypeptide or extended polypeptide is administered for the purpose of nerve repair following trauma.
56. Use of a polypeptide or extended polypeptide of any one of claims 1 to 41 in the manufacture of a medicament for use in a treatment as defined in any one of claims 45 to 55.
57. A method of treating a neurological disorder by administering to a patient in need thereof an effective amount of:
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I);
or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide or extended polypeptide possessing biological activity.
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I);
or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide or extended polypeptide possessing biological activity.
58. A method of claim 57 wherein said biological activity is neuroprotective ability.
59. A method of claim 57or 58 wherein said polypeptide or extended polypeptide is administered for the purpose of prevention of neuronal loss associated with a disorder of, or damage to, the nervous system, or for maintenance of the central nervous system (CNS).
60. A method of claim 59 wherein said neuronal loss is associated with a neurodegenerative disorder, nerve damage or ischemia.
61. A method according to claim 57 or 58 wherein said disorder is amyotrophic lateral sclerosis; spinal muscular atrophy; progressive spinal muscular atrophy;
infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome;
a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; motoneurone loss associated with ageing; autosomal or sex-linked muscular dystrophy;
Alzheimer's disease; Parkinson's disease; diabetic neuropathy; a peripheral neuropathy; an embolic or haemorrhagic stroke; alcohol-related brain damage;
or wherein said polypeptide or extended polypeptide is administered for the purpose of nerve repair following trauma.
infantile or juvenile muscular atrophy, poliomyelitis or post-polio syndrome;
a disorder caused by exposure to a toxin, motoneurone trauma, a motoneurone lesion or nerve damage; an injury that affects motoneurones; motoneurone loss associated with ageing; autosomal or sex-linked muscular dystrophy;
Alzheimer's disease; Parkinson's disease; diabetic neuropathy; a peripheral neuropathy; an embolic or haemorrhagic stroke; alcohol-related brain damage;
or wherein said polypeptide or extended polypeptide is administered for the purpose of nerve repair following trauma.
62. A method of treating a disorder of cardiac muscle by administering to a patient in need thereof an effective amount of:
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I);
or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide possessing biological activity.
a polypeptide comprising up to 50 amino acid residues, said polypeptide comprising a sequence of amino acids derived from the C-terminal E peptide of a Mechano Growth Factor (MGF) isoform of Insulin-like Growth Factor I(IGF-I);
or an extended polypeptide comprising said polypeptide and extended by non-wild-type amino acid sequence N-terminal and/or C-terminal to said polypeptide;
and said polypeptide possessing biological activity.
63. A method of claim 62 wherein said biological activity is cardioprotective ability.
64. A method according to claim 62 or 63 wherein said polypeptide or extended polypeptide is administered for the purpose of prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart;
to promote cardiac muscle synthesis; to improve cardiac output by increasing heart stroke volume; to treat a cardiomyopathy; in response to an acute heart failure or acute insult to the heart; to treat pathological heart hypertrophy;
or to treat congestive heart failure.
to promote cardiac muscle synthesis; to improve cardiac output by increasing heart stroke volume; to treat a cardiomyopathy; in response to an acute heart failure or acute insult to the heart; to treat pathological heart hypertrophy;
or to treat congestive heart failure.
65. A method accoding to claim 64 wherein said acute heart failure or acute insult comprises myocarditis or myocardial infarction.
66. A method of any one of claims 57 to 65 wherein said C-terminal E peptide is the Rat Eb peptide of SEQ ID NO: 13, the Rabbit Eb peptide of SEQ ID NO: 14, the human Ec peptide of SEQ ID NO: 27, the peptide of SEQ ID NO: 15 or the peptide of SEQ ID NO: 33 or 34
67. A method of claim 66 wherein said polypeptide or extended polypeptide comprises the sequence of SEQ ID NO: 13, 14, 15, 27, 33 or 34.
68. A method of claim to 59 wherein the sequence of said polypeptide is that of the sequence of the sequence of SEQ ID NO: 13, 14, 15, 27, 33 or 34.
69. Use of a polypeptide or extended polypeptide as defined in claim 57, 58, 62, 63, 66, 67 or 68 in the manufacture of a medicament for use in a treatment as defined in any one of claims 59, 60, 61, 64 or 65.
70. A polypeptide whose sequence is that of SEQ ID NO: 27, wherein one or both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 27 is in the D-form.
71. A polypeptide of claim 70 wherein both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 27 are in the D-form.
72. A polypeptide whose sequence is that of SEQ ID NO: 33, 34, 35 or 36.
73. A polypeptide of claim 70, 71 or 72 further comprising one to five additional amino acids at the C-terminus and/or one to five additional amino acids the N-terminus.
74. A polypeptide of claim 73 wherein one or more of said additional amino acids is a D-form amino acid.
75. A polypeptide of claim 74 wherein one additional D-form amino acid is present at the N-terminus.
76. A polypeptide of claim 75 wherein said one additional D-form amino acid is D-Arginine.
77. A polypeptide of claim 76 wherein no additional amino acids are present at the C-terminus.
78. A polypeptide of any one of claims 70 to 74 wherein one additional amino acid is present at the C-terminus and is Cysteine.
79. A polypeptide according to claim 78 wherein no additional amino acids are present at the N-terminus.
80. A polypeptide whose sequence is that of SEQ ID NO: 15 or 27, plus one additional Cysteine residue at the C-terminus and optionally one to four further amino acids at the C-terminus and/or one to five further amino acids at the N-terminus.
81. A polypeptide of claim 80 wherein one or both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 15 or 27 is in the D-form.
82. A polypeptide of claim 81 wherein both of the Arginine residues at positions 14 and 15 of SEQ ID NO: 27 or 15 are in the D-form.
83. A polypeptide of claim 80, 81 or 82 wherein one or more of said further amino acids is a D-form amino acid.
84. A polypeptide of claim 83 wherein one D-form amino acid is present at the N-terminus.
85. A polypeptide of claim 84 wherein said one D-form amino acid is D-Arginine.
86. A polypeptide of any one of claims 70 to 85 which is amidated at the C-terminus.
87. A polypeptide of any one of claims 70 to 86 which is PEGylated, or to which is attached a hexanoic or amino-hexanoic acid moiety.
88. A polypeptide of claim 87 wherein said PEGylation or attachment of a hexanoic or amino-hexanoic acid moiety is at the N-terminus.
89. A polypeptide of any one of claims 70 to 88 which is not PEGylated.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66280205P | 2005-03-18 | 2005-03-18 | |
US60/662,802 | 2005-03-18 | ||
GBPCT/GB2006/000773 | 2006-03-03 | ||
PCT/GB2006/000773 WO2006097682A1 (en) | 2005-03-18 | 2006-03-03 | Mechano growth factor peptides and their use |
PCT/GB2006/001012 WO2006097764A1 (en) | 2005-03-18 | 2006-03-20 | Mecano growth factor peptides and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2601227A1 true CA2601227A1 (en) | 2006-09-21 |
Family
ID=36649040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002601227A Abandoned CA2601227A1 (en) | 2005-03-18 | 2006-03-20 | Mecano growth factor peptides and their use |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1868637A1 (en) |
KR (1) | KR20080021588A (en) |
AU (1) | AU2006224334A1 (en) |
CA (1) | CA2601227A1 (en) |
WO (1) | WO2006097764A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI427084B (en) | 2006-06-09 | 2014-02-21 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
WO2009012443A1 (en) * | 2007-07-18 | 2009-01-22 | The Board Of Trustees Of The University Of Illinois | Nanoparticles for the elution of growth factors for recovery and regeneration of organs |
CN108490168A (en) * | 2018-03-27 | 2018-09-04 | 苏州长光华医生物医学工程有限公司 | Detect Mechano growth factor, the adamantane chemistry luminescence reagent box of its E peptide, preparation method |
CA3106085A1 (en) * | 2018-07-17 | 2020-04-23 | Helixmith Co., Ltd. | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9926968D0 (en) * | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
GB0202906D0 (en) * | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
GB0203552D0 (en) * | 2002-02-14 | 2002-04-03 | Beaumont Nicholas J | Peptide growth factor |
-
2006
- 2006-03-20 KR KR1020077023964A patent/KR20080021588A/en not_active Application Discontinuation
- 2006-03-20 AU AU2006224334A patent/AU2006224334A1/en not_active Abandoned
- 2006-03-20 WO PCT/GB2006/001012 patent/WO2006097764A1/en active Application Filing
- 2006-03-20 EP EP06726447A patent/EP1868637A1/en not_active Withdrawn
- 2006-03-20 CA CA002601227A patent/CA2601227A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006224334A1 (en) | 2006-09-21 |
EP1868637A1 (en) | 2007-12-26 |
KR20080021588A (en) | 2008-03-07 |
WO2006097764A1 (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060211606A1 (en) | Peptides | |
KR20180025895A (en) | Methods and compositions for treating diseases associated with aging | |
BG63490B1 (en) | The use of leptine as tumour cell proliferation inhibitor | |
EP4321527A1 (en) | Cell-penetrating peptide variant and use thereof | |
CA2601227A1 (en) | Mecano growth factor peptides and their use | |
US7408028B2 (en) | Peptides, antibodies thereto, and their use in treatment of central nervous system, damage | |
US8927498B2 (en) | Compositions and methods useful in enhancement of memory | |
EP2391377A2 (en) | Peptides, pharmaceutical compositions comprising same and uses thereof | |
KR20150140686A (en) | Methods for treatment of nephrotic syndrome and related conditions | |
JP2009505944A (en) | Nerve regeneration peptides and methods of use thereof | |
US20160271265A1 (en) | Insulin-like growth factor mimetics for use in therapy | |
JP6227523B2 (en) | Amyrodosis targets useful in therapeutic methods and for compound screening | |
EP3230308B1 (en) | Methods for treating and preventing cardiomyopathy | |
EP3256146B1 (en) | Dermatopontin as a therapeutic for metabolic disorders | |
US20210371478A1 (en) | Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor | |
US20110092427A1 (en) | Polypeptide and pharmaceutical composition containing the polypeptide | |
US20170081375A1 (en) | Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor | |
JP2006515168A5 (en) | ||
EP3261659B1 (en) | Compositions and methods for vascular protection against reperfusion injury after myocardial ischemia | |
US20190330289A1 (en) | Generation of brain and spinal cord neurons, cardiac myocytes, renal nephrons and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor | |
CN117881687A (en) | Polypeptide inhibitors and uses thereof | |
US20180008723A1 (en) | Multimeric compounds of a kringle domain from the hepatocyte growth factor / scatter factor (hgf/sf) | |
US20120245104A1 (en) | Novel retro-inverso leptin peptide antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |
Effective date: 20140320 |
|
FZDE | Discontinued |
Effective date: 20140320 |